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ABSTRACT 
Clinical and scientific understanding of the human prion diseases has advanced rapidly in recent 
years, and the possibility of an effective therapeutic agent being found now seems a realistic 
prospect.  Alongside the search for an effective therapy, a number of major obstacles must be 
overcome to ensure that clinical trials have the best possible chance of being successful, and to 
maximise the benefit that can be gained from any treatment that is found.  This thesis presents 
several projects that aim to contribute to this.  Improving early diagnosis is likely to be key to making 
the most of any agent’s therapeutic benefit. Currently most patients with prion disease are 
diagnosed at a late stage of disease, when there is likely to be substantial irreversible damage to the 
brain.  Chapters 2, 3 and 4 present work using the recently developed Direct Detection Assay in 
blood and cerebrospinal fluid, with the aim of improving accurate early diagnosis.  Past prion disease 
clinical trials have suffered from the lack of a validated outcome measure to monitor disease 
progression.  Chapter 6 presents a project carried out in the context of large prospective clinical 
studies of prion disease in the UK, in which a bespoke clinical rating scale has been developed and 
validated for use in prion disease clinical trials.  Chapter 5 presents a comprehensive study of the 
complex psychiatric and behavioural features of prion disease, including detailed clinical 
characterisation, observational study of symptomatic management, and investigation of factors 
underlying heterogeneity in these clinical features, including a genome-wide association study 
looking for genetic modifiers.  It is hoped that these different avenues of clinical and laboratory 
research will all help to establish a solid groundwork for upcoming clinical trials in prion disease, 
maximising the chances that they will be able to demonstrate a real and meaningful benefit for 
patients.
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CHAPTER 1.  INTRODUCTION 
An introduction to prion diseases 
The prion diseases are a group of neurodegenerative conditions affecting humans and animals, with 
a number of striking and remarkable characteristics.  Although the human diseases are rare, 
affecting around 1 or 2 people per million population each year1, they have stimulated great 
scientific interest and our understanding of the diseases and the pathophysiological processes 
underlying them has evolved rapidly and reached a relatively advanced stage in comparison with 
many other neurodegenerative conditions. 
 
The first clinical and pathological descriptions of the diseases that we now know as prion diseases 
were made in the 1920s, several decades prior to the discovery of the structure of DNA or the 
proposition of the “central dogma” of molecular biology2.  Since then there has been a gradual 
process of integrating our increasingly sophisticated understanding of molecular and cellular biology 
with the clinically and pathologically derived classifications of diseases, and with clinical and 
experimental observations about them.   
 
A number of observations about prion diseases presented major challenges to this process, as they 
seemed to contradict the accepted biological wisdom of the time.  Foremost amongst these was the 
observation that prion diseases were transmissible, despite the absence of any identifiable causative 
agent containing nucleic acid.  This is discussed in detail below.  As a result, prion diseases have 
often been thought of as having a “unique biology”1, and have been seen as an intriguing but 
esoteric field of research within biology.  Interestingly in recent years this has started to change, as 
what had been seen as “unique” properties of prion biology are increasingly thought to be relevant 
to other neurodegenerative conditions3, including some, such as Alzheimer’s disease, which are 
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extremely common and represent major public health challenges in the context of the ageing global 
population4,5. 
 
By way of introduction I will review our current understanding of a number of key concepts in prion 
biology, and then describe the range of different human prion diseases. 
 
Transmissibility of prion diseases 
Scrapie, a neurodegenerative disease affecting sheep and goats which is endemic in many parts of 
the world, was first proven to be transmissible in the 1930s6. Experiments in which healthy animals 
were inoculated with brain tissue from affected animals showed that, after a prolonged incubation 
period of up to 26 months, the inoculated animals succumbed to the same disease.  Experiments in 
which affected and unaffected flocks of sheep were alternately grazed on the same field, without 
any opportunity for direct contact, found that after 39 months members of the unaffected flock 
started to develop the disease.  This suggested transmission of the disease by an agent able to 
survive in the environment without the need for direct animal-to-animal transmission, and helped to 
explain some aspects of the observed epidemiology of the disease.  Further important observations 
were made from an “accidental experiment” in which scrapie was transmitted by subcutaneous 
injection of a vaccine preparation (against looping ill, an unrelated disease) derived from tissue 
including brain, spinal cord and spleen, some of which came from animals affected by scrapie.  
Despite the fact that the preparation had been treated with formalin to inactivate the looping ill 
virus, it was still able to transmit scrapie to some of the recipient animals.  
 
This early experience illustrates several important observations about the transmissibility of prion 
disease:  they may have unusually long incubation periods, they may be transmitted by multiple 
routes, and the infectious agent is resistant to conditions that would inactivate most previously 
recognised pathogens (such as formalin treatment). 
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Subsequently, it was established that several human neurodegenerative diseases were also 
transmissible, including Creutzfeldt-Jakob disease, which has become the archetypal human prion 
disease.  The evidence for this came both from experimental studies involving deliberate 
transmission of disease to animals (including a large number of experiments carried out at the 
National Institutes of Health in the USA and reviewed by Paul Brown and colleagues7), and also from 
observations made on a number of instances of accidental transmission by a variety of routes, which 
are discussed below.   
 
Strikingly, those diseases that were proven to be experimentally transmissible (through inoculation 
of affected brain tissue) included some that were known to be inherited in an autosomal dominant 
fashion, and which have subsequently been shown to be caused by specific autosomal gene 
mutations (all in the prion protein gene, PRNP)8,9.  This raised major doubts over the hypothesis that 
the conditions were caused by a classical pathogen such as a virus. 
 
A number of instances of accidental transmission of prion disease to or between humans have been 
reported and studied.  Two patients that were implanted with intracerebral electrodes that had 
previously been used on a patient with an undiagnosed illness that proved to be CJD, went on to 
develop the same disease, despite standard decontamination procedures being used.  The 
electrodes were subsequently implanted experimentally into the brain of a chimpanzee, who also 
succumbed to the disease10,11.  As well as clearly demonstrating transmissibility, this and other 
examples of brain-to-brain transmission by neurosurgical instruments provided an initial clue that 
the infectious agent causing prion disease is able to adhere to metallic surfaces, an observation that 
has ultimately led to a fertile avenue of research, including the work presented below in chapters 2, 
3 and 4. 
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Iatrogenic transmission of prion disease has also occurred on several independent occasions as a 
result of human-derived tissue being transplanted or inoculated into recipient individuals:  this 
includes the injection of growth hormone harvested from pooled cadaveric pituitary gland tissue, 
surgical use of cadaveric dura mater tissue, corneal transplant, and more recently whole blood 
transfusion12-14. 
 
Another example of accidental human-to-human transmission of prion disease that has been very 
intensively studied is that of the disease kuru, which caused an epidemic amongst the Fore linguistic 
group in the Eastern Highlands of Papua New Guinea.  It is thought that this was transmitted from 
person to person as a result of oral consumption of infected tissue at ritual endocannibalistic 
mortuary feasts 15. 
 
A final example of accidental transmission is that of bovine spongiform encephalopathy (BSE), which 
caused a major epidemic amongst British cattle during the 1980s and 1990s, being transmitted to 
humans and causing a novel human disease that is now known as variant CJD (vCJD)16.  This is 
discussed in detail below.  This illustrates that the diseases can be transmitted between different 
species, a fact that had previously been observed both experimentally and in accidental 
transmissions of scrapie.  Experimental transmission of prion disease to animals (particularly 
rodents) has become a mainstay of prion disease research, being used as a highly specific “bio-
assay”. The transmission of human prion diseases to experimental animals also creates uniquely 
robust animal models of human degenerative disease in which to test putative therapies, which is 
much more difficult in other conditions.  For example, efforts to produce animal models of 
Alzheimer’s disease have tended either to focus on one specific aspect of the pathophysiology (such 
as an amyloid precursor protein (APP) transgenic that exhibits some abnormal β-amyloid (Aβ) 
deposition, but no tau deposition), or elaborate double or even triple transgenics that aim to piece 
together a more complete range of clinical and pathological features17.  The extent to which these 
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models succeed in simulating the complex pathophysiological processes in the brain of a patient 
with Alzheimer’s disease, and to which observations made in these models (including the effects of 
putative treatments) will be applicable to patients is not at all clear.  An animal to whom a human 
disease has been directly transmitted and which will go on to develop a disease with the same 
constellation of pathological features seems a much more satisfactory model to use from first 
principles. 
 
PRNP, PrP and Prions 
It has become clear that the prion protein, encoded by the prion protein gene (PRNP), is absolutely 
central to the molecular pathology of all prion diseases. Early efforts to isolate the scrapie infectious 
agent from brain tissue of hamsters infected with scrapie identified a 27 – 30 kDa insoluble, 
protease-resistant protein that appeared to be present in all infectious isolates18.  A similar protein 
was also isolated from human brain tissue from patients with CJD.  Sequencing part of the primary 
amino acid structure of this protein allowed the coding nucleic acid sequence to be inferred, and this 
sequence was found in an autosomal gene, with closely homologous sequences in hamster and 
human, encoding a protein present in normal brain: the normal or cellular prion protein(PrPc)19,20.  It 
has subsequently been shown that transgenic animals that do not express the prion protein are 
entirely resistant to acquiring prion disease21, and also in more sophisticated experiments that 
“turning off” host prion protein expression after inoculation with infectious material will prevent the 
disease from progressing and may even reverse some of the pathological changes22,23.  The fact that 
all inherited prion diseases show linkage to the prion protein gene locus again suggests that this 
protein is the key molecular player in these diseases.  Understanding the prion protein gene, the 
prion protein, and the ways in which changes in this protein occur in prion disease is therefore vital 
if we are to understand the diseases themselves. 
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Figure 1.  The prion protein gene (PRNP).  This schematic shows the open reading frame of PRNP, 
with pathogenic mutations labelled in red, polymorphic variants labelled in green, and the 
octapeptide repeat section illustrated in purple. 
 
In humans the prion protein gene, on the short arm of chromosome 20, consists of two exons, the 
second of which contains the entire open reading frame for the prion protein24.  There are more 
than 30 known pathogenic PRNP mutations causing inherited prion diseases (which are reviewed 
below).  A number of non-pathogenic polymorphisms are also found in the gene.  The most 
important of these is the methionine/valine polymorphism at codon 129, which has been found to 
have a very profound modifying effect on many aspects of prion disease, including susceptibility, 
incubation times, rate of disease progression and clinicopathological phenotype1.  Other 
polymorphisms of interest include E219K, which affects susceptibility to some specific disease 
types25,26, and G127V, which has been found specifically in surviving members of the population in 
Papua New Guinea affected by the kuru epidemic, and appears to confer resistance to this disease27. 
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Figure 2.  Structure of PrPc.  This shows the predicted structure of the C-terminal portion of PrPc, 
with its associated carbohydrate molecules and GPI anchor.  
 
The normal cellular prion protein is widely expressed, with the highest concentrations in brain and in 
lymphoreticular tissues28.  It is a membrane-bound cell surface di-glycosylated protein with a 
glycosylphosphatidylinositol (GPI) anchor29, and consists of two regions, each of around 100 amino 
acids: an unstructured N-terminal portion, and a structured C-terminal portion with several alpha-
helices stabilised by a disulphide bond.  This normal form of PrP is soluble, and is sensitive to 
degradation by proteases, including proteinase K. 
 
In contrast, prion protein isolated from brain tissue of animals affected by scrapie, and from humans 
affected by prion disease (all denoted PrPSc - “PrP scrapie”) is insoluble, relatively resistant to 
digestion by proteinase K, and has a beta-sheet-rich structure and a strong tendency to aggregate30.  
The primary amino acid structure of PrPc and PrPSc are identical, so their strikingly different 
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properties are thought to be conferred by post-translational changes in the conformation of the 
protein. 
 
One of the properties of the infectious agent of prion disease that has been most challenging to 
explain is that of prion strain.  Many infectious diseases caused by micro-organisms such as bacteria 
or viruses demonstrate a strain phenomenon, whereby variations in the specific properties of the 
infectious agent and of the resulting clinicopathological disease entity are conserved on serial 
passage of the infection from one host to another.  In these diseases these strain characteristics are 
thought to be encoded primarily by variation in the nucleic acid genome of the causative organism.  
However prion diseases, caused by an infectious agent devoid of nucleic acid, also demonstrate a 
strain phenomenon.  On serial passage of infectious material derived from animals or humans 
affected by prion disease in experimental animals, such as inbred mouse lines, a number of distinct 
and consistent patterns (of incubation period, clinical features and pathological changes) may be 
seen31.  There is also variation in the biochemical properties of different PrPSc isolates, most notably 
in the banding pattern seen on Western blotting after partial digestion with proteinase K32.  There is 
a correlation between specific Western blotting signatures and specific clinicopathologically defined 
human prion strains33-35.   
 
It is thought that the strain characteristics of the prion disease infectious agent are encoded 
primarily by variation in the physical conformation of abnormally folded PrP31.  If the conversion of 
normal PrPc into disease-associated PrPSc involves a templating process, whereby the specific 
conformation of the misfolded protein is reproduced as this misfolding propagates, and this specific 
conformation confers specific pathogenic and biochemical properties, this could explain the 
conservation of prion strain characteristics.  The mechanisms by which the prion protein may take 
on multiple different abnormal conformations, how these are transferred to newly-misfolded 
proteins (even if these are proteins in a new host of a different species), and how these result in the 
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different biochemical properties of the protein and the different clinicopathological features of the 
diseases have not been determined. 
 
The human prion diseases 
Classification 
Based on our current understanding of the biology of prion disease as reviewed above, a rational 
basic scheme for classifying the human prion diseases is by aetiology.  They all involve the templated 
misfolding of PrPc into abnormal disease-associated forms, but the reason that this process begins 
varies between different disease types.  It may occur as the result of an identifiable genetic mutation 
in the prion protein gene (PRNP) (in inherited prion disease); it may be seeded by exposure to 
abnormally folded prion protein from an exogenous source (in acquired prion disease); or it may 
occur without any obvious cause, and in what appears to be a primarily random distribution (in 
sporadic prion disease).   
 
Within these groups we can sub-classify the diseases based on molecular or mechanistic factors, and 
on the basis of clinically-defined syndromes.  Historically, the latter method has predominated, with 
clinicians and pathologists observing recurring patterns of clinical symptoms, signs and 
neuropathological changes, and defining diseases on this basis (and often lending their names to 
them as eponyms).  More recently as our understanding of the molecular and mechanistic basis of 
the diseases has increased, it has been possible to use these to define disease sub-types.  Although 
these often coincide with those defined on a clinicopathological basis, this is not always the case, 
and the integration of these two approaches is not always straightforward. 
 
The classification scheme that I will use is shown in the diagram below.  Particular issues relevant to 
each aetiological disease type will be discussed in the relevant sections below.
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Sporadic prion 
disease 
Sporadic CJD 
PRNP codon 129 PrPSc Type 
MM 
1 
2 
3 
MV 
2 
3 
VV 
2 
3 
VPSPr 
PRNP codon 129 
MM 
MV 
VV 
Inherited prion 
disease 
Clinical syndrome PRNP mutation/haplotype 
Familial CJD 
E200K 
D178N 
4OPRI 
Others… 
GSS 
P102L 
A117V 
P105L 
Others… 
FFI D178N-129M 
Larger OPRI IPD 
6OPRI 
Others (7-, 8-, 9-, 10OPRI)… 
Others Y163X and others… 
Acquired prion 
disease 
Iatrogenic CJD 
Source of infection 
Pituitary hormones 
Dura mater graft 
Neurosurgical instruments 
Others… 
Variant CJD 
PRNP codon 129 Source of infection 
MM 
Bovine 
Blood-borne 
MV? 
Kuru 
Table 1. Classification scheme for human prion diseases.  Abbreviations: CJD = Creutzfeldt-Jakob 
disease; VPSPr = Variably protease sensitive prionopathy; GSS = Gerstmann-Straussler-Scheinker 
syndrome; FFI = fatal familial insomnia; OPRI = octapeptide repeat insertion; IPD = inherited prion 
disease; MM, MV and VV refer to PRNP codon 129 genotype; 1, 2 and 3 refer to PrPSc type as 
classified by Hill et al36. 
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Common features of all prion diseases 
Although there is remarkable clinical heterogeneity between different prion disease types, and 
indeed within them, there are some common features that they all share.  The diseases are all 
inexorably progressive, and ultimately fatal.  Their heterogeneity is particularly apparent in the 
earlier stages of the diseases, but they seem to gradually converge towards a more consistent 
clinical picture seen across all disease types in their final stages:  one of akinetic mutism, usually with 
rigidity and myoclonus. 
 
There are also neuropathological hallmarks of prion disease, which are seen to varying degrees in 
the post mortem brain in all disease types.  These are spongiosis, neuronal loss, deposition of 
abnormal prion protein and gliosis37,38.  The characteristics of these changes (e.g. the pattern of PrP 
deposition) vary greatly between disease types (and in fact are often used to distinguish between 
them37), but they are present in some form in all prion diseases. 
 
Sporadic prion disease 
Sporadic Creutzfeldt-Jakob Disease (sCJD) 
In terms of incidence, the most common type of prion disease is sporadic Creutzfeldt-Jakob disease.  
It occurs in around 1-2 people per million population per year in the UK, and the incidence appears 
to be similar in a wide range of populations worldwide where it has been studied, taking into 
account the varying intensity of surveillance39-44.  This results in between 60 and 100 new cases being 
diagnosed with sCJD in the UK each year (see www.cjd.ed.ac.uk for year-on-year figures).   
 
The disease typically manifests itself with a rapidly progressive neurocognitive syndrome, with the 
patient’s condition changing much more quickly than would be expected in any other 
neurodegenerative condition45.  The order in which different neurological systems are affected 
varies between different patients, leading to great heterogeneity in the early stages of the disease.  
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The most common presentation is with a rapidly progressive dementia, with physical neurological 
signs such as myoclonus and ataxia becoming more apparent as the disease progresses.  Some other 
patterns of early neurological deficit that may be seen include a predominantly visual disorder 
(known as the “Heidenhain variant”46,47, and a predominantly cerebellar disorder (known as the 
“Oppenheimer-Brownell variant”48).  A host of other less-frequently-encountered clinical 
presentations with focal neurological symptoms and signs have been reported in case reports and 
case series.  Psychiatric and behavioural symptoms are also common and have been recognised 
since the disease was first described:  these are considered in detail in Chapter 5 below.  The 
average duration of the illness from symptom onset to death is just 4 to 6 months, and in the most 
rapidly progressive cases may be only a few weeks33,35.  Atypical cases may have a less rapid 
progression and a longer duration.  Survival beyond 2 years of symptom onset is unusual, but is 
recognised in a small minority of cases.  As the rapidity of progression is often used as the “red flag” 
feature leading to consideration of the diagnosis (and indeed a duration of greater than 2 years rules 
out the diagnosis according to the WHO criteria), it is likely that atypical, more slowly progressive 
cases have been under-recognised.  This conclusion is supported by studies such as that by Bruton et 
al49 which ascertained cases by screening of archived brain tissue from patients with any history of 
dementia, and found that 8 of the 19 cases found to have the pathological changes of CJD had not 
been correctly diagnosed during life, and that most of these had an atypical clinical presentation 
with a duration of more than 3 years. 
 
Some of the factors accounting for this heterogeneity in the clinical presentation of sCJD have been 
identified, and provide valuable insights into the pathophysiology of the disease.  These include 
genetic variation in the prion protein gene, and variation in the biochemical properties of the 
abnormal disease associated prion protein (PrPSc) which can be determined by carrying out Western 
blotting of post mortem brain tissue after digestion with proteinase K (PK), and is thought to provide 
a surrogate marker for variation in prion strain36. 
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The polymorphism at codon 129 of the prion protein gene (PRNP) is very well established as both a 
determinant of susceptibility to sCJD and a modifier of the clinical presentation, including rate of 
disease progression1,50.  Individuals that are methionine/valine heterozygous at codon 129 are at a 
lower risk of developing the disease than those homozygous for either allele, and if they do then 
they tend to have a less rapidly progressive disease, and also have a different profile of clinical 
features, investigation findings and neuropathological changes34,35.  Several distinct isoforms of PrPSc 
can be found on Western blotting of PK-digested brain homogenate from sCJD patients, each 
producing a characteristic banding pattern.  Two different systems for classifying and naming these 
PrPSc types have been proposed, one based around there being two PrPSc types 33 and one proposed 
by the MRC Prion Unit36,51 in which there are 4 principal PrPSc types (see Table 2).  PsPSc type has also 
been shown to be significantly associated with specific clinical, investigational and neuropathological 
profiles34,35.   
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Type 
 as per Collinge et al. 
Type 
 as per Parchi et al. 
Prion diseases in which 
it has been found 
PRNP codon 129 
genotypes in which 
it has been found 
1 1 sCJD, iCJD MM 
2 1 sCJD, iCJD MM, MV, VV 
3 2A sCJD, iCJD MV, VV (MM rarely) 
4 2B vCJD MM 
Table 2.  Basic classification schemes for PrPSc that have been suggested by Collinge et al32,51 and 
by Parchi et al33.  The correspondence between different types in the two classification schemes 
has been the source of some controversy and may not be exact. 
 
There is an interaction between PRNP codon 129 genotype and PrPSc type, and a useful way to sub-
classify sCJD is on the basis of these two factors.  For example, Type 1 MM sCJD (i.e. a patient that is 
methionine homozygous at PRNP codon 129 and has type 1 PrPSc on Western blotting) will almost 
always have had a classical rapidly progressive sCJD phenotype, and is relatively likely to have had 
the typical investigation findings of periodic sharp wave complexes on electroencephalogram (EEG) 
and presence of 14-3-3 protein in the cerebrospinal fluid (CSF), compared with other sCJD patients34.  
Variation in neuropathological features also correlates with PrPSc type and codon 129 genotype: for 
example, Type 3 MV sCJD cases are typically found to have kuru-type plaques, particularly in the 
cerebellar cortex, while these are not seen in any other PrPSc type/codon 129 genotype combination 
of sCJD32. 
 
Age also represents a risk factor for development of sCJD, with most patients being diagnosed in 
their late fifties, sixties or seventies, and extremely few cases presenting before the age of 4052.  
Incidence appears to decline at older ages, although it is possible this is at least partly explained by 
lower rates of diagnosis in this age group due to less aggressive investigation and more frequent 
misdiagnosis as Alzheimer’s disease or another common age-associated neurodegenerative disease.  
Age also appears to act as a modifier of the clinical presentation, with a number of clinical features 
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being more common in patients with onset of disease at a younger age, and also a tendency to 
longer disease duration in younger patients53. 
 
sCJD has historically been thought of as a diagnosis of exclusion, with a focus on investigations 
looking for evidence of an alternative, reversible cause of rapidly progressive neurocognitive decline 
(such as an inflammatory, metabolic, or neoplastic process).  While it is the case that there are 
treatable conditions that may mimic the presentation of sCJD (which itself remains untreatable and 
invariably fatal) it is now usually possible to reach a positive diagnosis on the basis of clinical 
presentation and investigation findings.  Even in the absence of a disease-modifying treatment, this 
is valuable as it reduces the amount of time that is taken up with medical investigations (time that is 
extremely precious in the context of a rapidly progressive and fatal diagnosis), as well as the risks 
associated with these investigations.  For example, brain biopsy should rarely be necessary in the 
diagnosis of sCJD if patients are investigated appropriately54.  Making a timely positive diagnosis may 
also allow patients to play a more active role in planning their end-of-life care, and will allow 
patients to be enrolled into clinical studies, including therapeutic trials at an earlier stage:  issues 
related to this are discussed in detail below in Chapter 6. 
 
The criteria for diagnosis of sCJD have been formally set out by the World Health Organisation 
(WHO), and modifications have been introduced on the basis of new evidence and improved 
diagnostic technologies.  The most recently updated version of the criteria is shown in Table 3 
below.  The major change in this version was the inclusion of MRI scanning of the brain as a 
supportive investigation, which has substantial benefits for sensitivity of the criteria. 
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A. Clinical signs 
  
 
1. Dementia 
 
2. Cerebellar or visual dysfunction 
 
3. Pyramidal or extrapyramidal dysfunction 
 
4. Akinetic mutism 
  B. Tests   
  
 
1. Periodic sharp wave complexes on EEG 
 
2. Presence of 14-3-3 protein in CSF (in patients 
with a duration of less than 2 years) 
 
3. High signal abnormalities in caudate nucleus 
and putamen or at least two cortical regions 
(temporal, parietal, occipital) on DWI or FLAIR MR 
brain imaging sequences 
  Probable CJD 
  
 
Two from A and at least one from B 
  Possible CJD 
  
 
Two from A and duration less than 2 years 
   
Table 3.  Clinical diagnostic criteria for sporadic CJD, updated to include MRI brain scanning 
results.  Adapted from Zerr et al, 200934. 
 
The specific role of CSF in the diagnosis of sCJD is discussed in detail below in Chapter 3, and the 
development of new diagnostic techniques, which are not yet incorporated into the formal criteria, 
is discussed in Chapters 2 and 3. 
 
Variably protease sensitive prionopathy (VPSPr) 
In 2008, Gambetti et al55 reported 8 patients with what appeared to be a novel disease involving the 
prion protein, which they called Protease Sensitive Prionopathy.  The patients had a progressive and 
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fatal neurodegenerative disease, and on neuropathological examination of the brain were found to 
have an unusual pattern of abnormal PrP deposition. This abnormal PrP was also found to be 
predominantly protease-sensitive, in contrast to that found in sCJD, and produced a quite distinct 
pattern on Western blotting from that seen in any subtype of sCJD.  Interestingly, all 8 of these 
patients were homozygous for valine at the PRNP codon 129 polymorphism (129VV).  Subsequently, 
however, further patients have been reported, including individuals with all codon 129 
genotypes56,57.  The non-129VV individuals reported were found to have relatively protease-resistant 
abnormal PrP, although still with the same distinct banding pattern on Western blotting.  The 
disease was therefore renamed Variably Protease-sensitive Prionopathy (VPSPr). 
 
The clinical presentation in these patients was with a combination of psychiatric symptoms 
(particularly affective symptoms and alteration in behaviour), a frontal-predominant cognitive 
decline, language dysfunction, parkinsonism and ataxia56,57.  Based on the 26 cases so far reported, 
there does appear to be some effect of codon 129 on the clinical presentation, with psychiatric and 
cognitive symptoms more prominent in 129VV individuals, while motor signs predominate in the 
129MV and 129MM individuals, who may also have myoclonus, which does not seem to occur in 
129VV patients.  In comparison with sCJD, this disease tends to have a longer duration, and a 
somewhat different (though overlapping) pattern of symptoms and signs.  It has not yet been 
reported whether this disease is transmissible to experimental animals, and so it is not clear whether 
it represents a true prion disease. 
 
There are no patients with this novel disease included in the clinical studies presented in this thesis.  
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Inherited prion diseases 
Around 10 to 15% of patients presenting with prion disease are found to have a pathogenic 
mutation in the prion protein gene (PRNP), and in most cases will have a family history of a similar 
illness consistent with autosomal dominant inheritance.  More than 30 pathogenic mutations have 
been identified24, although a relatively small number of these account for the majority of cases of 
inherited prion disease seen in practice.  The pathogenic mutations are either nonsense point 
mutations causing a single amino acid substitution (or rarely a premature stop codon resulting in a 
truncated protein), or insertion mutations causing expansion of the octapeptide repeat section of 
the protein.  The mutations are fully penetrant, apart from a few exceptions that are discussed 
below. 
 
The clinical phenotype of inherited prion disease is remarkably variable, and several distinct 
clinicopathological diseases were described prior to the demonstration that they were all caused by 
mutations in the same gene.  These canonical IPD syndromes are familial CJD, Gerstmann-Straussler-
Scheinker syndrome (GSS), and Fatal Familial Insomnia (FFI).  In addition it is now clear that some of 
the relatively common PRNP mutations (the octapeptide repeat insertions with 5 or more additional 
repeats) typically cause a relatively slowly progressive disease dominated by cognitive decline, which 
is quite distinct from the 3 canonical clinical syndromes58,59.  There are clear genotype/phenotype 
relationships, with particular PRNP mutations tending to cause particular clinical syndromes, 
although these relationships are not absolute and quite distinct clinical presentations are sometimes 
seen in different affected members of a single pedigree.  As in sCJD, the codon 129 polymorphism of 
PRNP acts as an important modifier of the phenotype in a number of the inherited prion diseases.  
The major clinical phenotypes of inherited prion disease are reviewed below. 
 
The diagnosis of inherited prion disease requires the presence of a pathogenic mutation in PRNP to 
be demonstrated in a patient with a compatible clinical presentation.  The clinical investigations 
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used to diagnose sCJD (presence of signal change on brain MRI, periodic sharp wave complexes on 
EEG, 14-3-3 protein in the CSF) may be abnormal in IPD, particularly familial CJD, but are less 
sensitive than in sCJD, and are largely made redundant by the highly sensitive and specific molecular 
test. 
 
As the genetics of inherited prion disease are now well understood, and a reliable molecular test is 
available to make the diagnosis, patients are often diagnosed at an earlier stage of their disease, and 
there is the potential for relatives that are at risk of carrying a pathogenic mutation to receive 
genetic counselling and to consider having a predictive genetic test. 
 
Familial CJD 
Some patients with a clinical presentation indistinguishable from that of sCJD have a pathogenic 
mutation in PRNP causing their illness.  The most common pathogenic PRNP mutation worldwide, 
E200K, usually causes a familial CJD phenotype.  It is unusual in that the age of disease onset can 
vary widely within a single pedigree, and some individuals carrying the mutation may reach old age 
(>80 years) without developing the disease60.  Another relatively common mutation, D178N, is 
subject to phenotype modification by the codon 129 polymorphism:  individuals with a 129V-178N 
haplotype will usually present with familial CJD, while a 129M-178N haplotype was found in the 
Italian pedigree in which FFI was first described61: this is reviewed below.  The smaller octapeptide 
repeat insertion mutations (most commonly 4-OPRI), also cause a familial CJD phenotype, although 
their inheritance is more complex as it appears that the mutation is only penetrant in the presence 
of a susceptibility haplotype on the wild type allele62.   Other mutations causing a CJD phenotype 
that are less commonly encountered in the UK include V210I63 and E211Q64. 
 
If compared on a group basis, there are differences between the clinical presentation of sCJD and 
familial CJD:  familial cases are younger, have longer disease duration, and are more likely to have 
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seizures, but on an individual basis it is not possible to distinguish on purely clinical grounds65.  
Although a convincing family history will often be given, the lack of full penetrance in some of the 
mutations causing familial CJD, combined with the commonly encountered issues of lack of an 
adequate family history or non-paternity, mean that it is not a rare occurrence to find a pathogenic 
PRNP mutation in a patient with apparently sporadic disease.  This is one reason why PRNP 
genotyping tends to be routinely offered to all patients with prion disease. 
 
Gerstmann-Straussler-Scheinker syndrome (GSS) 
The most common PRNP mutation in the UK is P102L, which causes GSS, a syndrome characterised 
by progressive ataxia and cerebellar dysfunction with relative preservation of cognitive function 
during the early stages of the disease.  Patients with GSS will often become so physically disabled by 
ataxia and dysarthria that cognitive testing becomes very difficult to perform before they have 
developed a marked dementia, although this does occur as the disease progresses.  There is a very 
large UK pedigree affected by the P102L mutation which has been extensively studied66.  Other 
mutations that cause GSS and which are encountered in the UK include P105L67 and A117V68.  The 
onset of GSS is typically at an earlier age than sCJD, and is influenced by the codon 129 
polymorphism:  MM patients typically develop symptoms between 35 and 50, while MV patients 
typically do so between 45 and 6066. The disease duration in GSS from onset of symptoms to death is 
variable, but the average is around 5 years66,69. 
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Fatal Familial Insomnia 
Fatal Familial Insomnia was first described in an Italian pedigree with a D178N mutation in PRNP61,70.  
The clinical syndrome in these patients consisted of intractable insomnia as the predominant early 
symptom, followed by autonomic dysfunction, myoclonus, spasticity and cerebellar dysfunction, and 
appeared to be quite distinct from the CJD-like illness of previously described carriers of this 
mutation. They were also found to have more dramatic and focal pathological changes (neuronal 
loss and gliosis) in the thalamus.  In contrast with previously described D178N cases, it was found 
that the affected individuals in this pedigree had a D178N mutation sharing a PRNP allele with 
methionine at codon 129, and it was suggested that the codon 129 polymorphism was having a 
dramatic modifying effect on the phenotype of the mutation61.  Since then the same mutation has 
been found in other patients and pedigrees, including in the UK, and the haplotype-genotype 
relationship seems to be less clear than initially thought.  Many patients with the 129M-178N 
haplotype have presented with a more CJD-like illness71-74.  Insomnia has also been increasingly 
recognised in other prion disease types (both sporadic and inherited), so that most patients with 
sleep disturbance as a presenting symptom of prion disease in fact have sporadic disease and do not 
carry the FFI mutation haplotype75.  Some have therefore suggested the existence of a “Sporadic 
Fatal Insomnia” syndrome, mimicking that of FFI but in the absence of a causative mutation.  It 
seems likely that there are unknown phenotypic modifiers accounting for these observations, and 
that the phenotypic spectra of the different pathogenic mutations/haplotypes overlap. 
 
Large octapeptide repeat insertion inherited prion disease (>4-OPRI) 
Whereas insertion of 4 additional octapeptide repeats results in a CJD-like illness as described above, 
larger insertions tend to produce a more slowly progressive disease with cortical dementia as its 
major manifestation, although again there is considerable phenotypic variability.  The best 
characterised of these is the 6-OPRI mutation: this affects a large kindred in the UK that has been 
extensively studied58,76, and has also been identified in a number of other independent kindreds77-80.   
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5-OPRI, 7-OPRI, 8-OPRI and 9-OPRI mutations have also been identified in patients with a broadly 
similar clinical phenotype81-84.  The most common clinical phenotype in these patients is of a slowly 
progressive dementia with prominent apraxia and early behavioural and psychiatric features, 
combined with relatively mild physical manifestations which may include ataxia, myoclonus, 
pyramidal and extrapyramidal features, dystonia and chorea.  In clear contrast with the typical GSS 
phenotype, patients may remain independently mobile and physically able until a stage when they 
have very marked cognitive impairment.  Disease durations may be up to 20 years or more, and age 
of onset is younger than in other forms of IPD, often in the third or fourth decade of life.  There is a 
clear effect of the codon 129 polymorphism on the age of onset in the large UK 6-OPRI kindred, with 
129MV individuals developing symptoms on average around 10 years later than 129MM 
individuals58. 
Y163X Inherited Prion Disease 
A very unusual familial disease affecting a kindred in Eastern England has recently been shown to be 
caused by a truncation mutation of PRNP: Y163X85.  The clinical phenotype is characterised by a very 
long “prodrome” of chronic diarrhoea, followed by development of a predominantly sensory 
peripheral polyneuropathy, autonomic dysfunction, and a slowly progressive dementia with 
seizures.  Pathologically there is remarkably widespread deposition of PrP amyloid, including in the 
gastrointestinal tract and peripheral nerves.  This truncation mutation results in loss of the GPI 
anchor that usually attaches PrP to the cell surface, which may account for the very unusual 
distribution of pathological amyloid deposits in this disease, and for its very unusual clinical 
phenotype. 
 
Acquired prion diseases 
Kuru 
During the 1950s, it was observed that specific tribes living in the highlands of Papua New Guinea 
(the Fore linguistic group) were affected by an epidemic of a progressive and fatal neurological 
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disease, particularly affecting females and young males86.  This disease was characterised by a 
progressive cerebellar syndrome, associated with tremor, choreiform and athetoid movements, and 
affective symptoms including emotional lability, but without a marked dementia until the late stages 
of disease.  It was observed that the practice of endocannibalistic ritual mortuary feasts, which was 
common among the Fore, might provide a route of transmission of this disease through the 
population.  In particular the specific customs regarding which individuals would consume specific 
body parts seemed to provide a plausible explanation for the distribution of the disease in the 
population.  This disease, Kuru, was found to be transmissible by inoculation of brain homogenate 
from affected individuals into primates87, and similarities between the neuropathological changes 
seen in kuru and in scrapie, as well as in various aspects of their clinical and epidemiological 
features, were noted88. 
 
The incidence of kuru has declined, with no cases occurring in younger individuals, consistent with 
cessation of cannibalism by 196089.  However, older individuals that were presumably exposed prior 
to this, did continue to develop the disease, with some new cases arising even after 2000, suggesting 
incubation periods of more than 40 years (and, taking into account the age at which male children 
stopped participating in endocannibalism, probably more than 50 years)90.  Study of this epidemic 
human prion disease has been extremely informative, with potentially great relevance to the vCJD 
epidemic in the UK which is discussed below.  In particular, comparing individuals that developed 
kuru with those that did not develop the disease despite being exposed, and comparing those with 
short and very long incubation periods has led to various important observations, particularly 
related to the genetics of this disease.  It appears that codon 129MM homozygous individuals were 
most susceptible to kuru, to the extent that the part of the Fore population with this genotype were 
almost “exhausted” by the epidemic, with few 129MM adults found amongst groups who had lived 
through the epidemic86.  Some 129MV and 129VV individuals did also develop kuru, but they 
appeared to be less susceptible and to have longer incubation periods, with the majority of very late 
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cases being heterozygous91.  PRNP genotyping in the population of Fore that had survived the kuru 
epidemic also identified a novel genetic variation, G127V, which has not been found in any other 
population92.  This appears to be protective against infection, and as a result has been subject to 
strong natural selection in areas affected by kuru and become much more common in those areas 
than in unaffected areas nearby.  
 
Iatrogenic CJD 
Transmission of a prion disease from one person to another as a result of medical intervention was 
first reported in 1974 in a patient who had received a cadaveric corneal graft from a patient that had 
died of pathologically confirmed CJD: the recipient developed symptoms of CJD 18 months after the 
transplant93.  Subsequently, small numbers of cases of transmission by implanted intracerebral 
electrodes and neurosurgical instruments have been reported10.  In these cases the clinical disease in 
the recipient seemed to closely resemble classical sporadic CJD, as described above.   
 
Much more numerous have been cases resulting from injection of cadaveric pituitary hormones, or 
surgical grafting of cadaveric dura mater tissue.  In both cases the pooling of cadaveric tissues from 
multiple different donors (thousands in the case of pituitary hormones), presumably including one or 
a very small number derived from individuals with a sporadic or inherited prion disease, seems to 
have resulted in many individuals being infected.   
 
Dura mater related iatrogenic CJD has been particularly common in Japan, and the vast majority of 
cases have occurred in patients receiving grafts from a single manufacturer94.  Again the clinical 
presentation of these patients seems to be very similar to those with sporadic CJD.   
 
In the case of recipients of cadaveric human growth hormone injections, approximately 1 in 100 
individuals receiving the relevant product are thought to have developed clinical CJD95, although 
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calculating the numbers exposed to the specific products known to pose a risk is not simple, and the 
risk may be as much as 6%96.  This is clearly far more than would be expected in the general 
population, providing compelling circumstantial evidence that the hormone injections are 
responsible.  Most cases of human growth hormone related iatrogenic CJD have occurred in France, 
the UK and the USA12, and new cases have continued to arise in the UK in the last few years (such as 
those included in the clinical data presented in this thesis).  This suggests incubation periods for this 
disease of 20 years or more, as use of the implicated cadaveric hormone preparations ceased in the 
mid 1980s12.  The clinical presentation of these cases often consists of a predominantly cerebellar 
syndrome initially, with dementia as a relatively late feature compared with classical CJD.  Some 
have observed that this has similarities with the clinical course of kuru (see above), and speculated 
that this may relate to the fact that both diseases result from peripheral exposure to infectious 
material of human origin, rather than direct inoculation into or onto the brain. 
 
Variant CJD 
During the 1980s an epidemic of bovine spongiform encephalopathy, a prion disease of cattle, 
developed in the UK97.  As it was known that this disease was transmissible, that prion diseases could 
be transmitted from one species to another, and that a very large number of people had potentially 
been exposed to material from cattle incubating the disease, this raised concerns that the disease 
might be transmitted to humans.  This prompted enhanced surveillance of clinical cases of prion 
disease in the UK.  In 1995 and 1996 the first cases of what appeared to be a new variant of prion 
disease were reported98-100, and in the following years increasing numbers of patients with the same 
novel clinicopathological presentation were identified.   
 
What became known as variant CJD (vCJD) was distinguished from sCJD in a number of ways.  
Patients were younger, with an average age at death of 26, and in subsequent years a clear bimodal 
age distribution of prion disease emerged.  Disease duration was longer, with an average of 14 
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months.  The clinical features and progression also appeared to be different, with patients often 
presenting with prominent psychiatric symptoms in the early stages of disease, before developing 
frank cognitive decline, neurological impairments and involuntary movements101,102.  The 
pathological features of this new disease were also distinct from those of sporadic CJD, with 
characteristic “florid plaques” of abnormal PrP in brain tissue99, and also a wider distribution of 
abnormal PrP deposition in the body, including lymphoreticular tissues such as the palatine tonsils, 
spleen and appendix103. 
 
vCJD also has a different profile from the other prion diseases in its typical clinical investigation 
findings.  A characteristic pattern of abnormality on brain MRI, with T2/FLAIR hyperintensity in the 
posteromedial thalamus (known as the pulvinar sign), has proved to be a useful diagnostic marker 
with a high level of specificity in the appropriate clinical context104.  In contrast with sCJD, the 
presence of 14-3-3 protein in the CSF is less commonly seen, and periodic sharp waves on EEG 
generally do not occur in vCJD105. The presence of abnormal PrP in peripheral lymphoreticular tissues 
allows tonsil biopsy to be used to make a tissue diagnosis without the need for brain biopsy: both 
PrP immunohistochemistry and Western blotting after protease K digestion can be applied to 
tonsillar tissue, with highly specific appearances in vCJD106. 
 
Diagnostic criteria based on these distinctive clinical and pathological features were established, and 
have been used for ongoing surveillance105,107.  These stipulate criteria for diagnosing “probable 
variant CJD” and “definite variant CJD”, the latter requiring neuropathological examination of brain 
tissue (either from biopsy or post mortem). 
 
The question of whether this newly identified clinicopathological syndrome was the result of 
transmission of BSE to humans was addressed in a number of ways.  Western blotting of brain tissue 
from individuals that had died of variant CJD, after digestion with protease K, produced a banding 
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pattern different from any previously described cases of sCJD, but similar to that produced by BSE 
brain tissue51.  It was found that macaque monkeys inoculated with BSE tissue developed florid 
plaques108.  Transmission studies in transgenic mice expressing human or bovine PrP found that 
innocula derived from BSE and vCJD brain tissues had very similar transmission properties, in terms 
of incubation period, and the nature and distribution of pathological changes, and that these were 
distinct from any sCJD-derived innocula109.  This suggested that BSE and vCJD were both caused by 
the same prion strain.  Taken together, all of this has provided widely accepted evidence that vCJD is 
caused by cross-species transmission of BSE. 
 
The number of patients diagnosed with vCJD in the UK continued to increase each year until 2000, 
and since then has gradually decreased.  In total, 177 cases of probable or definite vCJD have been 
diagnosed in the UK (www.cjd.ed.ac.uk), as well as small numbers in 11 other countries110.  In total 
around 200 individuals are thought to have reached criteria for a diagnosis of probable or definite 
vCJD worldwide. 
 
All of those cases formally classified as probable or definite vCJD have been homozygous for 
methionine at the codon 129 polymorphism of PRNP110.  This suggests that codon 129 plays a very 
strong role in determining susceptibility to vCJD.  However, it is possible that, as seen in kuru, non-
MM vCJD cases have substantially longer incubation periods and have not yet presented.  
Alternatively, codon 129 might have a significant phenotype-modifying effect, as seen in some of the 
inherited prion diseases, so that non-MM vCJD would not present with clinicopathological features 
that would meet the current diagnostic criteria.   A single case has been reported of an individual 
heterozygous at codon 129 in whom vCJD was the likely clinical diagnosis111, and in fact the clinical 
presentation and investigation findings were quite typical, as was his age.  This patient did not 
undergo tonsil or brain biopsy or post mortem examination, so a pathological diagnosis could not be 
made. 
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3 individuals with clinical vCJD had previously received non-leucodepleted red cell blood transfusions 
from donors who had themselves gone on to develop clinical vCJD, suggesting that they may have 
been infected with blood-borne prions.  These 3 patients were all MM homozygotes at codon 129.  
One further implicated blood transfusion recipient, who was heterozygous at codon 129, died of 
non-neurological disease but was found post mortem to have vCJD-type PrPSc deposition in the 
spleen and in one lymph node, but not in the brain112.  Spleen tissue from this individual has 
subsequently been shown to be infectious, transmitting disease to susceptible mice with similar 
transmission characteristics and neuropathology to equivalent tissue from 129MM “primary” vCJD 
patients113.  Another codon 129 heterozygote who was a haemophiliac and had received a large 
amount of plasma products, as well as some blood transfusions, was also found to have PrPSc 
deposition in the spleen after dying of an unrelated non-neurological disease, but the brain was not 
available for study114.  Issues related to blood-borne infectivity in vCJD are discussed in further detail 
in Chapter 2 below. 
 
In light of the potentially widespread exposure to BSE-infected material, and the possibility of very 
long incubation periods or chronic asymptomatic carrier states, attempts have been made to 
estimate the prevalence of asymptomatic vCJD infection in the UK population.  As PrPSc is known to 
be present in tonsils and appendix in vCJD patients103, including in appendix tissue removed prior to 
the onset of symptoms115,116, large archives of these tissues that have been surgically removed and 
stored have been examined to look for evidence of PrPSc.  Several studies of this type have been 
performed. The largest and most recent, based on 32,441 appendix samples, found evidence of 
abnormal PrP deposition on immunohistochemistry in around 1 in 2000 (95% confidence interval 
1248 to 3546)117.  The 16 positive samples were genotyped and found to include all codon 129 
genotypes.  If correct, it is not clear how this prevalence can be reconciled with the very low 
prevalence of clinical vCJD:  it may be that there is a relatively prevalent asymptomatic carrier state 
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with only a very small minority going on to develop neurological disease.  The possibility of a latent 
epidemic of individuals with much longer incubation periods cannot be entirely discounted, and 
experience from the study of kuru provides a precedent for longer incubation periods in non-MM 
individuals118.  However, the results of the appendix archive prevalence study would suggest that 
there are more than 10,000 MM homozygous individuals in the UK asymptomatically carrying the 
disease, and as this is the only established strong susceptibility factor for developing symptomatic 
disease, codon 129 certainly cannot explain this discrepancy.  A critical complimentary study, 
examining a similar archive of appendix samples that were removed prior to the appearance of BSE 
in the UK in order to show that the abnormalities seen are likely to be related to BSE exposure, is 
currently underway. 
 
The NHS National Prion Clinic 
The NHS National Prion Clinic offers specialist clinical assessment and follow-up for all cases of 
suspected prion disease in the UK.  In 2004, a national referral system for prion diseases was set up.  
All UK neurologists were asked by the Chief Medical Officer to refer all patients with suspected prion 
disease jointly to the National CJD Research and Surveillance Unit (based in Edinburgh) and to the 
NHS National Prion Clinic.  In addition to increasing access to specialist clinical care and improving 
surveillance, this also aimed to provide opportunities for large-scale clinical research.  This is one of 
the major roles of the National Prion Clinic.  The two major clinical research studies that have been 
carried out at the National Prion Clinic over the last 10 years are described in the following section.  
In addition to being an NHS specialist clinic, it forms part of the Medical Research Council (MRC) 
Prion Unit.  This allows the clinical research carried out through the National Prion Clinic to be 
closely integrated with the basic science research carried out at the MRC Prion Unit.   
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The PRION-1 trial and the National Prion Monitoring Cohort study 
Following promising results from work on inhibition of prion replication in vitro, the widely used 
anti-malarial drug quinacrine was proposed as a potential therapeutic agent in human prion 
disease119.  As its safety profile was already well established, it was felt that a clinical trial could be 
planned rapidly, and the Department of Health asked the MRC Prion Unit and National Prion Clinic to 
do this.  The resulting clinical trial, PRION-1, was an open-label, patient preference trial of quinacrine 
for all types of human prion disease, which recruited patients from 2001 to 2008 120.  In total the trial 
enrolled 107 patients with prion disease.  40 patients received quinacrine during the trial follow-up 
period.  Although an option for randomisation to immediate or delayed quinacrine was included in 
the trial design, only 2 patients chose to be randomised, and so the trial was essentially an 
observational study comparing patients who chose to take quinacrine with those that chose not to.  
Patients with moderately advanced disease at enrolment proved to be more likely to choose 
quinacrine than those in the early or late stages of disease, confounding the effect of quinacrine 
treatment on mortality, which was the primary endpoint.  When disease severity at enrolment was 
adjusted for, there was no significant effect of quinacrine treatment on survival.  Subsequent 
analysis of data collected using a battery of rating scales also showed no significant effect of 
quinacrine when adjusted for severity of disease at enrolment121.  This rating scales data is discussed 
in detail in Chapter 6 below. 
 
Following on from the PRION-1 trial, the National Prion Clinic has been running a large scale 
observational study which aims to enrol all patients with prion disease in the UK: the National Prion 
Monitoring Cohort.  This includes all cases of probable or definite sporadic Creutzfeldt-Jakob disease 
(sCJD), variant CJD (vCJD), iatrogenic CJD (iCJD), and inherited prion disease (IPD).  Also eligible for 
enrolment are asymptomatic individuals known to be at risk of inherited prion disease (tested 
asymptomatic gene mutation carriers or untested first degree relatives of those with a confirmed 
pathogenic PRNP mutation), or vCJD (recipients of implicated whole or leucodepleted blood 
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transfusion that have been notified of their risk by the Health Protection Agency).  A small group of 
healthy controls were also recruited (friends or relatives without pathogenic PRNP mutations or 
other known risk factors). 
 
The over-arching aim of the Cohort study is to prepare for future clinical trials in prion disease, and 
to maximise the chances that a trial will be able to demonstrate any beneficial effect from putative 
therapeutic agents.  By building up a large, detailed natural history data set from a cohort of patients 
followed up using a “trial-like” study protocol, the Cohort aims to provide a historical control group 
that will help to overcome the challenge of recruiting sufficient numbers of patients with these rare 
diseases to achieve the necessary statistical power for a robust clinical trial.  Another major aim is to 
develop and validate good clinical outcome measures for use in future prion disease clinical trials, as 
it was clear from the experience of PRION-1 that neither mortality, nor any of the rating scales 
commonly used in clinical trials for other neurological conditions performed well in a prion disease 
population.  I took primary responsibility for this aspect of the Cohort study and this project is 
presented in Chapter 6 below, where these issues are discussed in detail. 
 
In addition to these primary aims, the National Prion Monitoring Cohort also provides 
unprecedented opportunities for prospectively studying a variety of clinical aspects of the prion 
diseases in a large cohort of patients across the range of different types of prion disease.  I took 
advantage of this to carry out a comprehensive study of the behavioural and psychiatric features of 
the prion diseases, which is presented below in Chapter 5. 
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CHAPTER 2.  DEVELOPING NEW APPLICATIONS FOR THE DIRECT DETECTION 
ASSAY AS A BLOOD TEST 
Introduction 
The need for new non-invasive diagnostic tests for prion disease 
Diagnosis of the sporadic and acquired human prion diseases, as formalised in diagnostic criteria 
used internationally for surveillance purposes34,105 relies on identifying typical patterns of clinical 
features combined with supportive investigation findings (presence of 14-3-3 protein in the 
cerebrospinal fluid (CSF), periodic sharp wave complexes on electroencephalogram (EEG) or typical 
patterns of signal change on magnetic resonance imaging (MRI) of the brain) to reach a “Probable” 
diagnosis.  Large scale studies have shown that this results in a diagnostic specificity of only 71% for 
sporadic CJD 34, while for variant CJD specificity seems to be much higher105.  A “Definite” diagnosis 
of sporadic CJD can only be reached by confirming the presence of typical neuropathological 
changes (spongiosis, astrogliosis and deposition of abnormal prion protein (PrP) in a characteristic 
pattern) in brain tissue obtained either at autopsy or biopsy.  In the case of variant CJD (vCJD) it is 
possible to demonstrate the presence of abnormal protease-resistant PrP in lymphoid tissue from 
the palatine tonsils obtained at biopsy106. 
 
In practice, the current diagnostic process results in most patients being diagnosed at a late stage of 
disease, and the overwhelming majority of patients die without a “Definite” diagnosis being made.  
This delay in diagnosis has a major impact on patients and carers as most of the disease course is 
taken up with diagnostic uncertainty and multiple investigations, and also represents a major barrier 
to the design of therapeutic trials in prion disease.  None of the non-invasive investigation findings 
listed above are entirely specific for prion disease, and the development of a non-invasive test 
allowing accurate, early diagnosis of prion disease would have a major clinical impact. 
 
 39 
Blood-borne prion infectivity 
Following the emergence of vCJD in the UK during the 1990s, efforts were made to identify 
recipients of transfused blood that had been donated by individuals who subsequently went on to 
develop clinical vCJD.  By 2006, 66 such recipients had been identified, of whom 26 were still alive.  2 
of these recipients had already been diagnosed with vCJD, while a third was found to have abnormal 
prion protein in lymphoid tissue at autopsy but did not have symptoms of the disease when they 
died13.  Since then, one further member of this at risk group has also developed vCJD14.  This strongly 
suggests that these individuals have been infected with blood-borne vCJD prions, present in blood 
donated by individuals that were asymptomatic at the time of donation.  This raises major public 
health concerns about the safety of blood transfusion in the UK, where the number of people 
asymptomatically incubating vCJD remains unknown but may be as high as 1 in 2000 based on 
recent studies examining archived appendix tissue117. 
 
The presence of blood-borne infectivity in vCJD also raises the possibility of a blood-based test for 
the condition, if this infectivity and/or associated disease-specific factors could be directly detected.  
In addition to providing a non-invasive diagnostic test, this might have the potential to allow 
detection of infectivity in donated blood from individuals in the asymptomatic incubation period of 
vCJD:  the reported cases of blood-borne transmission involved blood donated several years prior to 
symptom onset, implying that circulating prions are already present at this stage. 
 
Efforts to detect disease-associated PrP in blood 
Existing laboratory diagnostic techniques (such as high sensitivity Western Blotting after digestion 
with protease K) failed to demonstrate the presence of disease-specific PrP species in blood from 
patients with vCJD103, so a new technique was needed.  As the concentration of prion/abnormal PrP 
in blood is likely to be very low based on estimates derived from rodent transmission studies122,123, 
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while normal PrP is relatively abundant in blood, a major challenge was to find ways of detecting 
these extremely small amounts, or of concentrating them to allow detection. 
 
In recent years a number of novel molecular techniques for the detection and/or amplification of 
disease-associated PrP species have been developed, and efforts have been made to adapt and 
apply these as blood tests.   
 
Approaches based on the Protein Misfolding Cyclic Amplification (PMCA) technique124, whereby the 
templated misfolding of PrPc is seeded by a test sample containing misfolded PrP and the 
accumulated misfolded protein is then detected, have shown some promise.  Quaking Induced 
Conversion (QuIC), a modified form of PMCA, combined with an immunoprecipitation step has been 
shown to detect extremely small amounts of brain-derived disease-associated PrP when vCJD brain 
homogenate is diluted into human plasma in work published by Orrú et al125. Up to 1014-fold 
dilutions (that would be estimated to contain only a few attograms of abnormal PrP per ml), could 
be differentiated from dilutions of non-prion disease brain homogenate.  The technique was also 
able to distinguish between serum and plasma taken from scrapie-infected hamsters (including one 
in the “preclinical” stage between inoculation and the onset of manifest neurological dysfunction) 
and that taken from uninfected hamsters.  However, at the time of publishing this work the authors 
had not had access to vCJD patient samples and so had not been able to assess the functioning of 
this assay in the actual analyte in which it might be applied as a clinical diagnostic test. 
 
Other techniques have been evaluated and shown some usefulness in identifying non-human 
animals infected with prion disease.  For example, using an anti-PrP capture antibody bound to a 
glass surface, a fluorescent-tagged detection antibody and then a scanning laser microscopy method 
to detect intensely-fluorescing targets, Bannach et al126were able to differentiate between plasma 
taken from scrapie-infected sheep and that from control sheep in a small study.  However, again no 
 41 
application of this technique to human vCJD patient samples has been published. 
 
A major challenge to this area of research is the scarcity of blood samples from patients with vCJD.  
Validation of a diagnostic assay would usually involve testing of a very large panel of disease and 
control samples, but this is not possible for vCJD, of which there have only ever been around 200 
clinical cases.  
 
The UK National Institute for Biological Standards and Control (NIBSC) CJD Resource Centre has 
proposed a step-wise framework by which putative blood-based diagnostic tests for vCJD may be 
evaluated:  this is made available at http://www.nibsc.ac.uk/pdf/CJDtest-draft1.pdf (link active as of 
8/11/13). It is based on the assumption that a successful assay would be able to detect, firstly, 
infected human brain and spleen diluted into plasma; secondly, scrapie-infected sheep plasma; and 
finally, human vCJD patient plasma.  They have also assembled an archive of relevant biological 
samples, including vCJD patient plasma samples, and access to these is granted by an expert 
committee based on an initial submission from the developers and the assay’s performance in each 
step of the process.   
 
Publications arising from this process have not given full details of the assay methodologies being 
evaluated, because of “commercial-in-confidence” issues (the possibility of large scale applications 
to blood transfusion safety brings with it potential commercial value).  One paper presented the 
performance of 6 different assays in testing the same panel of plasma samples, some spiked with 
varying dilutions of vCJD and control human brain and spleen, but not including any real vCJD patient 
samples127.  It concluded that some of these showed potential as blood-based diagnostic tests, as 
they detected vCJD tissue homogenates diluted down to concentrations thought to be similar to, or 
lower than, that of infectivity in patient blood.  A subsequent paper presented the results from 
evaluation of a single assay in all stages of the process, showing that it performed well in detecting 
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diluted brain and spleen homogenate in plasma, but had poor sensitivity for scrapie-infected sheep 
plasma and failed entirely to detect real vCJD patient plasma128.  
 
While the thinking behind this strict step-wise approach is understandable, and the aim of protecting 
the scarce resource of patient samples is entirely appropriate, the assumption that a single assay will 
be able to perform in the three different stages of the process, without any opportunity for 
empirical re-optimisation in each new analyte, may be questionable.  In particular, it may be that 
disease-associated PrP species present in brain or spleen homogenate will behave quite differently 
from those present endogenously in patient plasma samples (for example, as a result of differences 
in their conformation, their immediate biochemical environment and associated molecular species, 
or interactions with other molecular and cellular constituents of these analytes, or any combination 
of these). 
 
Through its close association with the National Prion Clinic, which has been involved in the clinical 
care of many patients with vCJD in the UK, the MRC Prion Unit has built up an archive of blood 
samples from patients with vCJD (as well as other prion disease types), which provides unrivalled 
opportunities for the development of diagnostic assays.  In the following sections, I will describe the 
development of the Direct Detection Assay at the MRC Prion Unit.  This is the only putative blood-
based vCJD diagnostic assay that has been shown to successfully detect vCJD patient samples in a 
masked sample panel129, and it forms the basis of the work presented in this chapter and in chapter 
3. 
 
Binding of prions to steel 
An early clue that human prion diseases were transmissible came from the observation that several 
patients exposed to metallic neurosurgical instruments or intracerebral electrodes previously used 
on patients with CJD went on to develop CJD themselves10,11.  This led to the observation that prions 
 43 
bind avidly to metal surfaces, including that of surgical steel130.  This property of prions has 
subsequently been used as the basis for a variety of novel laboratory techniques. 
 
These include the “Standard Steel Binding Assay” developed by members of the Molecular 
Diagnostics group at the MRC Prion Unit131, in which steel wires are used to transfer infectivity from 
mouse brain homogenate to a prion-susceptible cell culture. 
This prompted the investigation of steel as a capture matrix to bind and concentrate the abnormal 
PrP species in vCJD patient blood, which in turn led to the development of the Direct Detection 
Assay. 
 
The Direct Detection Assay 
The Direct Detection Assay (DDA) uses steel powder to capture disease-associated PrP-containing 
species from whole blood. These are then detected using an adapted enzyme-linked immunosorbent 
assay (ELISA) process.  The weak ferromagnetism of steel powder allows a magnet to be used to 
capture the steel during wash steps.  The assay also includes a heat shock step prior to incubation 
with the primary (PrP-binding) antibody, which aims to increase epitope availability.  The full details 
of the method are described under Materials and Methods below. 
 
Significantly, the assay does not include any protease treatment of the samples, so does not rely on 
the protease-resistance of some disease-related abnormal PrP in the same way as other established 
diagnostic assays.  As the anti-PrP antibody used in the assay does not bind preferentially to 
abnormally-folded PrP relative to normal cellular PrP132, the disease-specificity of the assay seems to 
be the result primarily of the avid steel-binding properties of the disease-associated PrP-containing 
species relative to normal cellular PrP. 
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A number of observations from the development of the DDA are of particular relevance to 
understanding its performance in different circumstances, and therefore to its development for 
further applications. 
 
Early work on the assay used blood from experimental animals (mice and hamsters) and human 
blood from normal healthy UK blood donors ‘spiked’ with brain homogenate from patients.  It 
became clear from this work that the optimum conditions for performance of the assay varied 
considerably in different circumstances.  Blood from mice infected with the RML prion strain could 
be differentiated from control mouse blood when diluted 1:10 prior to steel capture (but not when 
diluted 1:1 or 1:100), while blood from hamster infected with Sc237 prion strain could be detected 
at 1:1 dilution (but not 1:10 or 1:100) (unpublished data - see Figure 3).   
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A)  
B)  
Figure 3.  A) Differentiation of Sc237-infected hamster blood from controls at clinical end point of 
disease using DDA.  Primary antibody ICSM 18B.  B) Differentiation of RML-infected Tg20 mouse 
blood from controls at clinical end point of disease.  Primary antibody ICSM 10B.  Assay conditions 
and reagents in both experiments as per the standard protocol described in the “Materials and 
methods” section of this chapter below except for primary antibody in (B).  Data and images kindly 
provided by Dr Graham Jackson and Dr Julie Edgeworth, who carried out these experiments. 
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In experiments using normal human blood spiked with brain homogenate, a spiked-blood:DDA 
capture buffer dilution of 1:1 produced results showing differentiation between a dilution of 10-10 
vCJD homogenate and 10-6 normal homogenate (see Figure 4), suggesting that the assay was 
successfully detecting <40fg of abnormal PrP.   
 
Figure 4.  Reproduced from Edgeworth et al, 2011129.  Differentiation of vCJD brain homogenate 
diluted into normal human whole blood.  Bars show the mean of six replicates and are expressed 
relative to the cutoff value (three SDs greater than the mean chemiluminescent signal for a normal 
brain sample; dashed line).  Error bars show SDs.  *Two-tailed, unpaired t test.  The “spiked” blood 
was diluted 1:1 into the DDA capture buffer.  Conditions otherwise as per the standard DDA 
protocol described below. 
 
However, when the assay was subsequently applied to real patient samples, it was found that 
differentiation of vCJD patients from controls could only be achieved with a 1:100 dilution prior to 
capture (see Figure 5). 
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Figure 5.  Effect of dilution of blood into DDA capture buffer on differentiation between vCJD 
patient and normal control human whole blood samples.  Standard DDA protocol as described 
below in “Materials and methods” section used, apart from variations in dilution.  
 
Potential reasons for this variation in performance of the assay in different circumstances are likely 
to fall into two categories:  factors relating directly to the disease-specific PrP-containing species 
itself, and factors relating to other constituents of the analyte.  The former category would include 
prion strain characteristics, PrP conformation and epitope availability, aggregate size, characteristics 
of non-PrP constituents of the disease-specific PrP-containing species; the latter would include the 
presence of other metal-binding molecules in the analyte that could compete with the disease-
specific PrP-containing species, and the presence of components that would impair effective 
washing of the steel powder or other technical steps of the assay. It is useful to keep these 
possibilities in mind while investigating the application of the assay to different disease types, and to 
different analytes. 
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Validation of the Direct Detection Assay as a diagnostic blood test for vCJD 
Following extensive optimisation of the DDA protocol for use in human whole blood, its validity as a 
diagnostic test for vCJD was tested using a masked panel of samples, consisting of 21 patients with 
vCJD, 27 with sporadic CJD, 42 with other (non-prion) neurological diseases, and 100 normal controls 
(anonymized samples from healthy blood donors).  The protocol used for this experiment is that 
documented in detail below in the Materials and methods section.  Masked panel samples were 
tested alongside a quality control panel consisting of 6 known normal control samples and 2 samples 
from vCJD patients.  Samples were classified as reactive if the mean luminescent signal from three 
replicate wells exceeded a cut-off value, which was defined as the mean + 3 standard deviations of 
the normal samples in the quality control panel tested on the same plate.  Each sample in the 
masked panel was tested on two separate occasions, and was only classified as positive if it was 
reactive on both occasions.   
 
The results of this experiment have been published by Edgeworth et al129, and are shown in Figure 6.  
15 samples were classified as positive, and all of these were from patients with vCJD. This suggests 
an assay sensitivity for vCJD of 71·4% (95% CI 47·8% to 88·7%) and a specificity of 100% (95% 
CI97·8% to 100%).  3 of the 6 vCJD patient samples that were classified as negative were reactive in 
one of the assay runs but not the other.  Amongst the non-vCJD samples, 8 of the normal control 
samples were reactive in one assay run but not the other, and all other samples were non-reactive in 
both assay runs. 
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Figure 6.  Results of the masked panel experiment, reproduced from Edgeworth et al, 2011129.  Dark blue bars = healthy normal controls; turquoise bars = 
controls with other neurological diseases; green bars = patients with sCJD; red bars = samples testing positive in both assay runs (all vCJD); grey bars = 
vCJD patient samples testing negative in at least one assay run.  
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New applications for the DDA 
The primary objective in developing the DDA was to produce a blood-based diagnostic assay for 
vCJD, and a major secondary aim is to develop a screening test that can identify asymptomatic 
individuals during the incubation period of vCJD. However, the DDA may also have the potential to 
be applied to a range of other prion disease types and other analytes, both for use as a diagnostic 
test and as a biomarker for monitoring progression of disease or response to experimental 
therapeutic agents in clinical trials.  I have investigated several of these possible applications. 
 
Further work (that has been done since the projects presented here were completed) aiming to 
establish whether the DDA has sufficiently high levels of specificity to be applied as a screening test 
is discussed below in Chapter 7. 
 
The DDA in inherited prion disease 
Inherited prion diseases (IPD) can be reliably and rapidly diagnosed by demonstrating the presence 
of a pathogenic mutation on sequencing of the PRNP gene, in an individual with an appropriate 
clinical presentation.  There is therefore no need for a novel molecular diagnostic test for these 
conditions.  However, they present an ideal opportunity to investigate possible biomarkers for prion 
disease, for a number of reasons. 
 
As patients are often aware of their familial risk before symptoms develop, and disease progression 
can be relatively slow, diagnosis of IPD is often made at a much earlier stage than that of the 
sporadic or acquired prion diseases.  Indeed some individuals choose to undergo predictive genetic 
testing, so that they are “diagnosed” years or even decades before the onset of symptoms.  As a 
result of this, an effective therapeutic agent for prion disease would have the potential to be of very 
great benefit in IPD:  the most appealing way to treat a degenerative condition would be to initiate 
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treatment in the very early stages of disease, or even before symptom onset, so that the disease 
process could be slowed or halted before much irreversible damage has been done, and IPD 
presents the best opportunity for this.  However, to achieve this goal it would be extremely valuable 
to have a method for monitoring the disease (and any response to treatment) at a stage when there 
are minimal symptoms, or even no symptoms at all.  Therapeutic trials aiming to use clinical 
outcome measures to prove efficacy of a preventive treatment, or one that modifies a slowly 
progressive disease, are likely to require very long timescales and large numbers of patients.  A 
biomarker that could provide early evidence that the experimental therapeutic agent was indeed 
engaging with and modifying biological pathways relevant to the pathogenesis of the disease would 
be extremely valuable as an adjunct to clinical outcome measures.  Ultimately, if an effective 
therapeutic agent were found, such a biomarker might also help with deciding when to initiate 
treatment in “presymptomatic” individuals. 
 
As the DDA starts to be used as a clinical diagnostic test for vCJD, it is important to fully establish its 
specificity for this particular disease type, so that results can be appropriately interpreted.  Although 
samples from sCJD patients were included in the published masked panel experiment, there were no 
samples from patients with IPD.  Testing of IPD samples therefore also plays an important part in 
establishing the clinical role of the DDA as a test for vCJD.  I therefore investigated the performance 
of the DDA in inherited prion disease.  
 
Testing fractionated blood samples using the DDA 
Even before the accidental transmission of vCJD by blood transfusion there had been concern that 
prion diseases might be transmissible by this route, prompting research using animal bio-assays to 
assess the level of infectivity in whole blood and also in individual blood fractions122,123.  This 
informed the decision to institute the leucodepletion of red cell fractions and the discarding of 
plasma fractions from all UK blood donations since 1999133.  More recent work has used BSE-infected 
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sheep as a model for vCJD, and shown that all fractions of blood taken from infected sheep during 
the incubation period are able to transmit disease134:  this included whole blood, red cells, buffy 
coat, plasma, platelets, and leucoreduced red cells, leucoreduced plasma and leucoreduced 
platelets.   
 
Although, DDA positivity certainly cannot be seen as equating directly with infectivity, it may have a 
role as a surrogate marker indicating the presence of disease-specific abnormal PrP which may well 
include or co-exist with infective species. 
 
The counterintuitive need to dilute human blood samples 100-fold prior to steel capture in the DDA 
raises the possibility that there is an inhibitory factor present in whole blood that needs to be diluted 
for the assay to function.  If this factor could be separated from the disease-specific PrP-containing 
species detected by the assay by simple fractionation of blood this might allow the amount of 
analyte used in the assay to be increased and consequently improve the signal to noise ratio of the 
assay.  I therefore investigated the performance of the DDA in individual fractions of blood.  
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Materials and methods 
General methods for all molecular diagnostics work using Direct Detection Assay (DDA) 
As part of the Molecular Diagnostics team I contributed to the development of a standard protocol 
for the Direct Detection Assay as a diagnostic test for vCJD, which was used for the masked panel 
testing that was reported in Edgeworth et al, 2011129.  This was used for all experiments described 
below, except where modifications to the protocol are specifically noted. 
 
Standard Direct Detection Assay protocol for experiments with blood 
Stainless steel powder (<45µm, Goodfellow) is washed thoroughly using 2% triton-x-100 (Sigma), 
70% ethanol and sterile double-distilled water (ddH2O).  It is then separated into individual aliquots 
of 23mg of steel powder, each in 115μL ddH2O as a suspension and allowed to settle.  The 
supernatant liquid is removed immediately prior to use. 
 
DDA capture buffer is prepared with the following constituents:  101mM tris(hydroxymethyl)-
aminomethane (Tris) buffer at pH 8.4, 2.04% bovine serum albumin (BSA), 2.04% 3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulphonate (CHAPS) detergent, 1 complete protease 
inhibitor tablet (Roche)/50ml, and 10μL benzonase (Grade II, Merck)/50ml. 
 
All subsequent steps are carried out in a Containment Level III laboratory, adhering to all relevant 
local operating procedures. 
 
Blood samples to be tested are thoroughly thawed from storage at -70°C.  8μL of blood is mixed with 
792μL of DDA capture buffer, and the mixture added to a single 23mg steel powder aliquot.  This is 
then incubated overnight (17 +/- 2 hours) on an Eppendorf Thermomixer at a temperature of 18°C 
shaking at 650rpm. 
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Wash solution is prepared, consisting of phosphate-buffered saline and 0.05% Tween detergent.  
The supernatant is removed from each steel powder sample, and these are then each washed 5 
times using 1mL of wash solution for each wash.  After the fifth wash is removed, dry steel samples 
are “heat-shocked” for 5 minutes at 110°C, and then allowed to cool. 
 
Biotinylated anti-PrP antibody ICSM18B (D-Gen Ltd) is prepared at a concentration of 0.6μg/ml, and 
50μL added to each steel powder sample.  These are then incubated for 1 hour on a Thermomixer at 
37°C shaking at 750rpm. 
 
Supernatant is removed and samples are washed a further 3 times using 1mL of wash solution for 
each wash.  Horseradish peroxidase conjugated NeutrAvidin-HRP (Pierce) is prepared at 1:100 000 
dilution, and 50μL added to each dry steel powder sample.  These are then incubated for 45 minutes 
on a Thermomixer at 37°C shaking at 750rpm. 
 
Supernatant is removed and samples are washed a further 3 times using 1mL of wash solution for 
each wash.  Femto chemiluminescent SuperSignal reagent (Pierce) is prepared by mixing equal 
volumes of the 2 constituent parts as per the manufacturer’s instructions. 60μL is added to each 
steel powder sample.  Each steel powder sample is then resuspended in this liquid and separated 
equally between 3 wells of a black, 96-well, flat-bottomed ELISA plate (Greiner), so that each 
contains 20μL of Femto reagent and approximately 7.67mg of steel powder. 
 
A dilution series of NeutrAvidin-HRP giving dilutions of 1:1x106, 1:1x107 and 1:1x108 is also prepared.  
20μL of each of these is added to 3 wells. 
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A further 80μL of Femto reagent is then added to each well, and the plate is immediately read using 
a M100 plate reader (Tecan), using luminescence settings. The mean luminescent signal measured 
from the 3 wells for each sample is taken as the DDA result for that sample. 
 
Standard quality control panel for DDA experiments on blood 
Unless stated otherwise, in all DDA experiments described below test samples were tested alongside 
a standard quality control (QC) panel of at least 4 known normal control samples, and at least 1 
known DDA-positive vCJD sample.  A reference value, the “DDA Cut Off”, was calculated for each 
assay run, by calculating the Mean + 3 Standard Deviations of the luminescent signal from the 
normal QC samples.  The QC panel was deemed satisfactory if the mean luminescence reading for 
the vCJD sample(s) was greater than 1.4 times the DDA Cut Off (based on previous experiments 
using the same vCJD samples).  If this was the case, the results from the test samples in the same 
assay run were included in the analysis.  If the QC panel results were not satisfactory, then the test 
sample results were disregarded and the whole assay run was repeated. 
 
DDA in inherited prion disease. 
I used the standard DDA protocol to test a panel of blood samples from patients with inherited prion 
disease.  Some of these assay runs were kindly performed by laboratory technicians Ms Justine 
Korteweg, Ms Claire Grant and Ms Samantha Jones, under my supervision. 
 
A large number of EDTA whole blood samples from patients with inherited prion disease have been 
received and stored in the MRC Prion Unit, with written consent for their use in research studies 
provided by patients or next-of-kin.  These include sets of samples taken at different times from the 
same individuals, sometimes over the course of many years, and also samples taken from 
asymptomatic individuals who are known to carry a pathogenic PRNP mutation.  I identified all 
symptomatic patients that had at least 1 suitable EDTA sample stored, and identified the most 
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recently taken sample from each of these patients (i.e. the sample taken at the latest stage of their 
disease).  This yielded a total of 52 samples, from a range of inherited prion disease types, as 
documented below. 
 
PRNP mutation Number of patients/samples 
4-OPRI 3 
5-OPRI 4 
6-OPRI 15 
A117V 3 
D178N 4 
E200K 4 
G54S* 1 
P102L 14 
Q212P 2 
Y163X 2 
Total 52 
 
*G54S has been found in one patient with an atypical clinical neurodegenerative syndrome, and 
abnormal prion protein deposition at autopsy, but also in a number of healthy control individuals, so 
it is not conclusively known whether this is a pathogenic mutation or a polymorphism.  
 
Each of these samples was tested on at least 2 separate occasions using the DDA protocol above.   
Test samples were classified “DDA positive” if their mean luminescence reading was greater than the 
DDA Cut Off on both occasions that they were tested.  This was the same criterion used to classify 
samples as positive in the published masked panel experiment into the use of the DDA as a 
diagnostic test for vCJD129.  I also planned to test any other, earlier samples that had been taken 
from the same patients as those producing a positive result in the initial set of 52 samples, in order 
to investigate the timecourse of DDA positivity through the disease course. 
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Analysis for factors interacting with diagnosis/disease type to affect DDA result 
Information relating to each sample, including the date the sample was obtained, the date of onset 
of the patient’s illness, the patient’s date of birth and the date of the patient’s death (if deceased), 
was obtained from the records of the MRC Prion Unit and/or the NHS National Prion Clinic. 
Exploratory analyses were performed to look for factors that might interact with diagnosis/disease 
type in influencing the DDA result.  For example, were samples taken at a very late stage of disease 
more likely to produce a positive DDA result than samples taken from patients at an earlier stage of 
the same disease type?  This could provide clues as to the potential of the DDA as a biomarker of 
disease progression, and might also highlight possible confounding factors affecting the sensitivity of 
the test. 
 
The putative interacting factors examined were: 
1) Age of patient at time of sampling 
2) Time from onset of disease to sampling 
3) Time from sampling to death 
4) Time from sampling until testing (i.e. age of the sample itself when tested).   
 
DDA in fractionated variant CJD bloods 
In order to investigate the distribution of disease-associated abnormal PrP in vCJD patient blood 
fractions using the DDA, I identified blood sample sets stored at the MRC Prion Unit with appropriate 
research consent that had been taken from vCJD patients and healthy controls where there was 
whole EDTA blood and fractionated EDTA blood stored from samples taken on the same occasion.  
Fractionation of blood had been performed shortly after receipt of the samples at the MRC Prion 
Unit, using local operating procedures that have been standardized to ensure consistency of sample 
quality.  Fractionated blood sets consisted of (1) red cell/platelet fraction, (2) plasma fraction (where 
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“plasma 1” (upper part of plasma fraction after centrifugation) and “plasma 2” (lower part of plasma 
fraction) were stored separately, “plasma 1” was used), and (3) mononuclear cell fraction. 
 
The suitable sample sets identified included some vCJD sample sets from which the whole blood 
sample was known to produce a consistent strong positive DDA result in previous experiments, and 
also some from which the whole blood sample was known to be DDA-negative.  This provided the 
opportunity to assess whether testing any individual blood fraction might have advantages over 
testing whole blood with respect to sensitivity.   
 
Only a limited number of sample sets meeting the necessary criteria could be identified.  The 
samples sets included in this experiment are summarised below. 
 
Diagnosis Number of whole blood & fraction sample sets 
Normal healthy control 9 
vCJD 8 (NB: 1 set without plasma) 
 
Initially, each set of samples was tested using the standard DDA protocol, treating each blood 
fraction as if it were whole blood, with the exception of the very small MNC “pellet” which was 
resuspended in phosphate buffered saline (PBS) back to its original concentration in the blood 
sample from which it was derived (“1x” concentration).  Further experiments also tested a subset of 
MNC samples at a range of concentrations (1x, 2x, 5x, 20x).  Subsequently, some adaptations to the 
protocol were made in order to optimise the performance of the assay in fractions that showed 
some evidence of differentiation of vCJD from control samples. 
 
Plasma and RBC/platelet fractions were also tested after being diluted in PBS so that their final 
concentration while being incubated with steel powder and capture buffer would be as close as 
possible to their concentration in the assay using whole blood:  plasma fractions and red cell/platelet 
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fractions were diluted 5:7 in PBS.  This ratio was based on the typical proportions of each fraction 
produced from each whole blood sample. 
 
The standard QC panel as described above was used for each assay run. 
 
In addition to testing blood fractions individually, “reconstituted whole blood” was tested for a 
subset of samples, by mixing plasma, red cell/platelet and mononuclear cell fractions in a ratio of 
5:5:1 (based on the proportions usually obtained at fractionation), and then testing this mixture 
alongside the corresponding whole blood sample, using the standard DDA protocol. 
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Results 
DDA in inherited prion disease (IPD) 
The results obtained from the testing of the IPD sample panel are shown in Figure 7. 
 
3 of the 52 samples were classified DDA positive (ratio to Cut Off > 1 on 2 separate assay runs).  2 
were from patients with a P102L mutation, while one was from a patient with a 4-OPRI mutation. 
Unfortunately, the samples that tested positive were the only samples taken from these patients: 
there were no corresponding samples taken at earlier stages of disease available.  It was therefore 
not possible to pursue the plan to test a timecourse of earlier samples from the same patients at this 
stage. 
 
Illustrative scatter plots showing the relationship of the possible interacting factors (see Materials 
and Methods, above) to the mean DDA ratio to Cut Off for each sample are shown in Figure 8.   
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Figure 7.  Direct detection assay results for panel of 52 inherited prion disease whole blood samples, each tested on ≥2 occasions, grouped by PRNP 
mutation.  Yellow bars indicate samples where both assay runs produced a Ratio to Cut Off value > 1 (see Materials and Methods), and the sample was 
deemed “DDA positive”
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Figure 8.  Scatter plots showing relationship of mean DDA Ratio to Cut Off in the inherited prion disease panel to 4 putative interacting factors. 
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All of the information could not be established for all of the patients (e.g. some patients still alive so 
time from sample to death not available, clinical information on date of symptom onset not 
available for some patients).  From these it is apparent that the 3 DDA-positive samples were the 3 
oldest samples at the time of testing, suggesting a possible interaction between the age of a sample 
and DDA result.  This exploratory post hoc analysis is useful for identifying potential interactions and 
generating hypotheses, but these cannot be rigorously tested without an independent data set. 
 
To test the hypothesis that older samples were more likely to be DDA positive in an entirely 
independent data set, the data that had been obtained using an identical DDA protocol for the 
masked panel experiment published in Edgeworth et al, 2011129 was used.  This consisted of testing a 
large panel of samples including those from 21 vCJD patients, 35 sCJD patients, 42 patients with 
other non-prion neurological diseases, and 100 healthy controls (UK blood donors).  These 
experiments were carried out by my colleagues in the Molecular Diagnostics team, Dr Julie 
Edgeworth and Mr Mike Farmer.   
 
The relationship of sample age to DDA result (expressed as ratio to Cut Off) in all masked panel 
samples for which information on date of sampling was available is illustrated in Figure 9.  These 
consisted of 21 vCJD, 27 sCJD, 25 AD, 6 familial AD, 4 FTLD and 7 “prion-mimic” samples (from 
patients referred to the National Prion Clinic with clinically suspected prion disease who ultimately 
proved to have an alternative diagnosis).  As healthy control samples were anonymized it was not 
possible to establish the date of sampling. 
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Figure 9.  Relationship between DDA ratio to Cut Off and sample age in the samples tested in the 
masked panel experiment published in Edgeworth et al, 2011129. 
 
Linear regression analysis was performed on this data set with DDA ratio to Cut Off as the 
dependent variable, and age of sample and diagnostic category (dichotomised as vCJD or non-vCJD) 
as the independent variables.  This is summarised below: 
 
 Unstandardized 
Coefficients 
Standardized 
Coefficients 
  
Model B Std Error Beta t p value 
Constant 2.053 0.361  5.687 <0.001 
Age of sample 
(per year) 
0.104 0.025 0.389 4.115 <0.001 
Diagnosis (vCJD 
vs non-vCJD) 
-0.860 0.176 -0.463 -4.898 <0.001 
Linear regression with DDA Ratio as dependent variable (IBM SPSS Statistics). 
 
 65 
This shows that, even when adjusted for sample age, vCJD diagnosis remains a strong independent 
predictor of a higher DDA result, but also suggests that the age of a sample does indeed have a 
strongly significant effect on the DDA result.  If the non-vCJD samples are taken in isolation, there is 
no significant evidence of an association between sample age and DDA ratio to Cut Off (p = 0.46), so 
it is clearly the effect within the set of vCJD samples that is driving this association. It is important to 
note, however, that the only 10 samples tested in this experiment which were older than 2500 days 
were all from vCJD patients, and that these included the samples producing the 9 highest DDA ratios.  
It is not possible to make a like-for-like comparison with any non-vCJD samples of this age from this 
data, and the possibility that the specificity of the test is reduced in very old samples cannot be ruled 
out.  Thankfully this is unlikely to be relevant to the clinical use of the DDA, where it will be 
employed to test very recently acquired samples. 
 
DDA in fractionated vCJD bloods 
The results of the initial testing of individual blood fractions and corresponding whole bloods are 
illustrated in Figure 10. 
 66 
 
Figure 10.  DDA results from initial screen of individual blood fractions and corresponding whole blood samples from normal controls and vCJD patients.  
RBC/platelet fractions and plasma fractions were undiluted, MNC pellet was resuspended to original concentration (“1x”).  vCJD samples are divided 
into those for which the paired whole blood tested in the same assay runs was DDA positive (red bars) and those for which it was DDA negative (orange 
bars).  n1-n8 and v1-v8 denote different individuals from whom blood samples were taken; normal controls and vCJD patients respectively.  
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There was greater variability in the luminescent signal from normal control RBC/platelet fractions 
than from normal control whole bloods, with some normal control RBC/platelet fractions producing 
a DDA ratio to Cut Off of > 1.  However, as can be seen from Figure 10, 2 of the 3 vCJD RBC/platelet 
fraction samples tested that were paired with DDA-positive whole blood samples produced a DDA 
ratio to Cut Off > 1, while the same was not true of plasma or MNC fractions, where there seemed to 
be very little difference between normal control and vCJD samples.  This suggested that it may be 
the RBC/platelet fraction that harboured the majority of the PrP-containing species detected by the 
DDA, and prompted further investigation of this. 
 
In an attempt to reduce the high “background” signal from normal control RBC/platelet fractions, 
and also to allow more direct comparison of the relative contribution of each fraction to the overall 
DDA signal obtained from corresponding whole blood, I tested red cell/platelet fractions after 
diluting them back to their original concentration prior to fractionation (as described in Materials 
and Methods).  Each available vCJD sample and a panel of normal control samples were each tested 
on at least 2 separate occasions.  Results are shown in Figure 11 . 
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Figure 11. DDA results for pre-diluted RBC/platelet fractions from normal controls and vCJD 
patients (Mean + SD of Ratio to Cut Off from at least 2 independent assay runs for each sample).  
vCJD samples are divided into those for which the paired whole blood tested in the same assay 
run was DDA positive (red bars) and those for which it was DDA negative (orange bars).  n1-n6 and 
v1-v8 denote different individuals from whom blood samples were taken; normal controls and 
vCJD patients respectively. 
 
The overall mean DDA ratio to Cut Off for normal control RBC/platelet fractions was 0.48 (SD 0.2), 
while for vCJD RBC/platelet fractions paired with DDA positive whole bloods it was 1.33 (SD 0.57).  A 
2 tailed t test comparing these 2 groups gives a p value of 0.088.  To further investigate whether the 
PrP-containing species causing vCJD whole bloods to produce a positive DDA result is present in 
RBC/platelet fractions I directly compared the signal from the paired samples in this experiment, 
shown in Figure 12.  The correlation coefficient between these was 0.894, and Pearson’s R2 was 
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0.798 (p = 0.018), suggesting that 80% of the variation in signal from RBC/platelet fractions can be 
accounted for by variation in the corresponding whole blood sample. 
 
 
Figure 12.  Correlation of DDA ratio to Cut Off from vCJD whole bloods with corresponding 
RBC/platelet fractions. 
 
The results obtained from testing recombined blood fractions and corresponding whole bloods are 
shown in Figure 13.   
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Figure 13.  DDA results for recombined blood fractions (RBC/platelet + plasma + MNC fractions 
mixed in proportions matching those obtained at fractionation) and corresponding whole bloods. 
v1-v3 and n1-n6 denote different individuals from whom blood samples were taken; vCJD patients 
and normal controls respectively. 
 
None of the recombined blood fractions produced a DDA ratio to Cut Off consistently greater than 1, 
despite some being derived from whole blood consistently producing a strongly positive signal. 
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Discussion 
DDA in inherited prion disease 
The results documented above from testing of a panel of inherited prion disease blood samples have 
several important implications. 
 
At the time of testing, the 3 samples that were deemed DDA-positive were the first non-vCJD 
samples to have produced a positive result in the assay using the standard protocol as published in 
Edgeworth, 2011129, which is now being used as a diagnostic test for vCJD through the NHS National 
Prion Clinic.  This has clear implications for the specificity of the DDA as a test for vCJD.  This needs to 
be borne in mind when interpreting the result of the DDA in clinical practice, and ideally PRNP 
genotyping should be performed alongside the DDA as a definitive way to rule out IPD.  This is 
particularly pertinent as IPD can affect patients of a similar age to those typically affected by vCJD, 
and there is substantial overlap in the clinical features.  Since these experiments were carried out, 
further work has been done to establish the specificity of the DDA135.  This demonstrated a positive 
DDA result in 2 patients with sporadic CJD, but no false positive results from testing 5000 US blood 
donors, 200 UK blood donors, and 352 patients with non-prion neurodegenerative diseases.  This 
suggests that the assay is very highly specific to prion disease, but not entirely specific to variant CJD, 
and so lends further weight to the conclusion that the positive results from IPD patients in the 
experiments presented here were true positives. 
 
The large archive of blood samples from patients with inherited prion diseases held by the MRC 
Prion Unit presents a valuable opportunity to study the potential value of a blood-based biomarker 
for the progression of prion disease.  Blood samples have been taken at many different stages of 
progression of disease, often in the same individual patients.  This includes samples taken from 
carriers of pathogenic PRNP mutations at a time before they have developed symptoms. 
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Unfortunately, none of the IPD samples that were DDA-positive in this study were from patients with 
other earlier samples stored, so the immediate plan to test an associated time course of samples 
could not be pursued.  However, the fact that some IPD blood samples do appear to contain disease-
associated PrP that can be detected using the DDA suggests that it will be worth exploring this 
further: efforts are ongoing to improve the sensitivity of the DDA in general, and if this is successful 
it will be possible to revisit this panel of samples. 
 
The IPD results also provided a clue to identifying a factor that interacts with diagnosis in affecting 
the DDA result:  sample age.  The further analysis using data from the masked panel experiment 
suggests that in diagnostic groups associated with a positive DDA (i.e. vCJD and now IPD); older 
samples tend to produce higher DDA results.  There is no evidence that increasing sample age in 
other diagnostic groups can lead to “false positive” results (at least within the age-range of non-vCJD 
samples tested) if we conclude that the positive results in 3 IPD samples are “true positives”. 
This will have clear implications for interpreting the results of other experiments using older 
archived samples, but may also be relevant to the clinical use of the assay.  Samples being tested for 
clinical purposes using the DDA are likely to be days or weeks old, while the published sensitivity of 
the assay was established in a masked panel of samples including a number of very old samples.  It is 
therefore possible that sensitivity in new clinical samples will be less than that demonstrated in the 
masked panel, and this will need to be re-assessed prospectively by comparison with final clinical 
and/or neuropathological diagnoses as the clinical use of the DDA continues. 
 
In light of these observations, it is useful to reflect on some fundamental challenges and potential 
pitfalls in the development of diagnostic assays for very rare diseases.  In an ideal situation, the 
sample set in which a diagnostic assay is developed and optimised should be entirely independent 
from the sample set in which it is then validated once an optimised protocol has been established. 
 This was not possible in the development process of the DDA, as samples from patients with vCJD 
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are so rare: only 21 patients had suitable samples available and could be included in the masked 
panel experiment.  Many of the same vCJD patient samples, or different samples from the same 
patients, were included in both the empirical, iterative process of developing and optimising the 
assay, and the masked panel experiment by which its apparent diagnostic accuracy was 
demonstrated.  A potential problem with this approach is that the optimised assay may 
inadvertently rely on "off-target" differences between the disease and control sample sets in which 
it has been optimised (any variables other than diagnosis which happen to differ between the 
disease and control samples, such as sample age in this case, but also potentially random variation in 
other unknown variables), and that this confounding effect will not be eliminated at the validation 
stage because the same samples are used.  At the very least, one would expect this to result in an 
apparent reduction in the assay's performance when it is subsequently used in an independent 
sample set, including its prospective use in clinical practice - simply because it has not been 
optimised to work well in these specific samples.  This likely over-estimation of the assay's future 
performance is also relevant to our expectations when it is applied to different diagnostic groups 
and different analytes, as in the work presented in this chapter and the next. 
 
Although not ideal, the methodology used for the development and validation of the DDA was borne 
out of necessity; there is no way around the fact that the samples are very scarce.  The results of the 
masked panel experiment remain impressive and promising, but the methodological issues 
discussed here and the resulting caveats to the results wider applicability must be kept in mind when 
interpreting further work using the assay. 
 
DDA in fractionated variant CJD blood samples 
The study of the DDA’s performance in fractionated bloods from vCJD patients and controls did not 
show any clear advantage in testing any individual blood fraction over whole blood in terms of 
sensitivity or specificity for vCJD. 
 74 
 
The results suggest that, in some patients, the red cell/platelet fraction contains disease-associated 
PrP that can be detected using the DDA.  The DDA signal from these samples correlates well with the 
signal from corresponding whole bloods, which would be consistent with the PrP-containing species 
in whole blood which is detected in a positive DDA localising to the red cell/platelet fraction. 
However, the number of vCJD and normal control fractions available for testing was small and 
therefore the results must be interpreted with caution. 
 
We must also be very cautious in interpreting the absence of disease specific signal from the other 
blood fractions in these experiments, and should certainly not conclude that this represents 
evidence that they do not contain abnormal/disease-associated PrP, let alone infectivity.  The 
contribution made by other constituents of whole blood to the performance of the assay remains 
poorly understood, and it is possible that a “co-factor” present in whole blood and in the red-cell 
platelet fraction may allow disease-associated PrP in these analytes to be detected, while that in the 
other fractions is not detectable by the assay in its current form. 
 
The methods used for fractionation of bloods for laboratory analysis are not the same as those used 
for separation of red cells and plasma for blood transfusion purposes.  This represents a further 
major caveat to drawing any conclusions from this work with respect to the possible application of 
the DDA to screening blood products after fractionation, or to the likelihood of specific blood 
products used in clinical transfusion practice carrying infectivity.  Studies aimed specifically at this 
question, such as that by McCutcheon et al using BSE-infected sheep have used blood fractionation 
techniques that closely mimic those used in clinical practice134. 
 
Ideally, this study would be followed up with a larger study using a larger panel of independent 
samples, and at least some of these should be fractionated using methods similar to those used in 
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clinical practice to prepare therapeutic blood products.  However, this is not currently possible as 
the necessary samples do not exist in archive and recent trends in vCJD epidemiology mean there is 
no immediate prospect of obtaining new vCJD samples. 
 
General discussion and future plans 
The Direct Detection Assay is the first blood-based assay that has been shown to distinguish vCJD 
patient blood samples from control samples in a rigorous, blinded experiment129.  As such it 
represents a very promising new technique which may have many applications across the field of 
prion disease research and clinical practice, and possibly even in other related protein-misfolding 
diseases. 
 
However, as a novel technique that has been developed using a necessarily empirical approach and 
for a very specific application, it remains poorly understood in terms of the biochemical and 
biophysical processes that underpin it.  As a result, the process of adapting and applying the 
technique in different circumstances is challenging and requires a careful and rigorous approach. 
 
Alongside this work, efforts were ongoing to find ways to improve the performance of the DDA as a 
diagnostic test for vCJD, and to improve our understanding of how the assay works.  One 
observation from the early work on the DDA as reviewed above that has prompted further 
investigation is the surprising need to dilute a very small blood input volume (8μL) 100-fold in order 
for the assay to function adequately.  This seems somewhat paradoxical, since the concentration of 
abnormal PrP in patient blood is likely to be extremely low.  If we could find a way to increase the 
amount of blood input to the assay, or simply scale up the assay as a whole, then perhaps the 
performance of the assay could be improved.  The experiments presented below in chapter 4 
constitute part of this project. 
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If it does prove possible to significantly increase the sensitivity and overall performance of the DDA, 
then it will be worth revisiting the sample sets tested in this chapter: for example, it may prove 
possible to find abnormal PrP in more cases of IPD if the sensitivity of the assay is improved, and to 
complete the abandoned plan described above to investigate a timecourse of samples from before 
and after clinical onset of disease. 
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CHAPTER 3. DIRECT DETECTION ASSAY IN CEREBROSPINAL FLUID 
Introduction 
CSF in the diagnosis of neurodegenerative disease 
Examination of cerebrospinal fluid (CSF), sampled by lumbar puncture, forms part of the diagnostic 
process for many central nervous system disorders.  CSF is typically analysed for the presence of cells 
(blood cells or atypical/malignant cells), protein and glucose levels, and a wide variety of more 
specialised tests can be used depending on the clinical context and the diagnoses being considered. 
In neurodegenerative disorders it has become clear that the CSF can provide a “window” onto 
changes occurring in the brain: particularly by measuring the levels of specific disease-related 
proteins. 
This has been demonstrated most clearly, and studied most thoroughly, in Alzheimer’s disease.  The 
neuropathological hallmarks of Alzheimer’s disease are senile plaques: extracellular aggregations of 
β amyloid (Aβ), a protein encoded by the amyloid precursor protein (APP) gene; and neurofibrillary 
tangles: intracellular aggregations of hyper-phosphorylated tau, a protein encoded by the 
microtubule-associated protein tau (MAPT) gene136.  The aggregation of these proteins into 
insoluble, polymeric forms is thought to play a fundamental role in the pathogenesis of the disease.  
The levels of a particularly “amyloidogenic” isoform of β-amyloid, Aβ42, and of both phosphorylated 
tau (P-tau) and total tau (T-tau) can be measured in the CSF, and have been found to change in a 
characteristic way in patients with AD. 
Levels of CSF Aβ42 are reduced in patients with AD, typically to about 50% of normal levels.  The 
reasons for this are not clear, but it has been suggested that there may be a “sink effect” as the Aβ42 
is increasingly incorporated into senile plaques in the brain parenchyma and is pulled out of the 
CSF137.  Levels of CSF tau tend to be increased, with a particular increase in P-tau, and an increase in 
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the ratio of P-tau : T-tau.  These CSF parameters have been included in recent diagnostic criteria for 
Alzheimer’s disease138.   
They have also been extensively investigated in patients that might be in the very early stages of AD 
but would not yet reach the clinical diagnostic criteria (patients with mild cognitive impairment that 
is not affecting day-to-day functioning), and have been found to have value in predicting which of 
these patients will go on to develop Alzheimer’s disease139.  Along with other techniques such as in 
vivo imaging of amyloid deposition (using positron emission tomography (PET) with ligands that bind 
to amyloid)140 in patients with mild cognitive impairment, or even normal healthy people, this has 
led to a re-thinking of the definition of Alzheimer’s disease and the lexicon used to describe different 
stages of the disease, to include “prodromal” or “pre-dementia” Alzheimer’s disease to describe 
individuals in whom there is evidence of an ongoing Alzheimer’s type amyloid disease process, but 
who have not yet reached the clinical criteria for a diagnosis141.  This is part of an important re-
conceptualisation of neurodegenerative disease, acknowledging that the underlying molecular 
pathological process begins some time before the onset of clinical symptoms and that it may be 
possible to identify patients in the very early stages of disease, or even before the onset of clinical 
disease.  As efforts to find disease-modifying treatments progress, this possibility of achieving very 
early diagnosis becomes an important goal:  the benefit gained from any treatment that can stop or 
slow down the disease process is likely to be greatest if it can be started as early as possible. 
Efforts have been made to apply a similar approach to finding diagnostic markers of other 
neurodegenerative diseases, including Parkinson’s disease142, frontotemporal lobar degeneration143 
and Motor Neuron Disease144, by examining the CSF levels of a range of disease-related proteins.  
Although some promising candidates have been identified, these have not been found to have such 
clear diagnostic value (often showing significant differences on group-to-group comparisons, but 
with considerable overlap between groups), and no CSF parameters are currently included in the 
clinical diagnostic criteria for any of these conditions.  
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CSF in prion disease 
Current use of CSF in the diagnosis of prion disease 
In all types of prion disease the CSF typically has a normal cell count of 0-2 cells/μL145.  A pleocytosis 
(presence of increased numbers of white blood cells) suggests an alternative diagnosis, particularly 
an inflammatory disorder.  Total protein level is usually normal or only modestly elevated, and there 
is rarely evidence of intrathecal immunoglobulin synthesis.  Measurement of these “routine” CSF 
parameters, as well as other disease-specific tests such as polymerase chain reaction for viral DNA, 
play a vital role in ruling out alternative diagnoses that may produce a similar clinical presentation45.  
As these other conditions may be treatable (e.g. with antiviral or immunomodulatory agents), the 
initial phase of investigation of patients with prion disease tends to focus on ruling out these 
alternative diagnoses. As a result of this, there is a tendency for prion disease to be thought of as a 
diagnosis of exclusion, exacerbating the problem of late diagnosis, but some CSF tests can provide 
positive support for a diagnosis of prion disease, particularly sporadic CJD. 
 
14-3-3 Proteins 
The 14-3-3 proteins comprise a large family of intracellular proteins found in all eukaryotic cells, and 
constitute about 1% of the total protein content of brain neurons 146.  They are found in the CSF in a 
variety of conditions where there is rapid and extensive neuronal destruction.  They are detected 
using a qualitative assay, giving a positive, negative or “weak positive” result. 
The 14-3-3 assay is included in the World Health Organization’s diagnostic criteria for sporadic CJD 
(sCJD)34,147. 
The assay is typically positive in classical, rapidly progressive sCJD, with a sensitivity of 90-95% for 
the MM1 subtype 34,148.  However, it is less sensitive for longer duration cases, for younger patients, 
and for the acquired and the more slowly progressive inherited prion diseases 149.  The test is 
positive in only about 40% of cases of variant CJD 148,150. 
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Interestingly, successive studies over the years have tended to show a reducing sensitivity of the 14-
3-3 assay for sCJD 34,148,151-154.  This may well be related to the increasing recognition and inclusion of 
cases with atypical, more slowly progressive clinical features leading to more “false-negative” results 
in recent studies. 
 
There is some evidence that the 14-3-3 assay is more sensitive when performed at later stages of 
disease.  It has therefore been suggested that in cases where there is continuing diagnostic 
uncertainty there may be a role for repeating the assay at a later stage if the first is negative 148.  
However, in practice this is often superseded by a decision either to obtain a definitive tissue 
diagnosis (with brain biopsy), or that further investigations are no longer appropriate. 
 
The specificity of the 14-3-3 assay for prion disease is dependent on the population of patients being 
tested, but in many studies has been quite low, at around 70-80% 34,148.  A large multicentre, 
multinational study including 29,000 samples sent to national CSF testing centres suggested that its 
specificity for distinguishing sCJD from other neurodegenerative diseases was as high as 95 – 97%, 
but for distinguishing it from acute neurological conditions it was reduced to 82 – 87%155.  In patients 
with clinically suspected CJD, false positive results occur most commonly when the final diagnosis is 
inflammatory or malignant (including CNS tumours and paraneoplastic syndromes)148. 
 
Other causes of a positive result include recent stroke, infective encephalitis and subacute sclerosing 
panencephalitis (SSPE), but these diagnoses can usually be ruled out clinically or on the basis of 
other tests.  A raised CSF cell count has been shown to be highly significantly associated with an 
increased false positive rate148, and should always prompt investigation for other causes. 
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The specificity is not high enough for the test to have a role in screening unselected patients with 
dementia for prion disease 154. 
 
S100b Proteins 
These are a large family of calcium binding cytoplasmic proteins found in glia in the CNS, as well as 
widely outside the CNS.  They are detected using a quantitative assay.  Their levels are raised in the 
CSF in a large number of destructive diseases of the nervous system where there is extensive gliosis, 
including CJD.  As with the 14-3-3 proteins, they are more likely to be raised in rapidly progressive 
disease, where sensitivity is around 90%148.  However, the specificity is even lower than for 14-3-3156, 
and in practice they rarely add any further useful diagnostic information. 
 
Tau (τ) 
Tau is an intracellular micro-tubule associated protein, which is found in increased levels in the CSF 
when there is destruction of neurons.  In some disease states the Tau protein becomes 
hyperphosphorylated.  The levels of total Tau and hyperphosphorylated Tau can be measured using 
quantitative assays. 
 
The total Tau (T-Tau) level in the CSF is elevated in a wide variety of degenerative CNS disorders, 
including Alzheimer’s disease.  It is increasingly used, in combination with CSF Aβ42, as a diagnostic 
marker for Alzheimer’s disease, as discussed above137. 
 
In sCJD it is often elevated to a much higher level than in the more common slowly evolving 
degenerative disorders.  If a high threshold is used, the sensitivity is again high for rapidly 
progressive CJD, and the specificity seems to be similar to that of the 14-3-3 assay 148,157. 
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It has been suggested that CSF levels of hyperphosphorylated Tau (P-Tau) are particularly elevated in 
variant CJD (vCJD), such that the ratio of P-Tau to T- Tau is higher in vCJD than sCJD 158.  This may 
have a role in helping to distinguish between these two conditions. 
 
A more recent study compared levels of P-Tau and T-Tau in CSF from patients with CJD and in those 
with other non-CJD dementias, and suggests that a high ratio of T-Tau : P-Tau may have a role as a 
marker to distinguish these two groups159.  The study also looked at the relationship between the 
levels of CSF tau and the duration of survival after the sample was taken, and found that levels were 
higher in samples taken closer to the date of death.  One explanation for these results would be that 
T-Tau levels rise as an individual patient’s disease progresses, raising the possibility that this might 
be used as a biomarker of disease progression.  However, the results might also be explained by T-
Tau levels being higher in individuals with more rapidly progressive disease, who will tend to have 
their investigations including CSF examination closer to their date of death.  The study also found in 
a subset of patients that had more than one CSF sample taken, that the levels of T-Tau and the T-Tau 
: P-Tau ratio tended to be higher in the later sample, so it may be that these CSF parameters will 
have a role as a marker of disease progression, although this will require further investigation. 
 
Other Proteins 
Various other proteins have been considered as CSF markers for CJD, including Neuron-Specific 
Enolase, prostaglandins and interleukins.  However, these are less sensitive and specific than those 
above, and have little clinical utility.  The limited data available on Aβ42 in CJD suggest that it has 
little diagnostic significance157. 
 
Prion protein in CSF 
Prion protein (PrPc) is present in normal cerebrospinal fluid, detectable by Western blotting and 
ELISA techniques160. 
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As discussed above, it is known that diseases characterized by accumulation of a misfolded, 
aggregated form of a specific protein in the brain may result in changes in the measurable 
concentration of the monomeric form of this protein in the CSF (e.g. levels of Aβ42 are reduced in the 
CSF of patients with Alzheimer’s disease137).   
 
A study using ELISA to quantify the levels of PrPc in CSF from patients with sporadic CJD, as well as 
from those with a range of other degenerative and non-degenerative neurological conditions and 
from healthy controls showed that there was a significant reduction in the detectable concentration 
in CJD, but also in the other neurodegenerative conditions studied161.  The study also showed some 
correlation between disease severity and CSF PrPc concentration in CJD, Alzheimer’s disease and 
Lewy Body Dementia.  As the range of PrPc concentrations in CJD largely overlapped that in the other 
degenerative diseases, the potential for this parameter being used as a diagnostic test is limited, but 
the observation may be useful in understanding changes in CSF PrP in CJD and other disease states. 
 
The possibility of detecting abnormal, disease-associated forms of PrP in CSF from patients with 
prion disease has also been explored.  Efforts to detect protease-resistant PrP in CSF using Western 
blotting have failed 160.  Primate bio-assay experiments, carried out at the National Institutes of 
Health in the USA, assessed the infectivity of a range of different tissues and fluids including CSF 
from patients with CJD (both sporadic and familial) 7.  From 27 CSF samples inoculated into primates, 
4 transmitted the disease.  For comparison, inoculation of brain tissue from patients transmitted 
disease in 100% of cases, and inoculation of spinal cord tissue transmitted disease in 4 out of 6 
cases.  This suggests that in at least some patients, the infectious agent is present in CSF (assuming 
there has not been contamination with brain or other tissue).  As the infectious agent is thought to 
consist primarily of aggregated PrP, with its disease-causing and infective properties conferred by 
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conformational properties of the PrP aggregates, this suggests that it may be feasible to detect 
disease-specific forms of PrP in patient CSF. 
 
More recently, assays based on in vitro seeded conversion of PrPc into an aggregated form have 
been applied to CSF with some success.  These approaches are conceptually appealing, as they make 
use of a biochemical property thought to be very highly specific and central to the pathophysiology 
of prion diseases:  the templated conversion of normally folded PrP into a misfolded amyloid-rich 
form.  It would be hoped that this should lend them much greater specificity than measurement of 
the non-specific markers of neuronal damage currently used in clinical practice. 
 
The most promising of these, known as real-time quaking induced conversion (RT-QuIC)162, has been 
evaluated as a diagnostic CSF test.  This was developed from earlier techniques using protein 
misfolding cyclic amplification (PMCA), which were able to detect seeding activity in CSF from prion 
disease infected animals, but required laborious repeated rounds of amplification and Western 
blotting of the products of these reactions163,164.  RT-QuIC involves adding Thioflavin and a test 
sample to a preparation of recombinant PrP, which is then shaken repeatedly.  If the test sample is 
able to “seed” the conversion of the recombinant PrP into an aggregated amyloid-rich form, this will 
bind to the Thioflavin and emit fluorescence, which can be detected in real time. 
 
In a UK-based study, RT-QuIC was used to test CSF samples from 123 patients with 
neuropathologically confirmed sCJD, alongside a control group of 103 samples from patients that 
were clinically suspected to have CJD but subsequently found to have an alternative diagnosis165.  
The test was positive in 103/123 sCJD cases, and in 1/103 control cases, giving a sensitivity of 89% 
and a specificity of 99%.  A smaller study from Japan suggested sensitivity of greater than 80% and 
specificity of 100% 166.  These suggest that this technique may be superior to the established CSF 
assays reviewed above (14-3-3, Tau etc.) as a diagnostic test for sCJD.  A study testing dilute patient 
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brain homogenate using RT-QuIC tested samples from sCJD and vCJD patients:  while sCJD produced 
strong positive results, the assay was less efficient in detecting the abnormal PrP from vCJD brain165.  
None of the published studies have reported testing of vCJD patient CSF using RT-QuIC. 
 
These experiments suggest that CSF from patients with sporadic CJD contains molecular species 
capable of seeding the conversion of recombinant PrPc to an aggregated amyloid-rich form, which 
are not present in CSF from controls.  An “amplification” process ensues, with the misfolded 
recombinant PrP itself seeding further conversion.  Assuming that the seeding species is itself 
primarily composed of PrP, with this property conferred by its conformation, this again suggests that 
there are abnormal disease-associated PrP species in sCJD patient CSF. 
 
A number of other novel techniques for detecting disease-associated PrP in CSF have been 
published: these include combining PMCA with “SOFIA” (“surround optical fibre immunoassay”- a 
technique using capture with specific monoclonal antibodies and a novel laser-based detection 
method)167,168; and “SIFT” (“scanning for intensely fluorescent targets” after capture with 
monoclonal antibodies)169.  While they have not reached the same stage of validation as a diagnostic 
test as RT-QuIC, they have produced some promising results in small scale experiments, lending 
further support to the conclusion that detectable disease-associated PrP is present in the CSF of 
patients with sCJD. 
 
As the earlier work developing the Direct Detection Assay (DDA) for use in blood (as discussed in 
detail above, and culminating in the publication of Edgeworth et al, 2011129) suggested that this 
technique could detect very low levels of disease-associated PrP in the presence of significant levels 
of PrPc without the use of protease, it provides a promising candidate as a potential novel diagnostic 
CSF test. 
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Most of the evidence reviewed above for the presence of abnormal disease-associated PrP and/or 
infectivity in CSF comes from sCJD, in contrast with blood-borne infectivity for which the only 
evidence in human prion diseases is in vCJD.  It may therefore be more likely that the DDA will have 
a role as a CSF test in sCJD.  The distribution of infectivity in the tissues of patients with these 2 
conditions is known to differ greatly, with that in sCJD almost entirely restricted to the central 
nervous system (with very low levels detectable in the spleen), while that in vCJD is also very widely 
distributed in peripheral tissues103.  CSF may therefore be a more useful diagnostic analyte than 
blood in sCJD.  However, the DDA had only previously been proven to detect vCJD-associated 
abnormal PrP, and it is possible that there are vCJD strain-specific properties of the abnormal PrP 
species that allow their detection in the DDA, and might preclude its use as a test for sCJD. 
 
I investigated these issues, with the aim of adapting and validating the DDA as a diagnostic CSF test 
for prion disease. 
 
Relevance of previous work using DDA in blood 
From the earlier work on the DDA in blood, including that published in Edgeworth et al 2011129, 
there is evidence that the DDA can differentiate between blood samples from patients with vCJD 
and those from controls, by detecting vCJD-specific molecular species that bind to steel powder and 
are bound by a PrP-specific antibody.  As blood contains relatively large amounts of PrPc and the 
antibody used binds to both normal PrPc and misfolded PrP, the disease-specificity of the DDA seems 
likely to be conferred by differing steel-binding properties of the PrP-containing species in vCJD 
patient blood compared with control blood. 
 
It is not known, based on the previous work, to what extent the properties of the blood-borne vCJD-
specific PrP-containing species that allow their detection in the DDA are shared by PrP-containing 
species present in other tissues or fluids, or in other disease types.  It is known that different prion 
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strains may lead to accumulation of abnormal PrP with very different biochemical properties170,171, 
so it cannot be assumed that abnormal PrP in sCJD will behave in the same way as that in vCJD in the 
assay.  In addition it is not known what contribution is made to the performance of the assay by 
other factors present in blood that may interact with the disease-specific PrP-containing species, for 
example by affecting its steel-binding properties. 
 
In preparation for testing patient CSF samples it was therefore important to address several 
fundamental unanswered questions: 
 
Key questions to address 
Can normal PrPc produce high signal in the DDA? 
The detection of very low levels of abnormal PrP in the context of high background level of PrPc in 
patient blood suggests that PrPc does not in itself produce high signal in the DDA when it is used in 
blood, but this needs to be investigated in other analytes, as it may have a major impact on the 
sensitivity and specificity of the test (by affecting its signal-to-noise ratio).  To investigate this I 
planned to test an analyte containing large amounts of PrPc (wild type FVB mouse brain 
homogenate)alongside an analyte differing only in the absence of PrPc (PrP-knockout FVB mouse 
brain homogenate) at a range of dilutions. 
 
Can the DDA detect vCJD-specific PrP-containing species in the absence of blood? 
In order to address this question, I planned to test vCJD patient and control brain homogenate 
diluted into the DDA capture buffer, in the absence of blood, and if necessary re-optimise the assay 
conditions.   
 
Can the DDA detect vCJD-specific PrP-containing species in the presence of CSF? 
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Prior to testing prion disease patient CSF samples, I planned to investigate whether any factors 
present in normal CSF inhibit the performance of the DDA, by testing dilute vCJD patient and normal 
brain homogenate in the presence of CSF at different concentrations, and comparing this with the 
same concentrations in the absence of CSF. 
 
Can the DDA detect sCJD-specific PrP-containing species in the presence of CSF? 
As discussed above, there are reasons to think that the DDA would have a more useful role as a CSF 
test in sCJD rather than vCJD, and so having shown detection of vCJD-associated abnormal PrP in the 
presence of CSF, I planned to carry out equivalent experiments using sCJD brain homogenate, prior 
to proceeding with testing of diagnostic patient samples. 
 
Can the DDA differentiate vCJD or sCJD patient CSF samples from controls? 
Finally I planned to assemble a panel of vCJD, sCJD and control diagnostic CSF samples and test these 
using the DDA. 
 
Availability of samples 
In comparison with working with blood, a number of particular challenges are presented by planning 
assay development experiments with CSF.   
 
CSF is typically sampled (at lumbar puncture) in small quantities, and usually on only one occasion 
during the investigation of a patient with a neurological illness, including a suspected prion disease.  
Once samples have been used for diagnostic testing, the volumes available for use in research are 
often very small.  In order to conserve these small and precious samples (particularly those taken 
from patients with very rare diseases), as much as possible, it is necessary to take a carefully 
considered strategy to the process of assay development; a “trial and error” approach is likely to 
quickly exhaust the available analyte. 
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Whereas large numbers of anonymised blood samples taken from normal healthy people can be 
obtained from the blood transfusion services (e.g. the UK’s NHS Blood Transfusion), it is very unusual 
for normal healthy people to have CSF samples taken, so these are rarely available for use as control 
samples.  A compromise is to use CSF samples that have been taken from patients with neurological 
symptoms or diagnoses that are unlikely to cause any major changes in the CSF constituents. 
 
Obtaining CSF at autopsy can allow much larger samples to be taken, but may limit the applicability 
of findings to samples obtained at lumbar puncture during life, as there may be a risk of 
contamination of the fluid with brain or other tissue, or changes in the constituents of the CSF after 
death due to loss of active homeostatic mechanisms. 
 
The experiments presented here represent exploratory work seeking to demonstrate proof of 
principle that the Direct Detection Assay may function as a CSF test, and justify further larger scale 
work with larger sample sets and using more “pure” control samples which would be needed to 
validate an assay robustly. 
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Materials and methods 
CSF samples 
In order to assemble a panel of CSF samples for testing I searched the MRC Prion Unit database for 
all archived CSF samples and reviewed the associated clinical information to identify suitable 
samples with appropriate consent in place to allow their use in research.  Ten samples from patients 
with confirmed prion disease diagnoses were identified from this initial search.  These were all 
samples of CSF obtained at autopsy, from patients with a range of different prion disease diagnoses 
(see Table 4). 
 
I subsequently made arrangements (in collaboration with Professor Sebastian Brandner, Consultant 
Neuropathologist at University College London Hospital) for large volume CSF samples to be 
routinely collected at autopsies for patients with suspected prion disease carried out at University 
College London Hospital whenever appropriate consent was provided, in order to prospectively 
accumulate further samples.  These included samples from patients with a range of prion disease 
types and also some from patients found to have an alternative, non-prion diagnosis at autopsy (see 
Table 4). 
 
To obtain samples of CSF collected at lumbar puncture during life, we collaborated with the 
Neuroimmunology Department laboratory at the Institute of Neurology, University College London, 
to identify archived diagnostic CSF samples for patients with prion disease, and also a panel of CSF 
samples for patients that had an alternative non-degenerative diagnosis to act as controls.  19 
samples were identified as an initial panel.  These samples are also listed in Table 4, along with brief 
diagnostic/clinical details.  All lumbar puncture CSF samples had been processed on receipt to the 
Neuroimmunology Department Laboratory with centrifuge at 2500 rpm for 9 minutes at room 
temperature, and then the acellular supernatant stored at -80°C (personal communication from Mr 
Miles Chapman, Senior Laboratory Technician, Neuroimmunology Department).  Following transfer 
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to the MRC Prion Unit they were stored at -70°C.  There was no difference in the processing or 
storage of samples from patients with suspected prion disease and those from other patients. 
 
Clinical details related to the samples were obtained from existing databases (MRC Prion Unit tissue 
archive database, and Dementia Research Centre CSF database), with confirmatory information 
obtained from review of clinical notes where necessary. 
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Diagnosis & other clinical info Method of collection Number of samples 
Non-neurodegenerative controls* Lumbar puncture 12 
Non-prion, neurological disease 
controls 
AD Post mortem – prospective 1 (Large volume) 
Vascular 
and AD 
Post mortem – prospective 1 (Large volume) 
Anti-VGKC 
encephalitis 
Post mortem – prospective 1 (Large volume) 
Lewy body 
disease 
Post mortem – prospective 1 (Large volume) 
Definite sCJD Lumbar puncture 4 
Post mortem – archived 2 
Post mortem – prospective 9 
Definite vCJD Lumbar puncture 1 
Post mortem – archived 3 
Inherited prion disease E200K Lumbar puncture 1 
P102L Post mortem – archived 2 
6-OPRI Post mortem – archived 2 
7-OPRI Lumbar puncture 1 
Definite iatrogenic CJD (growth hormone) Post mortem - archived 1 
Table 4.  Details of CSF samples assembled.  AD = Alzheimer’s disease.  VGKC = voltage gated 
potassium channel.  *Diagnoses of non-neurodegenerative controls:  Schizophrenia (4), epilepsy 
(2), headache (2), depression, conversion disorder, small fibre neuropathy, autism.   
 
Brain homogenate samples 
Brain homogenate samples were used for several experiments, to provide a source of abnormal 
disease-associated PrP that could be “spiked” into either buffer or CSF.  These were all archived 
samples prepared previously by colleagues at the MRC Prion Unit.  Prior to use they were stored at 
10% of their original concentration in phosphate-buffered saline (PBS), at -70°C.  They included:  
vCJD patient human brain homogenate, sCJD patient human brain homogenate, normal human brain 
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homogenate, wild-type FVB mouse brain homogenate; PrP-null knockout FVB mouse brain 
homogenate. 
  
Standard DDA protocol for experiments with CSF and dilute brain homogenates 
The starting point for the project was the standard direct Detection Assay protocol developed for its 
use as a blood test, and used to generate the masked panel data published in Edgeworth et al, 
2011129.  This was used as the initial standard protocol, with variations introduced as the project 
progressed, which are detailed in the relevant sections below.  The standard protocol adapted for 
use with CSF or dilute brain homogenate was as follows: 
 
Stainless steel powder (<45µm, Goodfellow) is washed thoroughly using 2% triton-x-100 (Sigma), 
70% ethanol and sterile double-distilled water (ddH2O).  It is then separated into individual aliquots 
of 23mg of steel powder, each in 115μL ddH2O as a suspension and allowed to settle.  The 
supernatant liquid is removed immediately prior to use. 
 
DDA capture buffer is prepared so that the concentrations of its constituents after addition of the 
test sample, will be as follows:  100mM tris(hydroxymethyl)-aminomethane (Tris) buffer at pH 8.4, 
2% bovine serum albumin (BSA), 2% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulphonate (CHAPS) detergent, 1 complete protease inhibitor tablet (Roche)/50ml, and 10μL 
benzonase (Grade II, Merck)/50ml. 
 
For the standard protocol the test sample is diluted 1:100 into the DDA capture buffer, and the 
initial concentrations of the buffer constituents are identical to that used for the blood experiments 
described in Chapter 2:  101mM tris(hydroxymethyl)-aminomethane (Tris) buffer at pH 8.4, 2.04% 
bovine serum albumin (BSA), 2.04% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulphonate 
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(CHAPS) detergent, 1 complete protease inhibitor tablet (Roche)/50ml, and 10μL benzonase (Grade 
II, Merck)/50ml. 
All subsequent steps are carried out in a Containment Level III laboratory, adhering to all relevant 
local operating procedures. 
 
CSF and/or dilute brain homogenate samples to be tested are thoroughly thawed from storage at -
70°C.  Using the dilution required for each experiment, test samples are mixed with DDA capture 
buffer to give a final volume of 800μL, and the mixture added to a single 23mg steel powder aliquot.  
This is then incubated overnight on an Eppendorf Thermomixer at a temperature of 18°C shaking at 
650rpm. 
 
Wash solution is prepared, consisting of phosphate-buffered saline and 0.05% Tween detergent.  
The supernatant is removed from each steel powder sample, and these are then each washed 5 
times using 1mL of wash solution for each wash.  After the fifth wash is removed, dry steel samples 
are “heat-shocked” for 5 minutes at 110°C, and then allowed to cool. 
 
Biotinylated anti-PrP antibody ICSM18B (D-Gen Ltd) is prepared at a concentration of 0.6μg/ml, and 
50μL added to each steel powder sample.  These are then incubated for 1 hour on a Thermomixer at 
37°C shaking at 750rpm. 
 
Supernatant is removed and samples are washed a further 3 times using 1mL of wash solution for 
each wash.  Horseradish peroxidase conjugated NeutrAvidin-HRP (Pierce) is prepared at 1:100 000 
dilution, and 50μL added to each dry steel powder sample.  These are then incubated for 45 minutes 
on a Thermomixer at 37°C shaking at 750rpm. 
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Supernatant is removed and samples are washed a further 3 times using 1mL of wash solution for 
each wash.  Femto chemiluminescent SuperSignal reagent (Pierce) is prepared by mixing equal 
volumes of the 2 constituent parts as per the manufacturer’s instructions. 60μL is added to each 
steel powder sample.  Each steel powder sample is then resuspended in this liquid and separated 
equally between 3 wells of a black, 96-well, flat-bottomed ELISA plate (Greiner), so that each 
contains 20μL of Femto reagent and approximately 7.67mg of steel powder. 
 
A dilution series of NeutrAvidin giving dilutions of 1:1x106, 1:1x107 and 1:1x108 is also prepared.  
20μL of each of these is added to 3 replicate wells. 
 
A further 80μL of Femto reagent is added to each well, and the plate is then immediately read using 
a M100 plate reader (Tecan), using luminescence settings. 
 
The mean luminescent signal measured from the 3 wells for each sample is taken as the DDA result 
for that sample. 
 
Quality control for experiments using CSF and dilute brain homogenate 
When this project was begun, the only samples known to produce a reliable positive result in the 
DDA were whole blood samples from patients with vCJD.  It was therefore necessary to use these as 
positive control samples for quality control initially (as they were used in the experiments described 
in Chapter 2).  However, these samples represent a finite and extremely precious resource, as the 
total number of such samples stored is small, and at present there are no opportunities for acquiring 
new samples as there were no patients with vCJD currently alive in the UK at the time.  I therefore 
aimed to establish alternative positive and negative controls in the early stages of this project which 
did not require the use of vCJD patient blood.  These consisted of brain homogenate from a vCJD 
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patient and from a normal individual diluted in the DDA capture buffer, and are described in the 
course of the experiments below. 
 
Testing of dilute PrP-null and wild type FVB mouse brain homogenates 
Homogenated samples of (1) wild type FVB mouse brain, (2) PrP-null (knockout) FVB mouse brain, 
and (3) normal human brain were obtained (prepared by colleagues at the MRC Prion Unit).  Prior to 
use, these were stored at 10% of their original concentration in phosphate-buffered saline (PBS), at -
70°C.  10-fold dilution series of each brain homogenate were prepared using standard DDA capture 
buffer as diluent, to give concentrations of 10-2, 10-3 and 10-4.  These were then tested using the 
standard DDA protocol, including a further 1:100 dilution into DDA capture buffer, giving final brain 
homogenate concentrations during incubation with steel powder of 10-4, 10-5 and 10-6.  The results 
of this experiment are shown in Figure 14. 
 
Testing of dilute vCJD brain homogenate 
Samples of human brain homogenate taken from (1) a patient with vCJD, and (2) an individual 
without neurological disease were obtained (prepared by colleagues at the MRC Prion Unit).  Other 
aliquots of the same samples have previously been used in transmission bioassay and Western 
blotting experiments, confirming the presence of vCJD infectivity and protease-resistant PrP in the 
vCJD sample, and the absence of detectable infectivity or protease-resistant PrP in the normal 
sample.  These brain homogenate samples were stored at 10% of their original concentration in PBS, 
at -70°C prior to use.  A 10-fold dilution series of each was prepared using the standard DDA capture 
buffer to give concentrations ranging from 10-2 to 10-7.  These were then tested using the standard 
DDA protocol, including a 1:100 dilution into the DDA capture buffer, giving final brain homogenate 
concentrations during incubation with steel powder ranging from 10-4 to 10-9.  The results are shown 
in Figures 15 and 16 below. 
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A similar experiment was carried out using an alternative buffer in place of the standard DDA 
capture buffer. The buffer consisted of: Opti-MEM media (Gibco) + 10% Foetal calf serum + 1% 
penicillin/streptomycin + 10-4 PrP-null FVB mouse brain homogenate.  This buffer was based on that 
used in previous experiments by members of the Molecular Diagnostics group involving binding of 
brain-derived prion infectivity to steel wires for transfer to cell culture 131, as this had convincingly 
shown binding of infectivity to steel in the absence of blood.  The method was otherwise identical to 
that in the previous experiment.  The results are shown in Figure 17. 
 
Testing of vCJD brain homogenate/CSF spikes 
To test whether brain-derived vCJD-associated abnormal PrP could be detected with the DDA in the 
presence of CSF, 10-fold dilution series of vCJD and normal brain homogenate samples were 
prepared using one of the large volume non-prion neurological disease control CSF samples as 
diluent (obtained at autopsy from a patient with cerebrovascular disease and Alzheimer’s 
pathology), to give brain homogenate concentrations from 10-2 to 10-6.  These were then tested 
using the standard DDA protocol, including a further 1:100 dilution into the DDA capture buffer, 
giving final brain homogenate concentrations during incubation with steel powder ranging from 10-4 
to 10-8, and a final CSF concentration of 10-2.  The experiments were also repeated without the heat 
shock step of the standard DDA protocol. 
 
For these experiments, vCJD and normal brain homogenate diluted in DDA capture buffer to a 
concentration of 10-2 were used as positive and negative controls for quality control purposes, as the 
primary objective was to investigate the effect of the presence of CSF compared with results 
obtained in the previous experiments using brain homogenate diluted in DDA capture buffer (see 
above). 
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A further set of experiments were performed testing the same dilution series of brain homogenates 
diluted in control CSF, but with a modification to the standard DDA protocol so that the test sample 
was only diluted 1:10 in DDA capture buffer.  This gave final brain homogenate concentrations of 10-
3 to 10-7 and a final CSF concentration of 10-1.  Constituents of the DDA capture buffer were adjusted 
to ensure that their final concentration during the incubation with steel powder was unchanged.  
These experiments were also repeated without the heat shock step of the DDA protocol. 
 
The results of these experiments are shown in Figures 18 and 19. 
 
Further experiments were performed to investigate alterations of assay conditions and components 
aiming to optimise its performance with this analyte, and ideally to allow differentiation at lower 
concentrations of abnormal PrP.  All of these experiments consisted of varying one parameter from 
the standard DDA protocol at a time and comparing this directly with the standard protocol.   
 
Parameters investigated were:  
1) Heat shock temperatures of 70°C, 80°C, 90°C and 100°C 
2) Use of an alternative, more highly biotinylated batch of ICSM-18B antibody;  
3) Use of an alternative preparation of steel powder [316 vs 304].   
 
Results of these experiments are shown in Figures 20, 21 and 22. 
 
Testing of sCJD brain homogenate/CSF spikes 
To test whether brain-derived sCJD-associated abnormal PrP could be detected with the DDA in the 
presence of CSF, 10-fold dilution series of sCJD and normal brain homogenate samples were 
prepared using one of the non-prion neurological disease control CSF samples as diluent (obtained 
at autopsy from a patient with cerebrovascular disease and Alzheimer’s pathology), to give brain 
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homogenate concentrations from 10-2 to 10-6.  These were then tested using the standard DDA 
protocol, including a 1:100 dilution into the DDA capture buffer, giving final brain homogenate 
concentrations during incubation with steel powder ranging from 10-4 to 10-8, and a final CSF 
concentration of 10-2.  The experiments were also repeated without using the heat shock step of the 
standard DDA protocol. 
 
For these experiments, sCJD and normal brain homogenate diluted in DDA capture buffer to a 
concentration of 10-2 were used as positive and negative controls for quality control purposes, as the 
primary objective was to investigate the effect of the presence of CSF compared with results 
obtained in the previous experiments using brain homogenate diluted in DDA capture buffer (iii 
above). 
 
A further set of experiments were performed testing the same dilution series of brain homogenates 
diluted in control CSF, but with a modification to the standard DDA protocol so that the test sample 
was only diluted 1:10 in DDA capture buffer.  This gave final brain homogenate concentrations of 10-
3 to 10-7 and a final CSF concentration of 10-1.  Constituents of the DDA capture buffer were adjusted 
to ensure that their final concentration during the incubation with steel powder was unchanged.  
These experiments were also repeated without the heat shock step of the DDA protocol. 
 
The results of these experiments are shown in Figures 23 and 24. 
 
Testing of diagnostic patient CSF samples 
As there was evidence of differentiation between vCJD brain homogenate and normal brain 
homogenate diluted into CSF/buffer, albeit only at relatively high concentrations, I proceeded with 
testing real patient CSF.As none of the modifications to the standard DDA protocol had led to any 
consistent improvement in its performance, the unmodified standard protocol was used, with CSF in 
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place of blood.  A panel of samples was tested using the standard DDA protocol, in batches including 
several non-neurodegenerative control CSF samples (see Table 4) and several LP-derived CSF 
samples from sCJD +/- vCJD patients.  Overall, 11 control samples, 4 sCJD samples and 1 vCJD sample 
were each tested on 2 separate occasions. 
 
vCJD and normal brain homogenate diluted into 2 separate samples of PM-derived control CSF to a 
concentration of 10-2 were used as positive and negative controls respectively, for quality control 
purposes.  The 2 PM-derived CSF samples were also tested without addition of brain homogenate, 
for comparison. 
 
The results of the 2 separate assay runs on the same panel of samples were adjusted by 
standardising to the luminescent signal from a 1:10 million dilution of the NeutrAvidin reagent 
tested on the same plate.  Results for these experiments are shown in Figure 25. 
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Results 
Dilute PrP-null and wild type FVB mouse brain homogenates 
The results of this experiment are illustrated in Figure 14 (luminescence results shown on both 
standard and logarithmic scale). 
 
 
Figure 14.  Direct detection assay testing 3 brain homogenates at a range of concentrations:  PrP-
null FVB mouse brain, wild-type FVB mouse brain, and normal human brain.  Bars show mean and 
SD of luminescence across 3 replicate wells.  Each concentration of each brain homogenate was 
tested in 2 separate assay runs.  The same data is shown against linear and logarithmic scales in 
the two charts. 
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Wild type mouse brain homogenate produced much higher luminescent signal than equivalent 
dilutions of PrP-knockout mouse brain homogenate, suggesting that PrPc was binding to the steel 
powder and accounting for the high signal.  Although there was a dilution effect seen with PrP-
knockout mouse brain, with reducing signal from reducing concentrations, the absolute levels were 
much lower than for wild type brain homogenate.  Equivalent dilutions of normal human brain 
homogenate also produced higher luminescent signal than the PrP-knockout mouse brain (although 
not as high as the wild type FVB mouse brain), suggesting that human PrPc is also able to bind to the 
steel powder and be detected by the assay.  However, as it is not possible to directly compare this 
with a PrP-knockout human brain homogenate, confounding effects from other non-PrP constituents 
of the human brain homogenate cannot be entirely ruled out. 
 
Dilute vCJD brain homogenate 
As shown in Figure 15, testing a range of dilutions of vCJD and normal human brain homogenate in 
DDA capture buffer suggested that the assay could differentiate vCJD from normal at higher 
concentrations (10-4).  However, at lower concentrations, there was not reliable differentiation, and 
the luminescent signal was not significantly above that produced by steel powder without any 
biological sample added. 
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Figure 15.  Direct detection assay testing vCJD and normal human brain homogenates at a range of 
dilutions in the standard DDA capture buffer.  Bars show mean luminescence and SD across 3 
replicate wells. 
 
Following on from these initial results, vCJD and Normal brain homogenates diluted to 10-4 
concentration were tested “head-to-head” on 5 separate occasions to ensure that there was robust 
and reliable differentiation.  These results are shown in Figure 16.  A paired 2 sample t-test 
comparing the adjusted means from 5 replicate assays for 10-4 dilution vCJD and normal brain 
homogenate, gives a p value of 0.0059. 
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Figure 16.  Repeated DDA testing of vCJD and normal human brain homogenates diluted to 10-4 in 
standard DDA capture buffer, on 5 separate occasions.  Bars show mean and SD of luminescent 
signal across 3 replicate wells (adjusted in proportion to the mean luminescent signal from a 
standard 10-7 dilution of NeutrAvidin tested on the same plate, to allow direct comparison of 
results from different assay runs).  
 
On the basis of these results, 10-4 dilutions of vCJD and normal brain homogenate were used as 
positive and negative controls for subsequent experiments. 
 
The experiments using the alternative Opti-MEM based buffer did not produce evidence of 
differentiation of vCJD from normal brain homogenate at any of the concentrations tested, as shown 
in Figure 17. 
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Figure 17.  Direct detection assay testing vCJD and normal human brain homogenates at a range of 
dilutions in Opti-MEM-based buffer (see Materials and methods above for details).  Bars show 
mean luminescence and SD across 3 replicate wells. 
 
vCJD brain homogenate/CSF spikes 
The results for testing of vCJD and normal human brain homogenates diluted into CSF at a range of 
dilutions are shown below.  Figure 18 shows results from the experiment using a 1:100 dilution of 
spiked CSF into the DDA capture buffer (as used for blood in the standard assay protocol), and Figure 
19 shows results from the experiment using a 1:10 dilution.  
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Figure 18.  Direct detection assay comparing vCJD and normal brain homogenates diluted to a 
range of concentrations in CSF, with the “spiked” CSF diluted 1:100 into the DDA capture buffer.   
Brain homogenate concentrations shown are the final concentrations during incubation with steel 
powder (i.e. after dilution into DDA capture buffer).Brain homogenates diluted to 10-4 in DDA 
capture buffer (without CSF), unspiked CSF, and buffer-only controls included for comparison.  
Bars show mean and SD of luminescence across 3 replicate wells. 
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Figure 19.  Direct detection assay comparing vCJD and normal brain homogenates diluted to a 
range of concentrations in CSF, with the “spiked” CSF diluted 1:10 into the DDA capture buffer.  
Brain homogenate concentrations shown are the final concentrations during incubation with steel 
powder (i.e. after dilution into DDA capture buffer).  Brain homogenates diluted to 10-2 in CSF and 
then diluted 1:100 into DDA capture buffer, unspiked CSF at 1:10 and 1:100 dilutions, and buffer-
only controls were included for comparison.  Bars show mean and SD of luminescence across 3 
replicate wells. 
 
Comparing these results with those obtained from testing vCJD and normal brain homogenates 
diluted in DDA capture buffer in the absence of CSF (as shown in Figures 15 and 16 above), suggests 
that the presence of CSF, at concentrations up to 1:10, does not prevent the assay from 
differentiating vCJD from normal brain homogenate, when this is present at a concentration of 10-4 
during the incubation with the steel powder. 
 
Some secondary observations can also be made.  There does not appear to be any consistent 
differentiation of vCJD from normal brain at lower than 10-4 concentrations of brain homogenate.  
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The protocol involving 1:10 dilution of the spiked CSF is able to differentiate initial (pre-dilution) 
samples with a brain homogenate concentration of 10-3, while the protocol involving 1:100 dilution 
can only reliably differentiate samples at a concentration of 10-2. 
 
Another observation illustrated by Figure 19 is that unspiked CSF diluted 1:10 into DDA capture 
buffer consistently produced higher luminescent signals than samples that contained the same 
amount and concentration of the same CSF sample, but also contained brain homogenate, even 
when this was at very low concentrations. Possible reasons for this are discussed below. 
Optimising assay parameters for vCJD brain homogenate spiked CSF 
Figures 20, 21 and 22 show three examples of optimisation experiments in which assay parameters 
were varied to look for any improvement in the assay’s performance (when used to differentiate 
between CSF spiked with vCJD brain homogenate, and CSF spiked with normal human brain 
homogenate).  In each experiment one parameter was varied while all other aspects of the standard 
DDA protocol as described above were maintained.  Parameters investigated were primary antibody 
batch and concentration (Figure 20), heat shock temperature (Figure 21) and steel powder batch 
(Figure 22).  “304” and “316” steel are alternative stainless steel alloys with slightly different nickel 
and carbon contents (both manufactured by Goodfellow). 
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Figure 20. Direct detection assay comparing vCJD and normal brain homogenates diluted to a range of concentrations in CSF and spiked CSF diluted 
1:100 into DDA capture buffer, with variation in primary antibody batch and concentration as indicated.  Bars show mean and SD of luminescence across 
3 replicate wells.
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Figure 21. Direct detection assay comparing vCJD and normal brain homogenates diluted to a 
range of concentrations in CSF and spiked CSF diluted 1:100 into DDA capture buffer, with 
variation in heat shock temperature used. 
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Figure 22. Direct detection assay comparing vCJD and normal brain homogenates diluted to a 
range of concentrations in CSF and spiked CSF diluted 1:100 into DDA capture buffer, with 
variation in steel powder batch used.  Bars show mean and SD of luminescence across 3 replicate 
wells. 
 
sCJD brain homogenate/CSF spikes 
The results for testing of sCJD and normal human brain homogenates diluted into CSF at a range of 
dilutions are shown below.  Figure 23 shows results from the experiment using a 1:100 dilution of 
spiked CSF into the DDA capture buffer (as used for blood in the standard assay protocol), and Figure 
24 shows results from the experiment using a 1:10 dilution. 
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Figure 23.  Direct detection assay comparing sCJD and normal brain homogenates diluted to a 
range of concentrations in CSF, with the “spiked” CSF diluted 1:100 into the DDA capture buffer.  
Brain homogenate concentrations shown are the final concentrations during incubation with steel 
powder (i.e. after dilution into DDA capture buffer).  Brain homogenates diluted to 10-4 in DDA 
capture buffer (without CSF), unspiked CSF, and buffer-only controls included for comparison.  
Bars show mean and SD of luminescence across 3 replicate wells. 
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Figure 24.  Direct detection assay comparing sCJD and normal brain homogenates diluted to a 
range of concentrations in CSF, with the “spiked” CSF diluted 1:10 into the DDA capture buffer.  
Brain homogenate concentrations shown are the final concentrations during incubation with steel 
powder (i.e. after dilution into DDA capture buffer).  sCJD, vCJD and normal brain homogenates 
diluted to 10-2 in CSF and then diluted 1:100 into DDA capture buffer, unspiked CSF at 1:10 and 
1:100 dilutions, and buffer-only controls were included for quality control and comparison.  Bars 
show mean and SD of luminescence across 3 replicate wells. 
 
Again there did not appear to be any successful differentiation of sCJD from normal brain 
homogenate, at any of the dilutions tested.  The same phenomenon whereby unspiked CSF samples 
diluted 1:10 produce higher luminescent signal than the same concentration of the same CSF in the 
presence of dilute brain homogenate was observed, as in the equivalent experiment with vCJD. 
 
Testing of diagnostic CSF samples 
The results from this experiment are shown in Figure 25.   
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Figure 25.  Testing of diagnostic, lumbar puncture CSF samples from 11 non-neurodegenerative control patients, 4 sCJD patients and 1 vCJD patient using 
standard Direct Detection Assay protocol.  Each sample was tested on 2 separate assay runs, and the results are combined by standardising to the 
luminescent signal produced by a standard 1:10m dilution of NeutrAvidin tested on the same plate.  vCJD and normal brain homogenates diluted to 10-2 
in 2 different PM-derived non-prion control CSF samples (giving final brain homogenate concentration of 10-4 during incubation with steel powder), the 2 
PM-derived control CSF samples unspiked, and buffer-only controls were included for quality control and comparison.   
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Unexpectedly, the samples from patients with prion disease produced consistently lower 
luminescent signal than those from non-degenerative controls.  Comparing the adjusted mean 
luminescent signal results from these 2 groups (controls vs prion disease, including sCJD and vCJD) 
with a 2 tailed t-test gives a p value of 0.0087. 
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Discussion 
The series of experiments described above represent early attempts to apply the direct detection 
assay, which had been developed and validated specifically as a blood test for vCJD, to cerebrospinal 
fluid. 
 
As has been discussed in Chapter 2 above, the assay itself remains quite poorly understood, and its 
development and validation as a blood test relied heavily on empirical testing under a very large 
number of different conditions until a successful combination was found.  From previous experience 
in applying the assay to blood taken from mice or hamsters, and from experiments involving blood 
spiked with brain homogenate (see Introduction to Chapter 2), it was clear that the assay was very 
sensitive to changes in conditions, in ways that could not easily be predicted or explained.  As a 
result, it was difficult to make predictions about what effect changing any constituent element or 
condition of the assay would have, and this made the process of planning its application to CSF very 
challenging. 
 
Unfortunately CSF does not lend itself well to a process of empirical, exploratory assay development, 
where it would often be useful to test a very large number of different combinations of conditions, 
as it is typically sampled in very small volumes.   
 
One way in which this issue was dealt with was to make use of larger volume CSF samples obtained 
post mortem for some elements of the experiments described, but this is not ideal, and introduces a 
number of potentially problematic issues.  The non-prion control CSF samples obtained at post 
mortem (see Table 4) were taken from patients that had died with an alternative neurological 
illness: namely Alzheimer’s disease, or Alzheimer’s disease with coexisting cerebrovascular disease.  
The constituents of these patients’ CSF are likely to have been affected by the disease from which 
they were suffering, and it is possible these changes might have had an impact on the assay.  For 
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example, other non-PrP aggregated amyloid proteins might interact with disease-associated PrP in 
the spiked CSF, or might compete with it for binding to the steel.  The principal aim of the 
experiments using these CSF samples was to demonstrate that the presence of CSF did not interfere 
with the ability of the assay to detect disease-associated PrP, even at higher concentrations.  It was 
felt that it was reasonable to prioritise availability of larger samples over having very strict and 
“clean” control CSF, but this does represent a compromise.   
 
In other parts of the project where diagnostic CSF samples obtained at lumbar puncture were being 
tested, it was necessary to have more closely matched control samples for the results to be 
meaningful.  Comparing lumbar puncture samples from prion disease patients with post mortem 
control samples would be unsatisfactory.  I used CSF samples obtained at lumbar puncture from 
patients with symptoms or diagnoses not typically associated with any known changes in the CSF.  It 
is important to remember that these are not “normal” CSF samples, but for the purposes of these 
experiments they provide reasonable control samples for comparison.  
 
If work on the DDA in CSF reached a stage where a potential diagnostic assay for clinical use was 
being validated, the choice of control samples would need to be carefully considered.  While 
comparison with entirely normal control samples from healthy volunteers is scientifically appealing, 
it must be remembered that the role of a clinical diagnostic test is usually to distinguish between a 
specific condition and other conditions that might produce similar clinical features.  The results will 
therefore be more useful in practice if a comparison group of samples from patients with other 
diagnoses are included – this approach was taken in the masked panel experiment validating the 
DDA as a vCJD blood test129. 
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The results of these experiments suggest that the standard Direct Detection Assay is able to detect 
brain-derived vCJD-associated abnormal PrP in the presence of CSF, but that the same is not true for 
sCJD-associated abnormal PrP.   
 
vCJD brain homogenate could only be differentiated from normal brain homogenate at a 
concentration of 10-4 or above, whether in the presence of CSF or not.  In contrast, previous 
experiments involving testing of vCJD brain homogenate spiked into normal control blood published 
in Edgeworth et al 2011129 showed that concentrations from 10-7 to 10-10 of vCJD brain homogenate, 
in the presence of blood, produced significantly higher luminescent signal in the assay than a 10-6 
concentration of normal brain homogenate in blood, with the impression of a dilution effect in the 
luminescent signal across the dilution series of vCJD brain homogenate: this is shown in Figure 5 in 
the Introduction of Chapter 2 above, which is reproduced from Edgeworth et al 2011129.   
 
The reasons for this striking discrepancy must either relate to the effect of the presence of blood in 
the assay, or on other conditions or constituents that varied between these previous experiments 
and the current experiments.  This should be investigated further, including seeking to determine 
whether one or more components in normal blood act as cofactors for the assay improving its 
sensitivity.  If these could be identified, they could be added to the buffers used for non-blood 
analytes. 
 
Conclusions on current performance in diagnostic (lumbar puncture) CSF samples 
The results of the testing of diagnostic CSF samples using the standard DDA protocol shown in Figure 
25 are striking, but are not easy to explain.  The luminescent signal produced by the sCJD and vCJD 
samples was consistently lower than that from the non-neurodegenerative controls, some of which 
produced very high signals.   
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Addressing the control samples first, it was striking that compared with normal control blood 
samples; the DDA results from these control CSF samples were much more variable, with some 
individual samples consistently producing very high signals across multiple occasions of testing.  
Given that none of these samples had been in any contact with tissue from patients with prion 
disease, it is likely to be PrPc being detected in these samples; we know from experiments described 
above that PrPc is able to produce high signal in the DDA in the right circumstances(see Figure 14).  
Might it be that the control samples producing very high DDA signal contain relatively high 
concentrations of PrPc?  This would be worth exploring:  methods of quantifying PrPc such as ELISA 
could be used, and the results correlated with the DDA results. 
 
Possible explanations for unexpected results in testing of patient CSF 
The finding that the sCJD and vCJD patient CSF samples produced consistently lower luminescent 
signal than controls was unexpected, but consideration of how this might be explained may raise 
important questions about how the DDA works and suggest valuable avenues for further work. 
Previously published work has shown that the total levels of PrP in CSF are reduced in patients with 
sCJD161.   If the output of the DDA when used in CSF is dominated by the concentration of PrPc in the 
test sample rather than the presence or absence of abnormal disease-associated PrP, then the lower 
signal from the CJD samples might be simply accounted for by the lower levels of total PrP.  Why 
should this be the case in testing patient CSF, but not in testing dilute brain homogenate, brain-
homogenate spiked CSF or patient blood?  The overall protein content of CSF is very low in 
comparison with that of blood, or of brain homogenate.  It is possible that other, non-PrP proteins 
present in blood and brain homogenate play an important role in the functioning of the assay.  A 
model of competitive binding might explain this:  as the detection antibody in the DDA does not 
distinguish normal from disease-associated PrP, and I have shown that normal PrP can produce high 
luminescent signals in the DDA in the right context, it seems likely that “blocking” of binding of PrPc 
to the steel would play an important part in the assay.  If this blocking is achieved by other protein 
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species present in the blood or brain-homogenate, but absent from CSF, this could explain the 
observed results.  This might also account for the surprising observation of unspiked CSF producing 
higher luminescent signal than the same CSF spiked with normal control brain homogenate. 
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CHAPTER 4.  FURTHER WORK ON THE DDA AS A VCJD BLOOD TEST 
Introduction 
Following on from the work on the Direct Detection Assay as a blood test for vCJD (as published in 
Edgeworth et al, 2011129), and further work exploring other applications for the test (including that 
described in the previous two chapters), a number of important unanswered questions remain 
regarding the assay. 
 
One striking observation from the previous work on the DDA as a blood test for vCJD is that the 
optimised assay involves testing only 8μl of blood, diluted 100-fold into the DDA capture buffer.  
When one of the fundamental challenges of designing a vCJD blood test was to find a way to detect 
the very small amounts of abnormal disease-associated PrP thought to be present in blood, it seems 
counter-intuitive to use such a small amount of the analyte.  I planned exploratory experiments to 
investigate ways of scaling up the assay, aiming to increase the signal to noise ratio (i.e. the ratio of 
luminescent signal produced by vCJD samples to that produced by normal control samples) and 
thereby improve the sensitivity of the assay. 
 
Materials and methods 
These experiments used the standard DDA protocol for blood (as documented in detail in the 
Materials and methods section of Chapter 2 above) as a starting point.  Modifications to this 
standard protocol introduced in the course of the experiments are described below. 
 
A small panel of vCJD and normal control whole blood samples that had previously been used in the 
published masked panel experiment and were known to produce positive and negative DDA results 
respectively was used. 
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Pooling multiple replicate steel powder samples 
Six replicate samples sets, each consisting of 1 vCJD and 3 normal control whole blood samples, were 
tested using the standard DDA protocol (24 samples in total).  Immediately prior to transferring the 
steel powder to the 96-well plate, 5 replicates of each sample were combined, to give 1 single 
(23mg) sample and 1 pooled, quintuple sample (115mg) for each blood sample.  These were than 
each split across 3 wells of the plate as per the standard protocol, except that in order to allow equal 
separation of the 115mg steel samples these were suspended in 180μl of Femto reagent which was 
then split into 3 x 60μlacross the 3 wells (rather than 60μl split into 3 x 20μl).  All wells were then 
topped up to give a total of 100μl Femto reagent in each well, as in the standard protocol. 
 
Use of 24 well plates with wider wells 
Adding larger steel samples to the small wells of a 96-well plate led to piling of steel in the wells.  As 
the luminescent signal was detected from above each well, only the luminescence produced by steel 
particles on the top surface of the pile would be able to reach the detector and increase the overall 
luminescent signal.  This could account for the failure of simply increasing the amount of all the 
constituents being added to the plate (by pooling 5 samples immediately prior to transferring to the 
plate as in the above experiment) to proportionately increase the luminescent signal produced.  I 
therefore investigated the use of alternative plates with wider wells.  24-well plates were obtained, 
with each well having an area of1.9cm2 (compared with approximately 34mm2 for a 96-well plate). 
 
Initially the above experiment using single and pooled, quintuple steel samples was repeated using 
the 24 well plates.  Again the pooled 115mg samples were resuspended in 180μl of Femto reagent as 
in the previous experiment.  All wells on the 24-well plates were topped up to a total volume of 
600μl of Femto reagent (increased from the 100μl used for the 96 well plates), to ensure even 
coverage of the steel within the larger wells.  
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Increasing the blood input of the assay using 24 well plates 
Next, 3 replicate panels of 1 vCJD and 3 normal control samples were tested using: 
1) the standard DDA protocol except for use of 24 well plates (Greiner) (with adjustments to 
the Femto reagent volumes as described in the previous experiment), with 8μl of blood and 
23mg of steel powder. 
2) as above, but volume of blood increased to 16μl. 
3) as above, but volume of blood increased to 16μl and amount of steel increased to 46mg. 
 
Results 
Pooling multiple replicate steel powder samples 
The results of this experiment are shown in Figure 26 below.  While the luminescent signal produced 
by the pooled quintuple vCJD sample was higher than that from the single sample, it was increased 
only by a factor of 1.69, and there was a relatively greater increase in the signal from the normal 
control samples, so that the positive to negative ratio was reduced.  As each of the five samples 
combined for the pooled sample were identical to the single sample, we can assume that the pooled 
sample contained 5 times the quantity of bound NeutrAvidin, and would therefore expect it to 
produce 5 times the luminescent signal when mixed with an excess of the chemiluminescent 
reagent. 
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Figure 26.  Direct detection assay testing of vCJD and normal control whole blood samples, as 
standard single samples and as quintuple, pooled samples combined immediately prior to 
aliquotting onto the plate, using standard 96 well plate. Bars show mean and SD of luminescence 
across 3 replicate wells. 
 
An observation made during this experiment provides a possible explanation for the fact that this 
was not the case.  When 38.3mg of steel was added to a well of the 96-well plate (each 115mg 
combined sample split across 3 wells), there was piling of the steel in the small well.  As the 
luminescent signal is detected from above each well while the plate is stationary, the luminescent 
signal that is able to reach the detector will come from those steel particles on top of the pile, and as 
such is likely to be more closely related to the surface area of the top of the pile rather than the total 
amount of steel.  Adding more steel to a small well may produce a taller pile without greatly 
increasing the surface area visible to the detector.  This is illustrated in Figure 27.  This issue could 
explain a “ceiling effect” in experiments aiming to increase the signal to noise ratio of the assay. 
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Figure 27.  Schematic diagram showing suggested explanation for apparent ceiling effect when scaling up the assay using small welled plates.  
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Use of 24 well plates with wider wells 
To investigate the above hypothesis directly the same experiment was repeated with 24-well plates 
used in place of the 96-well plates.  The results of this experiment are shown in Figure 28. 
 
Figure 28.  Direct detection assay testing of vCJD and normal control whole blood samples, as 
standard single samples and as quintuple, pooled samples combined immediately prior to 
aliquotting onto the plate, using 24 well plates. Results from 2 separate plates are combined by 
standardising to the luminescent signal produced by a standard 1:10 million dilution of 
NeutrAvidin tested on the same plate.  Bars show mean and SD of luminescence across 3 replicate 
wells. 
 
The pooled, quintuple vCJD sample now produced a luminescent signal 3.13 times that of the 
corresponding single sample.  However the signal from the pooled normal samples was also 
increased, and the ratio of the vCJD sample to the mean of the normal control samples was 4.15 for 
the pooled samples compared with 6.65 for the single samples; i.e. there had been no benefit to the 
signal to noise ratio of the assay. 
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Increasing the blood input of the assay using 24 well plates 
The results of this experiment are shown in Figure 29 below, and the key findings shown below: 
Blood volume (μL) Steel amount (mg) 
Ratio of luminescent signal 
vCJD : mean of normals 
8 23 2.50 
16 23 3.96 
16 46 5.52 
 
 
Figure 29. Direct detection assay using 24 well plates and increasing amounts of blood and steel, 
using panel of vCJD and normal control whole blood samples.  Bars show mean and SD of 
luminescent signal across 3 replicate wells.  The assay could not be completed for sample n3 in the 
8μl blood/23mg steel sample set for technical reasons (steel lost during wash steps). 
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Discussion 
This chapter describes a small set of exploratory experiments aiming to better understand and 
improve the functioning of the Direct Detection Assay as a blood test for vCJD.  These experiments 
formed part of a wider project of the Molecular Diagnostics group aiming to improve on the 
standard assay, by improving our understanding of how the assay works, and by exploring 
interesting or unexpected observations from previous work, such as the need to dilute blood for the 
assay to be successful in detecting vCJD patient blood. 
 
The results suggest that it may be possible to achieve some improvements in the signal to noise ratio 
of the assay by increasing the amount of blood and steel used, but that this requires some technical 
modifications to the assay (including use of larger-welled plates to allow dispersal of the larger 
amounts of steel in the well). 
 
These experiments were very small and their conclusions should be interpreted with caution: they 
would require replication in larger sample sets to confirm their conclusions more robustly.  
Nevertheless, they are included here partly to provide examples of this empirical method of assay 
development, and the challenges this presents. 
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CHAPTER 5. PSYCHIATRIC AND BEHAVIOURAL FEATURES OF HUMAN PRION 
DISEASE 
Introduction 
Behavioural disturbance and psychiatric symptoms (BPS) have been recognized since the earliest 
descriptions of prion disease172, but there has been relatively little research into their prevalence, 
phenomenology and treatment, or their molecular pathophysiological basis. When vCJD first 
appeared in the UK in the 1990s, psychiatric features were noted to be relatively prominent, 
particularly in the early phase of the illness, and this has been well studied in the context of the UK 
CJD surveillance system 102,173.  As a result, the presence of “early psychiatric symptoms” (specifically 
“depression, anxiety, apathy, withdrawal, delusions”) is included in the WHO diagnostic criteria for 
vCJD107.  A recent review of 106 pathologically confirmed cases of vCJD concluded that these early 
psychiatric symptoms were present in 92%105. 
 
In 2005, Wall et al reported a retrospective study of psychiatric symptoms in all sCJD cases evaluated 
at the Mayo clinic over 25 years, based on detailed review of clinical case notes174. This included 126 
patients and found that psychiatric symptoms (excluding sleep disturbance) were present in 26% of 
cases at presentation, in 80% within the first 100 days after onset, and in 89% at any stage of their 
illness.   
 
Appleby and colleagues have used retrospective casenote review175 and meta-analysis of published 
cases176 to investigate patterns of symptoms in sporadic CJD, and suggest the existence of a distinct 
“affective sCJD variant”. 
 
Published experience of pharmacological treatments in prion disease has focused on putative 
disease-modifying agents.  Interestingly, chlorpromazine and the tricyclic antidepressants are among 
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a number of agents that have been found to inhibit prion replication in vitro119,177 and their use in 
prion disease patients has been published in a handful of case reports178-181, but these reported their 
failure to halt the progression of the disease rather than any usefulness to treat psychiatric 
symptoms.  Beyond this there is no previously published evidence on which to base the symptomatic 
treatment of BPS in patients with prion disease. 
 
In contrast, BPS in Alzheimer's disease (AD) and other common dementias have received increasing 
clinical and scientific attention in recent years.  They are recognised as a major cause of morbidity in 
themselves, and are associated with poorer outcomes for patients and more stress for carers182,183.  
Large scale research into their treatment has produced unexpected and important results in terms of 
both efficacy and safety.  For example, meta-analysis of clinical trials using atypical antipsychotics for 
agitation and aggression in AD has shown only very modest efficacy compared with placebo 184 and 
substantial safety concerns, with a significant increase in mortality (odds ratio 1.54) 185.  This 
highlights the importance of systematic study of these symptoms to allow safe and evidence-based 
care of patients.  Several studies have used factor analysis to show that BPS in AD tend to occur in a 
small number of clusters or “subsyndromes”186,187.  All studies have reported psychosis, mood and 
hyperactivity/agitation clusters (although specific names used vary). 
 
The project presented in this chapter uses systematically collected clinical data from 357 patients 
(317 patient-years of follow-up) that have been studied in the context of the PRION-1 trial and/or 
the National Prion Monitoring Cohort, to carry out a comprehensive study of the behavioural and 
psychiatric features of the human prion diseases. 
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Patients and Methods 
Patients 
All patients were referred to the NHS National Prion Clinic, and were enrolled in the PRION-1 trial 
and/or the National Prion Monitoring Cohort.  Uptake of enrolment in these clinical research studies 
is extremely high (>95% in the Cohort), so they provide a highly representative sample of patients 
seen in this clinical setting. 
 
Asymptomatic individuals known to be at risk of prion disease were also enrolled in the Cohort.  
Individuals were eligible if they were known to have received a transfusion of whole or 
leucodepleted blood donated by a person who later developed vCJD, or if they were an 
asymptomatic first degree relative of a patient with IPD (and had not had a negative genetic test).   
These at risk individuals are included in selected parts of the analysis below where specifically noted. 
 
Clinical data from PRION-1 and the Cohort study 
Theses clinical studies are described in detail in Chapter 1 above.  PRION-1 was an open-label, 
patient preference trial of quinacrine for all types of human prion disease, which recruited patients 
from 2001 to 2007.  The trial showed no effect of quinacrine on survival or any of the rating scales 
used as secondary outcome measures120,121.  For the purposes of this study the PRION-1 clinical data 
is therefore regarded as natural history data, irrespective of treatment with quinacrine.  The 
National Prion Monitoring Cohort is an ongoing natural history study of all types of prion disease, 
which has been enrolling patients since October 2008. In both studies, patients were enrolled and 
followed up throughout their disease course whenever possible, with clinical data recorded by a 
neurologist at each assessment.   For the analysis presented here, 3 particular sets of data have been 
used to identify patients with BPS:  
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1) First symptoms.  These were recorded for all patients, specifically including the presence of 
behavioural and psychiatric symptoms at onset. 
2) Symptoms at time of assessment.  The presence and severity/frequency of a range of specific 
symptoms were recorded at each assessment.  These included “Hallucinations”, and 
“Depressive symptoms”.* 
3) Indications for drug prescription.  Details of all drugs prescribed during the period of study 
were recorded, including indication for treatment.  
 
Investigation results including PRNP genotype and MR brain imaging were also collected whenever 
possible.  MR imaging was reviewed by a specialist neuroradiologist (Dr Harpreet Hyare), and the 
presence/absence of pathological signal change in 3 specific areas noted (cortex, striatum, and 
thalamus).   Neuropathological data was collected for those patients that had tonsil or brain biopsy 
and/or autopsy. 
 
Brief Psychiatric Rating Scale (BPRS) 
The BPRS was administered at all PRION-1 assessments when the patient was able to co-operate.  
The scale used was a slightly modified version of that developed by Ventura et al188 from the original 
scale developed by Overall and Gorham189, operationalized for rating from video records.  The scale 
consisted of 24 items, each scored on a 1-7 scale.  14 items were rated from the subject’s verbal 
response to structured, scripted questions, and 10 from the behaviour observed throughout the 20-
minute interview.  The majority of the assessments were video-recorded, and then reviewed and 
scored by a consultant psychiatrist (Professor Angus Mackay), blinded to the score given by the 
interviewer and to any treatment. 
                                                          
*In PRION-1 symptoms were classified as “Absent”, “Slight” or “Significant”, whereas in the 
Cohort they were classified as occurring “Never”, “Rarely”, “Often” or “Always”.  For the 
purposes of this analysis these have been reclassified as “Absent”, “Slight/Rarely”, or 
“Significant/Often/Always”. 
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MRC Prion Disease Rating Scale (MRC-PDRS) 
Rates of clinical decline are highly variable both within and between prion disease types.   As a 
result, time-from-onset cannot be used to separate patients into early-, mid- and late-stages of 
disease, and it is more meaningful to use a direct measure of functional impairment as an indicator 
of progression. 
 
Published analysis of rating scales data from the PRION-1 trial showed that a novel combination 
scale (combining elements of the Barthel Index190, the Clinician’s Dementia Rating Sum of Boxes191 
and the Glasgow Coma Score192) has advantages over any individual scale as a global measure of 
progression for all types of prion disease121.  Chapter 6 of this thesis describes work developing and 
validating a novel rating scale based on combined elements of these three existing scales, as a 
bespoke scale for use in prion disease clinical trials.  This work has also now been published193.  The 
new scale, the Medical Research Council Prion Disease Rating Scale (MRC-PDRS), has been 
completed at Cohort assessments since May 2010.  As its 3 constituent scales were completed at all 
assessments throughout both PRION-1 and the Cohort, it can be imputed for all other assessments.  
It gives a score from 0 (maximal impairment, worst score) to 20 (no impairment, best score). 
 
Clinical Casenote Review 
The clinical casenotes of selected patients identified from the research data were reviewed in detail, 
including all of those prescribed medication for BPS.  The review aimed to obtain more clinical detail 
of the BPS, including their timecourse, phenomenology, and any reported effects of treatment 
(beneficial or adverse). 
 
Genome-wide Association and Candidate SNP Analysis 
Genome–wide association analysis was performed on a subset of 170 cases (113 sCJD, 33 IPD, 22 
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vCJD and 1 iCJD) and 5200 UK controls provided by the Wellcome Trust Case Control Consortium 
(WTCCC).  Cases were classified according to the presence or absence of 3 phenotypes (psychotic 
features at any stage, mood disorder at any stage, and psychiatric symptoms at onset) as described 
above.  Analyses were carried out comparing (1) cases with each phenotype (Prion+) with cases 
without the phenotype (Prion–), and (2) Prion+ cases with controls (i.e. 2 analyses for each of the 3 
phenotypes, giving a total of 6 analyses).  Individuals were included if they had been genotyped 
previously for inclusion in the genome-wide association study of susceptibility to prion disease 
published by Mead et al, 2012194.   Genotyping and quality control had been carried out previously 
for the earlier study, and this current study used the archived genotype data.  
For detail of patient and control samples, genotyping, quality control and analysis see Mead et al.  In 
the current study, Fisher’s exact test was used for the association analysis because of the relatively 
small number of patients.  518 938 SNPs were included in the analysis after quality control.  Ethnic 
outliers detected using a multidimensional scaling plot were excluded.  
 
A small selection of candidate SNPs were also specifically examined in a hypothesis driven manner, 
in light of the limited statistical power that could be achieved in the genome-wide analysis given the 
relatively small number of cases.  By reviewing previously published genome-wide association 
studies in psychiatric conditions characterised by psychosis and/or mood disorder (schizophrenia 195, 
bipolar affective disorder 196-198 and major depressive disorder 199a list of candidate SNPs were 
identified that have shown association with these conditions at genome-level significance, on the 
basis that these might also show association with the behavioural/psychiatric phenotypes in prion 
disease.  These SNPs are listed in Table 20 below.  The codon 129 polymorphism of PRNP (SNP 
rs1799990), was also included as this is known to modify other aspects of the phenotype of prion 
disease (as reviewed above) and also to confer susceptibility to prion disease (as shown in the GWAS 
for prion disease mentioned above 194). There was no evidence of population structure in the UK and 
no corrections were made. 
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Statistical Analysis 
Statistical analysis was performed using Microsoft Excel and IBM SPSS Statistics.  Logistic regression 
analysis was used to model: 
(1) The effect of MRC-PDRS score on the odds of specific BPS being present at the time of 
assessment, with disease type included as a covariate to account for the uneven distribution 
of disease types across the range of MRC-PDRS scores; 
(2) Factors predicting the presence of specific BPS in all symptomatic patients, with age at 
onset, gender, disease type and PRNP codon 129 genotype as covariates (279/ 317 patients 
had all data available and were included); 
(3) Factors predicting the presence of specific BPS in sCJD patients, with age at onset, gender, 
PRNP codon 129 genotype and distribution of pathological signal change on MR brain 
imaging as covariates (103/204 patients had all data available and were included).   
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Results 
Patients 
PRION-1 and the Cohort (up to 28/08/2011) provide clinical data on a total of 374 patients, including 
204 with sporadic CJD, 25 with variant CJD, 80 with inherited prion disease, 8 with iatrogenic prion 
disease due to exposure to contaminated human growth hormone, 30 at risk of inherited prion 
disease, and 10 at risk of variant CJD (Table 5).  The remaining 17 patients were found to have an 
alternative, non-prion diagnosis after enrolment: either at autopsy or as result of additional 
investigation results (e.g. elevated serum voltage-gated potassium channel antibody) or clinical 
progression that was not in keeping with prion disease (e.g. spontaneous recovery).  These non-
prion patients are excluded from the analysis. 
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  Diagnosis Number of Patients 
  Symptomatic At Risk 
  Sporadic CJD 204 - 
Definite 102 - 
Probable 82 - 
Possible 20 - 
  
  
Codon 129 MM 89 - 
Codon 129 MV 48 - 
Codon 129 VV 32 - 
Not genotyped 35 - 
  Variant CJD 25 10 
Definite 18 - 
Probable 7 - 
  
  
Codon 129 MM 24 4 
Codon 129 MV 1 2 
Not genotyped 0 4 
  Iatrogenic CJD (hGH) 8 - 
Definite 4 - 
Probable 4 - 
  
  
Codon 129 MM 1 - 
Codon 129 MV 5 - 
Codon 129 VV 1 - 
Not genotyped 1 - 
   Inherited Prion Disease 80 30 
Insertion mutations: "IPD-OPRI" 
   
  
4-OPRI 3 0 
5-OPRI 8 1 
6-OPRI 19 2 
Point mutations: "IPD-Point" 
   
  
P102L 24 11 
A117V 7 2 
E200K 8 8 
D178N 4 6 
Y163X 3 0 
Others (P105L, Q212P, V210I, E211Q) 4 0 
   
Table 5.  Summary of patient diagnoses.  hGH = Human growth hormone.  OPRI = Octapeptide 
repeat insertion. 
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All patients included here had a working clinical diagnosis of prion disease at the time of enrolment, 
and patients have only been excluded from the analysis if there is clear clinical or neuropathological 
evidence that they did not have prion disease.  This may lead to a small number of non-prion cases 
being included, but this is in keeping with the population seen in clinical practice.  Neuropathological 
diagnosis of neurodegenerative disease during life is rare, and so a degree of diagnostic uncertainty 
must be acknowledged and clinical decisions made in this context. 
 
Grouping of behavioural and psychiatric symptoms (BPS) 
Symptoms occurring together in individual patients seemed to be divisible into the 3 main groups 
that have been established from factor analysis in Alzheimer’s disease: psychotic symptoms; 
agitated symptoms; and mood disorder.  Commonly described symptoms and behaviours, and how 
these were grouped, are shown below. 
 
Psychotic symptoms Agitated symptoms Mood disorder 
“Hallucinations” “Agitation” “Low mood” 
“Paranoia”  “Aggression” “Depression” 
“Delusions” “Behavioural disturbance” “Emotional lability” 
+/- “Agitation” “Resistiveness” “Apathy” 
+/- “Aggression” “Wandering” “Suicidality” 
+/- “Behavioural disturbance” “Panic attacks” 
“Shouting” 
“Withdrawal” 
“Anxiety” 
 
Prevalence of BPS 
The prevalence of BPS (overall and by symptom group) occurring at any stage of disease is shown in 
Table 6.  253/317 (80%) of symptomatic patients had BPS noted at any stage of disease.  There was 
variability between disease types, but even the lowest prevalence (in IPD-point) was over 70%.  
Psychotic symptoms were most common in vCJD and sCJD, while depressive symptoms were more 
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common in vCJD and IPD.  Agitated symptoms were most common in IPD-OPRI (but may be 
underestimated overall for reasons discussed below). 
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    At disease onset At any stage 
  n Any BPS Only BPS Any BPS Any Agitated Any Psychotic Any Mood 
All patients 317 141 44.5% 28 8.8% 253 79.8% 57 18.0% 117 36.9% 132 41.6% 
sCJD 204 88 43.1% 15 7.4% 161 78.9% 33 16.2% 87 42.6% 68 33.3% 
vCJD 25 23 92.0% 6 24.0% 24 96.0% 7 28.0% 12 48.0% 16 64.0% 
iCJD 8 2 25.0% 0 0.0% 6 75.0% 0 0.0% 2 25.0% 4 50.0% 
IPD All 80 28 35.0% 7 8.8% 62 77.5% 17 21.3% 16 20.0% 44 55.0% 
IPD OPRI 30 16 53.3% 5 16.7% 26 86.7% 10 33.3% 7 23.3% 15 50.0% 
IPD Point 50 12 24.0% 2 4.0% 36 72.0% 7 14.0% 9 18.0% 29 58.0% 
 
Table 6.  Prevalence of behavioural disturbance and psychiatric symptoms in all symptomatic patients and in individual prion disease types, at disease 
onset and at any stage of disease. 
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Some patients developed BPS at an early stage, before the onset of dementia and/or progressive 
neurological symptoms, while others only developed symptoms in the context of established 
neurocognitive decline. 
 
The prevalence of BPS at onset for each disease type is also shown in Table 6.  BPS were particularly 
common at onset in vCJD, but also common in IPD-OPRI and sCJD.  BPS as the only symptoms at 
onset occurred in a smaller proportion of patients, in a similar pattern across disease types.  The 
presence of behavioural disturbance at onset was separately recorded and was more common than 
any individual BPS-group. 
 
Description of BPS 
Synthesising information from the various sources described above, the characteristics of the 
psychiatric and behavioural symptoms seen in these patients can be described.  Unless specifically 
noted, patients from all prion disease types are considered together. 
 
Psychotic symptoms 
Psychotic symptoms occurred with and without associated agitation or behavioural disturbance.  By 
far the most common was visual hallucinosis.  Visual hallucinations occurred both in the context of 
other progressive visual symptoms (such as visual distortion and agnosia), and as an isolated 
phenomenon.  Distressing visual distortions and illusions were also common.  Several patients 
described unpleasant splitting and twisting of faces and other objects: “like a Picasso”.  In terms of 
hallucination content, there was a striking abundance of animals, and also human figures.  In a few 
instances, patients described multi-modal hallucinations (e.g. seeing, hearing, feeling and smelling 
rats crawling over the body) but this was rare and was always associated with a particularly florid 
visual hallucinosis. 
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In more advanced patients episodes characterized by a wide-eyed, staring and sometimes fearful 
expression were frequently observed.  Some of these patients had previously reported visual 
hallucinations at an earlier stage. 
 
A smaller number of patients were noted to have delusions, occurring both with and without 
hallucinations.  Delusional content tended to be relatively simple (e.g. delusions of theft or 
infidelity).  A number of patients were noted to have fixed ideas based on a failure to distinguish 
events on television from reality.  Several patients reported vivid sensory experiences outside the 
limits of their real sensory field, such as 'seeing' someone in another part of the house or a distant 
location ('extracampine' hallucinations), often with associated delusional thought content. 
 
Possible Schneiderian first-rank symptoms were noted in 2 patients with vCJD.  A 54 year old man 
with irritability, agitation, visual hallucinations and myoclonus reported feeling “as if someone is 
taking over my mind”, and a 30 year old man was noted to have “thought interference, delusional 
thinking and possible hallucinations” prior to the onset of any frank neurological symptoms. 
 
Agitated symptoms 
Agitation and behavioural disturbance (including aggression) also frequently occurred in the absence 
of psychotic features.  Typical descriptions included “irritability”, “resistiveness” and “hostility”.  
Other over-active behaviours such as wandering and repetitive vocalizations were also included in 
this group. 
 
In contrast with psychosis, these symptoms were commonly noted to occur in response to 
environmental or physical stimuli (most commonly administration of personal care). 
 
In some patients, particularly those in the early stages of IPD-OPRI, non-psychotic behavioural 
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disturbance occurred in the context of disinhibition, impulsivity and other signs of frontal lobe 
dysfunction. 
 
Patients with advanced disease often showed evidence of agitation without any behavioural 
evidence of hallucinations.  This was often reactive to stimulus and often co-existed with stimulus-
sensitive myoclonus and an exaggerated startle response, which are common features in the late 
stages of all prion diseases.  This was observed in some patients who had had agitated symptoms 
noted earlier in their disease course, but also in many who had not. 
 
Mood disorder 
Some patients who were studied in the early stages of disease, and also during the 
presymptomatic/at-risk phase had symptoms of low mood combined with typical biological 
symptoms consistent with a “classical” depressive illness. 
 
Patients in the early stages of vCJD were often noted to have predominant symptoms of social 
withdrawal, irritability, anxiety and low mood, in keeping with previous descriptions of this patient 
group. 
 
Patients in the early to mid-stages of disease were more commonly noted to have emotional lability, 
characterized by sudden, unprovoked episodes of tearfulness (or more rarely laughing or elation).  
Patients at this stage were also often noted to have social withdrawal and apathy, albeit in the 
context of deteriorating expressive language and frontal executive function. 
 
Affective symptoms in patients in the late stages of disease could rarely be characterized.  Whereas 
the presence of agitated or psychotic symptoms may sometimes be inferred from the behaviour of a 
hypokinetic and mute patient, this is rarely true of mood disorder. 
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Suicidal ideation was noted in a few cases, all in the early to mid-stages of IPD.  This varied from a 
patient with minimal cognitive impairment making enquiries regarding physician-assisted suicide, to 
a patient with marked frontal executive deficits voicing suicidal intent impulsively and with 
incongruous affect.  Only one suicide attempt was identified from the clinical case notes reviewed (a 
patient in the early stages of IPD-OPRI took an overdose on the anniversary of his mother’s death 
from the same condition), and there were no completed suicides. 
 
Other symptoms 
Almost all symptoms noted could be classified into the three groups above, but a few others did 
occur.  Obsessive thoughts were reported in a handful of patients.  Compulsive or repetitive 
behaviours were included in the agitated symptom group.  One patient with IPD due to D178N 
mutation had a diagnosis of obsessive-compulsive disorder pre-dating onset of cognitive and 
neurological symptoms by many years.  A recurrent sensation of “déjà vu” and a strong sensation of 
derealization were reported by two patients in the very early stages of sCJD. 
 
BPS and Disease Progression 
Figure 30 shows the proportion of assessments at which (A) hallucinations and (B) depressive 
symptoms were noted to be present when patients were at different stages of disease progression, 
as assessed by the MRC-PDRS.It also shows the proportion of assessments where the presence of 
each symptom could not be assessed, predominantly because of aphasia and severe global 
impairment in late stage disease. 
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Figure 30.  Natural history of symptoms.  Prevalence of Hallucinations and Depressive Symptoms 
at all assessments grouped by stage of disease progression ((A)i and (B)i), and severity rating of 
Hallucinations and Depressive Symptoms at the follow-up assessment after a rating of "Often" or 
"Always" ((A)ii and (B)ii).  NB. Disease progression assessed by MRC-PDRS score (see text): 0 = 
maximal impairment, akinetic and mute; 20 = no functional impairment. 
 
It is important to note that the distribution of MRC-PDRS scores varies between different disease 
types:  the majority of sCJD patients already had low scores at enrolment, while many IPD patients 
were enrolled with much higher scores. 
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Depressive symptoms were observed at a similar rate across the range of functional impairment 
until the very severely impaired range where they often could not be assessed.  In contrast, 
hallucinations were not observed in the most mildly impaired, and became more prevalent as 
impairment increased.  In keeping with this, logistic regression showed a highly significant effect of 
MRC-PDRS score on the odds of hallucinations being present (p < 0.001), adjusted for disease type.  
There was no significant effect of MRC-PDRS on the odds of depressive symptoms being present (p = 
0.078), although there was some trend towards increasing depressive symptoms at greater levels of 
functional impairment (Tables 7 and 8). 
 
Independent variables 
Logistic Regression 
Odds Ratio 95% CI p value 
MRC Score Per point 0.935 0.909 - 0.963 <0.001 
Diagnosis sCJD 1 (ref) <0.001 
  
vCJD 0.327 0.122 - 0.874 0.026 
    iCJD 1.334 0.461 - 3.864 0.595 
  
IPD OPRI 0.083 0.025 - 0.279 <0.001 
    IPD Point 0.254 0.121 - 0.531 <0.001 
  
Constant 0.783 
 
0.171 
Table 7.  Logistic regression of MRC-PDRS score and disease type vs. Hallucinations 
 
Independent variables 
Logistic Regression 
Odds Ratio 95% CI p value 
MRC Score Per point 0.981 0.961 - 1.002 0.078 
Diagnosis sCJD 1 (ref) 0.328 
  
vCJD 1.31 0.661 - 2.597 0.439 
    iCJD 0.601 0.167 - 2.16 0.435 
  
IPD OPRI 0.644 0.37 - 1.12 0.119 
    IPD Point 0.858 0.497 - 1.482 0.583 
  
Constant 0.412 
 
<0.001 
Table 8.  Logistic regression of MRC-PDRS and disease type vs. Depressive Symptoms. 
 
To examine the natural history of BPS in individual patients, all assessments at which Hallucinations 
or Depressive symptoms were noted to be occurring “Often” or “Always” where the patient went on 
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to have another assessment were identified, and the severity of the symptom at this second 
assessment was noted (Figure 30).  Both symptoms improved at the second assessment in about 
40% of cases, and could no longer be assessed due to progression of disease in about 20% of cases.  
It was checked whether any of these patients had relevant symptomatic treatments (e.g. 
antidepressants, antipsychotics) started between these two assessments.  Only 8 of 58 serial 
assessment pairs identified for hallucinations, and 8 of 95 pairs identified for depressive symptoms 
captured initiation of a relevant symptomatic treatment, so most of those patients in whom the 
symptoms improved had not been treated, or continued on established treatment.  The small 
number of cases that were newly treated are analysed further under Pharmacological Treatment 
below. 
 
Brief Psychiatric Rating Scale (BPRS) in Prion-1 
The BPRS was completed in 39 of the 101 symptomatic patients in PRION-1.  The remainder were 
already too impaired at enrolment to complete the lengthy patient interview required.  As a result 
most of the BPRS data collected is from patients at an early stage of disease, and the more slowly 
progressive disease types are over-represented.  In total, 175 assessments were completed in these 
39 patients. 
 
126 of the BPRS assessments were video-taped and then reviewed by a consultant psychiatrist 
(Professor Angus MacKay), who was blinded to the original assessor’s score.  Figure 31 shows a 
Bland-Altman Plot for the total BPRS scores in these assessments, illustrating the level of agreement 
between the original assessor and the consultant psychiatrist.  There was a strong bias towards the 
original assessor giving a higher total score.   
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Figure 31.  Bland-Altman plot comparing total Brief Psychiatric Rating Scale (BPRS) scores given at 
the initial, face-to-face assessment (neurologist) and at review of the video-taped assessment 
(psychiatrist), from 126 assessments. The psychiatrist reviewing the video was blinded to the 
original assessor’s score. 
 
To assess the reliability of individual sub-components of the BPRS, Cohen’s Kappa scores were 
calculated for the agreement of individual symptom scores.  By convention Cohen’s Kappa values are 
interpreted using the descriptors proposed by Landis and Koch200, whereby <0 = “no agreement”; 0–
0.20 = “slight agreement”; >0.20–0.40 = “fair agreement”; >0.40–0.60 = “moderate agreement”; 
>0.60–0.80 = “substantial agreement”, and >0.80-1.0 = “almost perfect agreement”.  These results 
are shown in Table 9. They ranged from -0.03 (no agreement) to 0.47 (moderate agreement). If 
scores were collapsed so that each symptom was classified either absent or present (regardless of 
severity) and Kappas recalculated, they ranged from -0.04 (no agreement) to 0.66 (substantial 
agreement). 
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BPRS Subcomponent 
1 - 7 Score 
κ 
Present/Absent 
κ 
Somatic concern 0.22 0.41 
Anxiety 0.23 0.46 
Depression 0.26 0.40 
Suicidality 0.47 0.66 
Guilt 0.15 0.33 
Hostility 0.14 0.30 
Elated mood 0.10 0.18 
Grandiosity 0.00 0.00 
Suspiciousness 0.32 0.36 
Hallucinations 0.38 0.51 
Unusual thought 0.24 0.24 
Bizarre behaviour -0.01 -0.02 
Self-neglect -0.03 -0.04 
Disorientation / inappropriate affect 0.02 0.06 
Conceptual disorganisation 0.07 0.07 
Blunted affect -0.01 -0.02 
Emotional withdrawal -0.02 -0.03 
Motor retardation -0.02 -0.02 
Tension -0.01 -0.01 
Uncooperativeness 0.18 0.18 
Excitement 0.00 0.00 
Distractability -0.02 -0.03 
Motor hyperactivity 0.21 0.44 
Mannerisms and posturing 0.08 0.17 
Table 9.  Cohen’s Kappa (κ) values for agreement on individual BPRS subcomponents between the 
initial, face-to-face assessment (neurologist) and at review of the video-taped assessment 
(psychiatrist), from 126 assessments.  Kappa values have been calculated both for the 1 to 7 score 
used in the BPRS, and by collapsing these down to a dichotomous, absent/present score.  
 
In light of the generally poor levels of agreement, only the data from the consultant psychiatrist’s 
rescoring of the videoed assessments were included in further analysis.In total 126 BPRS 
assessments in 38 of the 101 symptomatic patients in PRION-1 were scored from video by the 
consultant psychiatrist (Professor Angus Mackay), and this data is presented here. 
 
Figure 32 shows the proportion of assessments at which each symptom sub-component was scored 
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as being present and the level of severity.  Most symptoms were very rarely scored as being present.  
Six of the seven most frequently recorded symptoms fall within the Mood Disorder grouping used 
above: Depression, Somatic Concern, Anxiety, Suicidality, Guilt and Self-neglect.  In contrast, the 
psychotic symptoms were very rarely recorded. 
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Figure 32.  BPRS.  Breakdown of BPRS by symptom category, showing proportion of assessments scored at each severity level (out of total of 139 
assessments in 38 patients). 
 152 
 
This provides a more detailed profile of the symptomatology in a sub-group of less severely impaired 
patients (those that were able to co-operate with the lengthy BPRS interview).  These results are in 
keeping with those presented above:  in the earlier stages of prion disease symptoms of mood 
disorder predominate, while psychotic symptoms are rare (but may emerge as disease progresses). 
 
Pharmacological Treatment 
Commonly prescribed classes of medication for BPS were antidepressants (for mood disorder and 
agitated symptoms), benzodiazepines (for agitated symptoms and psychotic symptoms), 
antipsychotics (for agitated symptoms and psychotic symptoms) and acetylcholinesterase inhibitors 
(for psychotic symptoms).   
 
For each drug class/symptom group combination, Table 10 shows the number of prescriptions and 
the duration of treatment that were studied, as well as details of reported efficacy, adverse events 
and reasons for discontinuation as established from review of the clinical case notes.  For all drug 
class/symptom group combinations most prescriptions were continued until death or advanced 
disease, or were ongoing at the end of the period of study.  None of the adverse events attributed to 
the treatments were severe, and they very rarely led to discontinuation.   
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Agitated symptoms
Benzodiazepines 39 5683 23 6 15.4% 4 10.3% 0 0.0% 0 0.0% 24 61.5% 8 20.5% Sedation (4)
Antipsychotics 23 7253 149 10 43.5% 3 13.0% 0 0.0% 0 0.0% 14 60.9% 7 30.4%
Extrapyramidal (2), 
Sedation (1)
Antidepressants 6 3995 750.5 1 16.7% 2 33.3% 1 16.7% 1 16.7% 0 0.0% 4 66.7%
Weight gain (1), 
Headache (1)
Psychotic symptoms
Benzodiazepines 32 3280 42 7 21.9% 4 12.5% 0 0.0% 0 0.0% 26 81.3% 1 3.1% Sedation (4)
Antipsychotics 31 6266 61 9 29.0% 6 19.4% 0 0.0% 1 3.2% 22 71.0% 4 12.9% Sedation (6)
AChE Inhibitors 5 2027 236 3 60.0% 0 0.0% 0 0.0% 0 0.0% 2 40.0% 3 60.0% None
Mood disorder
Antidepressants 45 18315 301.5 16 35.6% 4 8.9% 1 2.2% 2 4.4% 22 48.9% 13 28.9%
Sedation (1), Agitation (1), 
Weight gain (1), 
Unpleasant taste (1)
Medication class
Ongoing          
at last         
follow-up
Side effects noted
Median 
course 
length
Total
Duration of 
treatment (days)
Efficacy
Stopped due to…
Death or 
advanced 
disease
Number 
of 
prescrip-
tions 
studied
Lack of 
benefit
Side    
effects
Side      
effects
Clinical notes record…
 
Table 10.  Drug treatment of BPS.  Observational data for all drug classes prescribed 5 or more times for each symptom group.  NB: Some patients 
received more than one agent (most commonly antipsychotic and benzodiazepine) but in most these were not started simultaneously.  As far as possible 
the relative clinical benefit and/or adverse effects of each were determined from careful review of the clinical notes.  If this was not clear, the benefit or 
adverse effect was attributed to both.  Specific medications prescribed from each class are listed in the text. 
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Antidepressants for mood disorder 
There were 45 prescriptions of antidepressants for mood disorder, in 42 patients.  Drugs prescribed 
were Citalopram (21); Fluoxetine (7); Mirtazapine (6); Sertraline (3); Amitriptyline, Escitalopram (2 
each); Clomipramine, Paroxetine, Trazodone and Venlafaxine (1 each). 
 
In total 18,315 days of treatment were studied.  Most of this experience was in either sCJD cases, 
where treatment courses tended to be shorter (median 111 days), or in IPD cases, where courses 
were longer (median 565 days).  16 out of 45 (36%) prescriptions of antidepressants for mood 
disorder were noted to have apparent clinical benefit.  12/16 of these were in patients with IPD.  
Apparent adverse effects were noted in 4 cases (9%):  agitation, sedation, weight gain and a 
persistent unpleasant taste.  None of these were severe, and in only one case did they lead to 
discontinuation of the prescription (unpleasant taste).  21 patients (50%) died while being treated. 
 
Antipsychotics for psychotic symptoms 
There were 31 prescriptions of antipsychotics for psychotic symptoms, in 29 patients.  These were 
Quetiapine (14), Olanzapine (8), Risperidone (6), Haloperidol (2) and Levomepromazine (1).  
Quetiapine appears to have been favoured because of a wish to avoid worsening or precipitating 
extrapyramidal symptoms. 
 
In total 6,266 days of treatment were studied.  Most of this experience was in sCJD and vCJD cases, 
and most treatment courses were short (median 61 days).  However, a few patients with IPD and 
atypical sCJD had prescriptions continuing for several years.  9 out of 31 (29%) prescriptions of 
antipsychotics for psychotic symptoms were noted to have apparent clinical benefit.  An apparent 
adverse effect was noted in 6 cases (19%); this was sedation in all cases.  This often occurred in the 
context of severe neurological disability, and was not recorded as a reason for discontinuation of the 
prescription in any cases.  19 patients (66%) died while being treated. 
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Benzodiazepines for psychotic symptoms 
There were 32 prescriptions of benzodiazepines for psychotic symptoms, in 26 patients.  These were 
Lorazepam (12); Diazepam, Midazolam (6 each); Clonazepam (4); Temazepam (3) and Alprazolam 
(1). 
 
In total 3,280 days of treatment were studied.  Most of this experience was in late-stage disease.  In 
a number of cases myoclonus was noted as a joint indication.  Most treatment courses were short 
(median 42 days).  7 out of 32 (22%) prescriptions were noted to have apparent clinical benefit.  An 
apparent adverse effect was noted in 6 cases (19%); this was sedation in all cases.  This often 
occurred in the context of severe neurological disability, and was not recorded as a reason for 
discontinuation of the prescription in any cases.  21 patients (81%) died while being treated. 
 
Acetylcholinesterase inhibitors for psychotic symptoms 
There were 5 prescriptions of acetyl cholinesterase inhibitors for psychotic symptoms, in 5 patients.  
These were Donepezil (4) and Rivastigmine (1).   
 
In total 2,027 days of treatment were studied.  Prescriptions were started in moderately advanced 
patients, all of whom had hallucinations, and courses were relatively long (median 236 days).  3 out 
of 5 (60%) prescriptions were noted to have apparent clinical benefit.  No adverse effects were 
recorded.  2 patients (40%) died while being treated. 
 
Antipsychotics for agitated (non-psychotic) symptoms 
There were 23 prescriptions of antipsychotics for agitated symptoms, in 23 patients.  These were 
Quetiapine (11), Haloperidol (6), Risperidone (4), and Olanzapine (2).  Again, Quetiapine seems to 
have been favoured because of a wish to avoid worsening or precipitating extrapyramidal 
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symptoms. 
 
In total 7,253 days of treatment were studied.  This included very short treatment courses at the end 
stage of sCJD (minimum 7 days) and much longer courses in slowly progressive IPD-OPRI (maximum 
1506 days, median 149 days).  10 out of 23 (43%) prescriptions were noted to have apparent clinical 
benefit.  Apparent adverse effects were noted in 3 cases (13%): extra-pyramidal symptoms (2 cases) 
and sedation.  None of these were severe, and they were not recorded as a reason for 
discontinuation of the prescription in any cases.  11 patients (48%) died while being treated. 
 
Benzodiazepines for agitated (non-psychotic) symptoms 
There were 39 prescriptions of benzodiazepines for agitated symptoms, in 37 patients.  These were 
Midazolam (16); Diazepam (12); Lorazepam (7); and Clonazepam (4). 
 
In total 5,683 days of treatment were studied.  Most of this experience was in late-stage disease.  In 
a number of cases myoclonus was noted as a joint indication.  Most treatment courses were short 
(median 23 days).  A few courses were much longer (maximum 2472 days), particularly in slowly-
progressive IPD with chronic agitation and behavioural disturbance.  6 out of 39 (15.4%) 
prescriptions were noted to have apparent clinical benefit.  An apparent adverse effect was noted in 
4 cases (10.3%); this was sedation in all cases.  This often occurred in the context of severe 
neurological disability, and was not recorded as a reason for discontinuation of the prescription in 
any cases.  24 patients (65%) died while being treated. 
 
Antidepressants for agitated (non-psychotic) symptoms 
There were 6 prescriptions of antidepressants for agitated symptoms, in 5 patients.  These were 
Amitriptyline (2), Mirtazapine (2), Fluoxetine (1) and Sertraline (1). 
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In total 3,995 days of treatment were studied.  All 5 patients had IPD-OPRI, were treated at relatively 
early stages of disease, and treatment courses were long (median 750.5 days).  1 out of 6 (16.7%) 
prescriptions was noted to have apparent clinical benefit.  Apparent adverse effects were noted in 2 
cases (33%): weight gain and headache, and were recorded as a reason for discontinuation of the 
prescription in one case (headache).  No patients died while being treated. 
 
Effect of pharmacological treatments on natural history of BPS 
To obtain a more objective assessment of efficacy, patients who were assessed as having 
Hallucinations or Depressive symptoms “Often” or “Always” at a study assessment and then went on 
to have another assessment were identified, and those in whom any appropriate treatment was 
started in the intervening time were compared with those in whom it was not.  Only 8 of 58 serial 
assessment pairs identified for hallucinations, and 8 of 95 pairs identified for depressive symptoms 
captured initiation of treatment.  There was no significant difference in the number of patients 
improving with treatment or without for either symptom (Fisher’s exact tests). 
 
Factors Predicting Presence of BPS  
The full results for the logistic regression analyses for factors predicting presence of BPS are shown 
in Tables 11 - 18.  Nominal (uncorrected) p values are quoted below and in the tables. 
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Total
n n % Odds Ratio 95% CI p value
Diagnosis sCJD 170 70 41.18% 1 (ref) 0.001
vCJD 25 12 48.00% 0.654 0.175 - 2.443 0.528
iCJD 7 1 14.29% 0.1 0.01 - 0.955 0.045
IPD OPRI 29 7 24.14% 0.239 0.075 - 0.767 0.016
IPD Point 48 9 18.75% 0.189 0.075 - 0.476 <0.001
Per year 0.979 0.953 - 1.006 0.125
MM 159 54 33.96% 1 (ref) 0.008
MV 83 37 44.58% 1.959 1.064 - 3.607 0.031
VV 37 8 21.62% 0.488 0.201 - 1.181 0.112
Gender Male 134 50 37.31% 1 (ref)
Female 145 49 33.79% 0.944 0.556 - 1.601 0.831
Constant 2.646 0.303
Independent variables With psychotic symptoms Logistic Regression
Age at Onset
PRNP Codon 129
 
Table 11.  Logistic regression for variables affecting presence of psychotic symptoms in all types of 
prion disease (in 279 patients) 
 
Total
n n % Odds Ratio 95% CI p value
Diagnosis sCJD 170 57 33.53% 1 ref 0.372
vCJD 25 17 68.00% 3.044 0.838 - 11.054 0.091
iCJD 7 4 57.14% 1.689 0.326 - 8.741 0.532
IPD OPRI 29 15 51.72% 1.555 0.559 - 4.327 0.397
IPD Point 48 28 58.33% 1.96 0.917 - 4.192 0.083
Per year 0.984 0.96 - 1.009 0.204
MM 159 67 42.14% 1 ref 0.11
MV 83 43 51.81% 1.684 0.933 - 3.037 0.083
VV 37 11 29.73% 0.76 0.331 - 1.745 0.517
Gender Male 134 53 39.55% 1 (ref)
Female 145 68 46.90% 1.68 1.002 - 2.818 0.049
Constant 0.955 0.958
PRNP Codon 129
Independent variables With mood disorder Logistic Regression
Age at Onset
 
Table 12.  Logistic regression for variables affecting presence of mood disorder in all types of prion 
disease (in 279 patients)
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Total
n n % Odds Ratio 95% CI p value
Diagnosis sCJD 170 28 16.47% 1 ref 0.657
vCJD 25 8 32.00% 0.615 0.135 - 2.81 0.531
iCJD 7 0 0.00% <0.001 0 - ??? 0.999
IPD OPRI 29 10 34.48% 1.067 0.322 - 3.531 0.916
IPD Point 48 7 14.58% 0.511 0.18 - 1.45 0.207
Per year 0.966 0.936 - 0.997 0.03
MM 159 35 22.01% 1 ref 0.699
MV 83 13 15.66% 0.763 0.359 - 1.618 0.48
VV 37 5 13.51% 0.711 0.245 - 2.068 0.531
Gender Male 134 27 20.15%
Female 145 26 17.93% 0.961 0.511 - 1.809 0.902
Constant 2.172 0.476
Age at Onset
PRNP Codon 129
Independent variables With agitated symptoms Logistic Regression
 
Table 13.  Logistic regression for variables affecting presence of agitated symptoms in all types of 
prion disease (in 279 patients) 
 
Total
n n % Odds Ratio 95% CI p value
Diagnosis sCJD 170 74 43.53% 1 (ref) <0.001
vCJD 25 23 92.00% 9.682 1.687 - 55.584 0.011
iCJD 7 2 28.57% 0.359 0.06 - 2.159 0.263
IPD OPRI 29 16 55.17% 1.105 0.396 - 3.081 0.848
IPD Point 48 11 22.92% 0.297 0.128 - 0.692 0.005
Per year 0.991 0.966 - 1.017 0.493
MM 159 80 50.31% 1 (ref) 0.071
MV 83 37 44.58% 1.205 0.667 - 2.176 0.537
VV 37 9 24.32% 0.425 0.182 - 0.990 0.047
Gender Male 134 66 49.25% 1 (ref)
Female 145 60 41.38% 0.907 0.54 - 1.525 0.714
Constant 1.614 0.601
Independent variables With BPS at onset Logistic Regression
Age at Onset
PRNP Codon 129
 
Table 14.  Logistic regression for variables affecting presence of BPS at onset in all types of prion 
disease (in 279 patients)
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Total
n n % Odds Ratio 95% CI p value
Per year 0.935 0.889 - 0.984 0.01
MM 46 19 41.30% 1 (ref) 0.333
MV 33 17 51.52% 1.197 0.447 - 3.210 0.72
VV 24 6 25.00% 0.464 0.135 - 1.594 0.223
Gender Male 46 20 43.48% 1 (ref)
Female 57 22 38.60% 0.945 0.387 - 2.311 0.902
MRI Striatum Abnormal 79 32 40.51% 0.826 0.204 - 3.352 0.789
Normal 24 10 41.67%
Thalamus Abnormal 60 24 40.00% 0.813 0.266 - 2.484 0.717
Normal 43 18 41.86%
Cortex Abnormal 83 36 43.37% 1.205 0.342 - 4.242 0.771
Normal 20 6 30.00%
Constant 65.816 0.033
Independent variables With BPS at onset Logistic Regression
Age at Onset
PRNP Codon 129
 
Table 15.  Logistic regression for variables affecting presence of BPS at onset in sCJD (in 103 
patients) 
Total
n n % Odds Ratio 95% CI p value
Per year 0.962 0.917 - 1.009 0.113
MM 46 19 41.30% 1 (ref) 0.048
MV 33 20 60.61% 2.031 0.759 - 5.436 0.158
VV 24 6 25.00% 0.411 0.121 - 1.387 0.152
Gender Male 46 19 41.30% 1 (ref)
Female 57 26 45.61% 1.632 0.665 - 4.003 0.285
MRI Striatum Abnormal 79 35 44.30% 1.257 0.318 - 4.974 0.744
Normal 24 10 41.67%
Thalamus Abnormal 60 27 45.00% 0.816 0.271 - 2.456 0.717
Normal 43 18 41.86%
Cortex Abnormal 83 38 45.78% 0.961 0.281 - 3.284 0.95
Normal 20 7 35.00%
Constant
Age at Onset
PRNP Codon 129
Independent variables With psychotic symptoms Logistic Regression
 
Table 16.  Logistic regression for variables affecting presence of psychotic symptoms in sCJD (in 
103 patients) 
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Total
n n % Odds Ratio 95% CI p value
Per year 0.961 0.914 - 1.01 0.116
MM 46 14 30.43% 1 (ref) 0.599
MV 33 12 36.36% 1.522 0.538 - 4.304 0.428
VV 24 7 29.17% 0.824 0.239 - 2.845 0.76
Gender Male 46 12 26.09% 1 (ref)
Female 57 21 36.84% 2.024 0.784 - 5.226 0.145
MRI Striatum Abnormal 79 23 29.11% 1.169 0.292 - 4.674 0.826
Normal 24 10 41.67%
Thalamus Abnormal 60 16 26.67% 0.41 0.128 - 1.309 0.132
Normal 43 17 39.53%
Cortex Abnormal 83 25 30.12% 0.547 0.159 - 1.874 0.337
Normal 20 8 40.00%
Constant 8.89 0.257
PRNP Codon 129
Independent variables With mood disorder Logistic Regression
Age at Onset
 
Table 17.  Logistic regression for variables affecting presence of Mood Disorder in sCJD (in 103 
patients) 
Total
n n % Odds Ratio 95% CI p value
Per year 0.969 0.913 - 1.029 0.304
MM 46 5 10.87% 1 (ref) 0.179
MV 33 9 27.27% 3.327 0.92 - 12.038 0.067
VV 24 4 16.67% 1.585 0.34 - 7.386 0.558
Gender Male 46 7 15.22% 1 (ref)
Female 57 11 19.30% 1.812 0.575 - 5.709 0.31
MRI Striatum Abnormal 79 14 17.72% 1.452 0.259 - 8.14 0.671
Normal 24 4 16.67%
Thalamus Abnormal 60 10 16.67% 0.5 0.124 - 2.023 0.331
Normal 43 8 18.60%
Cortex Abnormal 83 15 18.07% 1.049 0.224 - 4.921 0.951
Normal 20 3 15.00%
Constant 0.675 0.863
Independent variables With agitated symptoms Logistic Regression
Age at Onset
PRNP Codon 129
 
Table 18.  Logistic regression for variables affecting presence of Agitated Symptoms in sCJD (in 103 
patients) 
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Presence of psychotic symptoms at any stage was independently predicted by specific disease types 
(sCJD > IPD) and codon 129 genotypes (MV > MM) with a high level of significance.  Presence of BPS 
at onset was independently predicted by specific disease types (vCJD > sCJD > IPD-Point).  Female 
gender reached borderline significance as an independent predictor of mood disorder at any stage 
(OR 1.68, p = 0.049), as did younger age at onset as an independent predictor of agitated symptoms 
(OR = 0.966 per year, p = 0.03), although in light of the degree of multiple testing these results 
should be treated with caution. 
 
In the sCJD-only analysis, the presence of BPS at onset was independently predicted by younger age 
at onset (OR = 0.935 per year, p = 0.01), and no other strongly significant predictors were found. 
 
Genome-wide association and candidate SNP Analysis 
Table 19 shows details of the SNPs with the most significant associations in each analysis.  No SNPs 
reached the standard threshold for genome wide significance in association studies (P<5 x 10-8). 
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Phenotype SNP Chr BP MAF 
Closest gene 
(RefSeq) 
Distance 
(kb) 
Prion+ vs Controls Prion+ vs Prion- 
GWAS          
p-value 
OR 
GWAS          
p-value 
OR 
  
Psychotic Features 
  
 
  
rs1055569 6 31548061 0.291 HCG26 Intragenic 2.66E-06 2.36 1.08E-04 2.49 
rs4413654 6 31549328 0.219 HCG26 1.164 3.69E-06 2.43 1.02E-04 2.63 
rs2516440 6 31548476 0.294 HCG26 0.312 4.48E-06 2.33 1.08E-04 2.49 
rs4077732 11 11493063 0.330 GALNTL4 Intragenic 2.96E-03 0.53 1.65E-06 0.30 
rs7231996 18 69417499 0.131 LOC100505817 249.395 0.01 1.81 3.14E-06 5.56 
rs6440974 3 156553159 0.099 LOC100507537 58.976 6.56E-05 2.59 4.47E-06 5.27 
  
Mood disorder 
  
  
  
rs7789850 7 140947080 0.026 AGK Intragenic 2.16E-06 4.60 2.46E-04 7.64 
rs12789145 11 94047384 0.084 PIWIL4 53.149 3.58E-06 0.00 7.75E-06 0 
rs6867820 5 121882424 0.224 SNCAIP 54.731 6.03E-06 2.24 9.74E-05 2.61 
rs1219407 11 121249388 0.073 SORL1 215.633 8.75E-05 2.60 3.94E-06 7.60 
rs478903 11 121190975 0.089 SORL1 181.294 1.35E-04 2.39 6.65E-06 6.17 
rs761998 20 14257952 0.352 FLRT3 Intragenic 0.02 0.64 6.69E-06 0.35 
BPS at onset 
  
  
  
rs10509125 10 61596872 0.402 ANK3 Intragenic 1.43E-06 2.09 3.50E-05 2.52 
rs561437 13 109734228 0.499 COL4A1 Intragenic 4.77E-06 0.49 1.15E-04 0.42 
rs7151968 14 47671186 0.205 LOC100506433 337.219 5.83E-06 2.12 1.60E-03 2.23 
rs4743805 9 106909655 0.165 SLC44A1 137.095 5.892E-03 1.66 6.35E-06 4.51 
rs9472202 6 44129264 0.208 C6orf223 47.592 3.778E-05 1.98 8.41E-06 3.32 
rs7040444 9 15049821 0.213 LOC389705 40.099 2.933E-03 0.52 1.17E-05 0.30 
Table 19. Most strongly associated single-nucleotide polymorphisms in each of the genome-wide association analyses:  Prion+ vs Controls and Prion+ vs 
Prion- for each of 3 psychiatric/behavioural phenotypes.  SNP = single-nucleotide polymorphism; Chr = chromosome; BP = base pair position; MAF = 
minor allele frequency; GWAS = genome-wide association; study; OR = odds ratio for minor allele; Prion+ = prion disease cases with phenotype; Prion- = 
prion disease cases without phenotype. 
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The single most significant association was in the Prion+ vs Controls analysis for psychiatric 
symptoms at onset, for a SNP (rs10509125) lying within the Ankyrin 3 (ANK3) gene (p = 1.43 x 10-6, 
OR 2.09). In the Prion+ vs Prion- analysis association for this SNP was less significant but effect size 
was greater (p=3.5 x 10-5, OR=2.52). 
 
A cluster of 3 SNPs on chromosome 6p were most strongly associated with the presence of psychotic 
features in the Prion+ vs Controls analysis (rs1055569; p = 2.66 x 10-6, OR 2.36), and also showed 
association in the Prion+ vs Prion– analysis (p = 1.08 x 10-4, OR 2.49).  These SNPs span the 5’ end of 
the non-protein-coding HLA complex group 26 (HCG26) gene. 
The most significant association in the mood disorder analyses was in the Prion+ vs Controls analysis 
for a SNP lying within the acylglycerol kinase (AGK) gene (rs7789850; p = 2.16 x 10-6, OR 4.6).  AGK 
encodes a mitochondrial membrane protein involved in lipid and glycerolipid metabolism. 
 
Closely associated SNPs rs1219407 and rs478903 which showed the strongest association with Mood 
Disorder in the Prion+ vs Prion- analysis lie about 200 kilobases from the SORL1 gene.  rs6867820, 
another SNP that showed association with Mood Disorder, lies 55 kilobases from the SNCAIP gene, 
which encodes Synphilin-1. 
 
Table 20 summarises the association results for the candidate SNPs identified from previously 
published GWAS in psychiatric conditions (schizophrenia195, bipolar affective disorder 196-198 and 
major depressive disorder 199 and in prion disease194.  The SNP implicated by the prion disease GWAS 
is PRNP codon 129.  As expected, this showed some association in all of the analyses comparing 
prion disease patients with controls, and this was particularly strong in the analysis of patients with 
BPS at onset vs controls: patients with variant CJD are over-represented in this group and codon 129 
is known to be very strongly associated with this disease sub-group.  None of the candidate SNPs 
identified from GWAS in psychiatric conditions showed evidence of association with the 
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behavioural/psychiatric phenotypes in prion disease in our analysis, in light of the number of tests 
being performed. 
 166 
SNP Chr MAF
Closest 
gene 
(RefSeq)
Identified 
in GWAS 
for…
Reference
GWAS        
p-value
OR
GWAS        
p-value
OR
GWAS        
p-value
OR
GWAS        
p-value
OR
GWAS        
p-value
OR
GWAS        
p-value
OR
rs6932590 6 0.27 PRSS16 Schizophrenia Stefansson et al 0.35 0.82 0.86 0.96 0.23 0.79 0.64 0.89 0.67 0.93 0.42 1.23
rs3131296 6 0.15 NOTCH4 Schizophrenia Stefansson et al 0.01 0.43 0.4 0.71 0.02 0.49 0.68 0.85 3.42E-03 0.44 0.3 0.67
rs9960767 18 0.05 TCF4 Schizophrenia Stefansson et al 0.54 0.75 0.32 0.59 0.8 0.91 0.55 0.74 0.93 0.97 0.65 0.81
rs12807809 11 0.17 NRGN Schizophrenia Stefansson et al 0.24 1.3 0.59 1.17 0.01 1.66 0.02 1.95 0.88 0.97 0.16 0.68
rs13211507 6 0.12 PGBD1 Schizophrenia Stefansson et al 0.09 0.56 0.4 0.71 0.14 0.65 0.68 0.85 0.58 0.87 0.21 1.64
rs6913660 6 0.19 HIST1H2BJ Schizophrenia Stefansson et al 0.17 0.7 0.18 0.66 0.63 0.9 0.87 0.96 0.69 0.92 0.99 1.01
rs1938526 10 0.06 ANK3 BPAD Ferreira et al 0.95 1.02 0.49 0.74 0.79 1.09 0.59 0.8 0.37 1.29 0.87 1.07
rs1064395 19 0.16 NCAN BPAD Cichon et al 0.31 1.26 0.45 1.25 0.29 1.25 0.42 1.26 0.16 1.31 0.18 1.48
rs2251219 3 0.39 PBRM1 BPAD/MDD McMahon et al 0.2 1.26 0.27 1.29 0.28 1.2 0.38 1.22 0.1 1.29 0.09 1.46
rs2289247 3 0.41 GNL3 BPAD/MDD McMahon et al 0.04 1.44 0.04 1.58 0.17 1.26 0.23 1.3 0.07 1.32 0.06 1.51
rs4238010 12 0.13 CCND2 MDD Muglia et al 0.18 1.37 0.88 1.05 0.86 0.96 0.07 0.58 0.48 1.16 0.33 0.76
rs1799990 20 5E+06 PRNP Prion disease Mead et al 0.02 0.51 0.58 0.83 3.40E-03 0.46 0.25 0.68 2.70E-04 0.46 0.07 0.56
3988578
SNP implicated in GWAS for prion disease (PRNP  codon 129)
0.35
28365356
27199404
61970389
19222735
52559827
52702297
SNPs implicated in GWAS for psychiatric conditions
27356910
32280971
51306000
124111495
Mood disorder BPS at onset
Prion+ vs Controls Prion+ vs Prion- Prion+ vs Controls Prion+ vs Prion- Prion+ vs Controls Prion+ vs Prion-
Candidate SNPs identified from other GWAS
Psychotic symptoms
BP
Table 20.  Summary of association results from our analysis for candidate single nucleotide polymorphisms identified from previously 
published genome-wide association studies of psychiatric conditions (schizophrenia, bipolar affective disorder and major depressive disorder) 
and prion disease.   BPS = behavioural disturbance or psychiatric symptoms; SNP = single-nucleotide polymorphism; Chr = chromosome; BP = 
base pair position; MAF = minor allele frequency; GWAS = genome-wide association study; OR = odds ratio for minor allele; Prion+ = prion disease 
cases with phenotype; Prion- = prion disease cases without phenotype; BPAD = bipolar affective disorder; MDD = major depressive disorder.
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Discussion 
This work represents a comprehensive study of the behavioural and psychiatric manifestations of 
the human prion diseases, using clinical data from a large prospective study carried out by a single 
team.  The findings expand on those of previous smaller studies, such as that from the Mayo clinic 
based on retrospective casenote review of 126 sCJD cases seen over 25 years174, and studies of vCJD 
by the UK National CJD Research and Surveillance Unit102,173. 
 
Behavioural and psychiatric features were common in all types of prion disease studied, and there is 
significant heterogeneity both within and between disease types.  This should inform clinical care as 
these symptoms represent a significant burden of morbidity for patients and carers, but may easily 
go unreported and unrecognized unless clinicians are vigilant for them.   
 
Knowledge of the natural history of these symptoms is also valuable in guiding discussions with 
patients and families, and in making decisions about care.  For example, it is clear from these results 
that psychotic symptoms tend to emerge as the diseases progress, and this should be borne in mind 
by clinicians seeing patients in the early stages of disease. 
 
Most clinical features of prion disease, which result from the irreversible loss of brain functions, do 
not recover once they have appeared.  In contrast, this study shows that BPS fluctuate and improve 
in a substantial proportion of patients.  This suggests that improving these symptoms with 
pharmacological or other interventions is feasible, but also that improvement may occur without 
any specific intervention.  This is particularly important to bear in mind when interpreting apparent 
benefit from treatment, both in clinical practice and in therapeutic research. 
 
The differential diagnosis of neurodegenerative diseases relies largely on the recognition of 
characteristic patterns of clinical features (although biochemical and imaging techniques are making 
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an increasing contribution).  Awareness of the prevalence and phenomenology of BPS in prion 
disease should thereby assist with diagnosis.  For example, visual hallucinations are well-recognized 
as features of Dementia with Lewy Bodies (and are included in the consensus diagnostic criteria for 
that disease201), but this study shows that they are also common in prion disease. 
 
Poor agreement of BPRS 
In addition to the BPRS, a wide range of different clinical assessments of neurological and cognitive 
function carried out in the PRION-1 trial were video-taped.  An analysis of the inter-rater 
concordance between the neurologist carrying out these assessments and a senior neurologist 
reviewing the video tape has been published by Carswell et al 202.  The BPRS was not included.  This 
showed that, apart from assessments relying largely on non-visual, non-auditory information (such 
as assessment of muscle power, or deep tendon reflexes) agreement was generally excellent, and 
concluded that video-taped assessments could be usefully incorporated into the design of clinical 
trials for prion diseases and other similar neurocognitive conditions. 
 
This is in strong contrast to the findings presented above for BPRS, where agreement was generally 
very poor and the neurologist making the assessment face-to-face tended to give substantially 
higher scores (implying more severe symptomatology) than a senior psychiatrist scoring from video.  
Several factors may be contributing to this.  The clinicians carrying out the PRION-1 assessments 
were neurologists and will have had less experience and training in the assessment of psychiatric 
symptoms, compared with the assessment of neurological and cognitive functions.  Even using a 
structured rating scale such as the BPRS, the assessment of these psychiatric symptoms may be 
challenging.  This is particularly true in a population of patients with co-existing physical and 
cognitive deficits, which is not the population for whom the BPRS was designed.  For example, the 
BPRS includes subcomponents assessing “somatic concern” and “disorientation/inappropriate 
affect”.  Deciding how to score these in patients with multiple disabling physical symptoms and 
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significant cognitive impairment is difficult, and open to variable interpretation on the part of the 
individual assessor.  The results suggest that while the assessing neurologists often erred on the side 
of scoring these as present, the psychiatrist scored them as absent unless they were clearly present 
and were not accounted for by physical or cognitive deficits.  It is also possible that the assessing 
neurologists’ scores were influenced by observations made during other parts of their clinical 
assessment, rather than purely from the responses given to the structured BPRS questions which 
were available to the psychiatrist.  For example, the same investigator will have taken a general 
clinical history of the patient’s recent progress and symptoms from the patient and their relatives 
and carers during their visit, and if this included reports of psychiatric symptoms this may have 
influenced their scoring of the BPRS even if these were not reported by the patient themselves 
during the structured interview. 
 
Overall, these results raise substantial concerns about the validity of the BPRS as a tool for assessing 
behavioural and psychiatric symptoms in this patient population, particularly when administered by 
non-psychiatrist clinicians.  The most significant problem identified is that the Scale could not be 
completed at all in the large majority of patients, as it relies on the patient themselves co-operating 
with a lengthy structured interview.  Several rating scales have been developed and validated 
specifically for assessing BPS in patients with dementia, such as the Neuropsychiatric Inventory 
developed by Cummings203, although there has been no published validation of any of these in a 
prion disease population.  These are usually administered by interview of a closely-involved carer, 
and are designed to be more robust to interference from cognitive or physical symptoms. 
 
BPS are key clinical features of the prion diseases and their assessment should be part of any future 
clinical trial, although they are not likely to form part of a primary outcome measure assessing 
disease progression as this study has shown that they fluctuate through the disease course (this is 
discussed in detail in chapter 6).   Validation of a suitable clinical rating scale for inclusion in trial 
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protocols and amenable to statistical analysis should therefore follow on from the work presented 
here.  To this end, the Neuropsychiatric Inventory has now been adopted as part of the routine 
assessment battery of the Cohort study, based on the results of the study presented here.   
 
Challenges in studying BPS in prion disease 
In comparison with the more common dementias, there are a number of particular challenges to 
studying BPS in prion disease.  Prion diseases are rare, with only around 1 or 2 new cases per million 
population each year.  To study large numbers of patients it is therefore necessary to enrol patients 
from a wide geographical area over a long period of time.  Patients deteriorate very rapidly in the 
majority of cases (particularly those with sCJD).  Patients are often at an advanced stage of disease 
when the diagnosis is made, making it impossible to study a large part of the disease course 
prospectively.  Prospective study of rapidly progressing cases is also challenging, as even very 
frequent follow-up assessments may fail to capture substantial clinical change.  Any study of the 
phenomenology of psychiatric symptoms relies on patients describing their internal experiences.  
Expressive language dysfunction is recognized as a hallmark of prion disease and often occurs as one 
of the earliest cognitive changes.  Patients with prion disease thereby lose the ability to describe 
their internal experience of any psychiatric symptoms, leaving carers, clinicians and researchers to 
interpret behaviours as evidence of these.  For example, a wide-eyed, fearful expression without 
obvious cause in a mute patient may be the result of visual hallucination, but it is not possible to 
confirm this or to establish the phenomenology of the symptom. 
 
In this study systematically, prospectively collected data was prioritized over retrospective review of 
clinical casenotes whenever possible, in order to minimize bias and allow direct and fair comparison 
of patients.  However, as a consequence, the prevalence of BPS may be somewhat underestimated, 
particularly in more rapidly progressing cases where prospective study is particularly challenging.As 
no symptoms from the agitated (non-psychotic) symptom group were rated routinely at all 
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assessments (while hallucinations and depressive symptoms were), the agitated group is likely to be 
relatively underestimated. 
 
To allow the above analysis to be performed it was necessary to classify the diverse symptoms 
described by patients, carers and health professionals into a manageable number of symptom 
groups.  Three were used: psychotic symptoms, agitated (non-psychotic) symptoms, and mood 
disorder.  This division performed well in terms of providing a simple system that encompassed 
almost all symptoms noted in the study, and allowing the data to be presented and analyzed in a 
relatively straightforward way.  It also fits well with our overall clinical experience of this patient 
group, and with previously published work using factor analysis in other neurodegenerative 
diseases.  However, it is important to note that any attempt to group complex disease 
manifestations in this way will inevitably be an over-simplification, and will lead to symptoms that 
are biologically distinct being grouped together.  For example, the pathophysiology underlying a 
depressive illness in a person with very early disease may have little in common with that underlying 
emotional lability in a more advanced patient with frontal lobe dysfunction.  This will make it more 
difficult to demonstrate biological associations with these symptom groups. 
 
In the logistic regression analyses strong associations were identified between several 
biological/clinical variables and the psychotic symptom group, but not mood disorder or agitated 
(non-psychotic) symptoms.  This might be explained by these latter groups being more biologically 
heterogeneous, while the psychotic symptom group, which was dominated by a single well-defined 
symptom (visual hallucinosis), is likely to be more homogeneous. 
 
Although this does represent a limitation of this study, more sophisticated sub-grouping of 
symptoms would not be possible to achieve from the available data, and would ideally be based on 
detailed phenomenological descriptions of symptoms that are often impossible to obtain in these 
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patients. 
 
Pharmacological treatment of BPS in prion disease 
The drug treatments commonly used for BPS in this patient population (antipsychotics and 
benzodiazepines for agitated and psychotic symptoms, antidepressants for mood disorder) are 
reported to have a clinical benefit in a proportion of patients.  Limitations apply to any observational 
treatment study and must certainly be taken into account when interpreting these results, 
particularly in light of the observation from this study of spontaneous improvement in these 
symptoms in a substantial proportion of patients.  The impact of non-pharmacological measures 
introduced alongside drug treatment, or spontaneous improvement in symptoms may easily be 
misattributed to a recently prescribed drug.  The study of treatment was unblinded and 
uncontrolled, and relied on retrospective review of case notes for evidence of benefit and adverse 
events.  Ideally this study should be followed up with more robust clinical trials of the promising 
symptomatic treatments that it has identified. 
 
The use of antipsychotic medication in patients with dementia has been shown to be associated with 
a significant increase in mortality, partly explained by an excess of cerebrovascular events204,205.  It is 
important to consider whether the same risks exist in patients with prion disease.  Most 
antipsychotic treatment courses in the patients studied were relatively short, principally because of 
the very rapid progression of disease.  However there are an important minority (mostly with IPD) 
where progression is slower, and treatment courses longer.  Patients with prion disease are also 
younger than the dementia population in whom the risk has been demonstrated (mean age of 
patients treated with antipsychotics in this study was 51.2 years).  Baseline risk of cerebrovascular 
disease is therefore likely to be lower, and it seems likely that this would reduce the risk of this type 
of adverse event.  However, this study is certainly not powered to demonstrate a small change 
against the very high background mortality of a prion disease population, so a similar risk cannot be 
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ruled out. 
 
Overall, it seems likely that any risk associated with antipsychotic treatment will have less clinical 
impact in the context of rapidly progressive prion disease than in other slowly progressive dementias 
for the reasons described.  Nevertheless, clinicians should keep these theoretical risks in mind when 
making decisions with individual patients, particularly those with more slowly progressive disease 
types.  
 
This study did not allow any systematic assessment of non-pharmacological interventions for BPS in 
prion disease.  A major challenge to the study of non-pharmacological interventions in dementia has 
been a lack of standardization making direct comparison difficult206,207, and this is particularly true in 
a group of patients studied in a wide variety of clinical contexts over a long period of time. 
 
Nevertheless, from the casenotes reviewed and the clinical experience of the National Prion Clinic 
team more generally, it is clear that non-pharmacological interventions can play a vital role in caring 
for patients with these symptoms.  The involvement of suitably trained and experienced carers, and 
the care of patients in appropriate, calm and containing settings, seem to be particularly valuable. 
 
Biological mechanisms underlying BPS in prion disease 
Studying the remarkable heterogeneity of prion disease can provide valuable insights into the 
underlying disease process:  the strong disease-modifying effect of the codon 129 polymorphism of 
PRNP is perhaps the defining example of this. 
 
There were a number of significant associations in the logistic regression models for factors 
predicting the presence of BPS.  The association of psychotic symptoms with particular disease types 
 174 
and codon 129 genotypes, and of BPS at onset with diagnosis of vCJD suggests that the propagating 
prion strain is a dominant factor in causing these symptoms. 
 
The presence of hallucinations was strongly associated with MRC-PDRS, the measure of functional 
decline, whereas the presence of depressive symptoms was not.  This may suggest that 
hallucinations are more closely and directly related to the underlying disease process than 
depressive symptoms.  In the absence of organic brain disease, depressive symptoms are much more 
common than hallucinations, and a proportion of those recorded in this study may represent a 
secondary, “normal” reaction (i.e. mediated by brain areas unaffected by the organic pathology). 
 
Interestingly, in the logistic regression models restricted to sCJD, age at onset was an independent 
predictor of the presence of BPS at onset.  This raises the possibility that the presence of psychiatric 
symptoms at onset may to some extent be a feature of prion disease in younger people, as opposed 
to being primarily a feature of the vCJD prion strain.  In a study using pooled data from a large 
number of published clinical cases, Appleby and colleagues also concluded that younger sCJD 
patients were more likely to present with particular symptoms, including affective symptoms and 
behavioural disturbance176. 
 
As this clinical feature is currently used as a criterion for diagnosing vCJD105 this is an interesting 
possibility: if older vCJD patients were less likely to exhibit this feature, it would be more difficult to 
distinguish them from the more numerous sCJD cases.  This is of particular interest in the context of 
the evolving vCJD epidemic in the UK, where future patients presenting with longer incubation 
periods will tend to be older.  
 
The exploratory genome-wide association studies looked for genetic loci associated with three 
behavioural/psychiatric phenotypes in the context of prion disease.  As the number of patients 
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included was relatively small these studies are only powered to detect very strongly associated SNPs, 
and the lack of any reaching genome-wide significance certainly does not rule out the possibility that 
there are genetic modifiers of these phenotypes.  Hypotheses are proposed here for follow up in 
other cohorts of prion disease or related neurodegenerative diseases208.  Reviewing the most 
strongly associated SNPs from this study identified several loci that may be of interest as they have 
previously been implicated in genetic studies of psychiatric or other neurodegenerative disorders. 
 
The strongest evidence of association was for a SNP lying within the ANK3 gene, in the analysis of 
psychiatric features at onset.  There is strong evidence for association of other SNPs within ANK3 
with bipolar disorder from a large collaborative genome-wide association study196, although the 
genotyped SNPs reported in that study showed no evidence of association in this analysis.   Ankyrin 3 
is thought to participate in the maintenance/targeting of ion channels and cell adhesion molecules 
at the nodes of Ranvier and initial axon segments209.  The SNPs on chromosome 6 that were found to 
be trending towards association with psychotic features in prion disease lie within a chromosomal 
region (6p21.3-22.1) that has been implicated in genetic studies of susceptibility to both 
schizophrenia and bipolar disorder, without a single locus emerging as the dominant source of 
association195,210.  It is possible that this apparent inconsistency is related to the unusual patterns of 
recombination around the Major Histocompatibility Complex which also lies in this region211.  4 of 
the top 5 candidate genes for schizophrenia risk listed on SzGene.org lie within this region 
(www.szgene.org).  Although conclusions drawn from this study must be conservative because of 
the small patient numbers and the failure of any SNPs to reach genome-wide significance, this 
suggestion of an overlap with the genetics of “primary” psychiatric disorders is intriguing. 
 
Large genome wide association studies using both SNPs and copy number variants (CNVs) have 
previously identified genetic loci with an effect across multiple psychiatric and neurodevelopmental 
conditions, with the overlap between risk loci for schizophrenia and bipolar disorder being 
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particularly well established 212-216.  This has been interpreted as evidence that there are genetic risk 
factors for psychosis that are not disease-specific 214.  It is conceivable that a genetic factor 
conferring susceptibility to schizophrenia or bipolar disorder might also increase the likelihood of an 
individual developing psychotic features in the context of neurodegenerative disease.   Our results 
provide an intriguing hint that this may be the case in prion disease, and we wish to encourage 
further investigation of this hypothesis. 
 
The findings of this study should help to inform the diagnosis and care of patients with prion disease, 
and also prompt further research seeking to replicate and expand on these findings in independent 
prion disease cohorts.  Comparison with similar studies in other diseases may also shed a revealing 
light on the mechanisms underlying these important and complex manifestations of 
neurodegeneration. 
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CHAPTER 6.  DEVELOPING A NEW CLINICAL RATING SCALE FOR USE IN PRION 
DISEASE CLINICAL TRIALS 
 
Introduction 
General introduction and aims 
A principal, over-arching aim of the whole field of prion disease research (as well as 
neurodegenerative disease research more widely) is to find disease-modifying therapeutic agents 
that will be of benefit to patients affected by these conditions.  Up to now, no agent has been shown 
conclusively to alter the progression of any prion disease in patients217.  For this goal to be achieved, 
two major phases must be completed: the preclinical stages, whereby potential therapeutic agents 
are identified and tested in the laboratory setting using in vitro and/or in vivo experiments, until 
there is sufficient evidence to support a potential therapeutic effect for patients; and the clinical 
stages, whereby the agent goes through a series of clinical trial phases to assess its safety, and finally 
its efficacy. 
The preclinical phase of therapeutic research in prion disease has seen considerable success, with 
several classes of agents showing promise in both in vitro and in vivo models217.  
 
The transmissibility of prion disease both within and between mammalian species, leading to fatal 
neurodegeneration that faithfully reproduces the clinicopathological features of the human disease, 
provides a uniquely robust opportunity for laboratory validation of experimental therapeutics for a 
human neurodegenerative disease.  As a result of these animal models, unparalleled in 
neurodegenerative disease, and rapidly advancing understanding of the molecular pathogenesis of 
prion disease, development of putative therapeutic agents for use in human trials (both small 
molecules and monoclonal antibodies that bind to PrPc) has now reached an advanced 
stage22,23,132,218-221.   
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However, if the promise of these agents is to be realised, it is vital that the methodology used in 
clinical trials is optimised to maximise the chances that any real beneficial effect will be 
demonstrated.  Even a highly effective therapeutic agent may fail to produce conclusive results 
without an optimal trial design. 
 
Previous clinical trials and other treatment studies in human prion disease 
In planning how to optimise the design of future trials it is useful to review therapeutic studies that 
have been performed in the past, and consider the relative merits and weaknesses of the methods 
used.  A systematic review of clinical studies in prion disease carried out in 2008222 found only one 
double-blind randomised controlled trial (using the analgesic agent flupertine), but also reviewed a 
number of small case series and case reports that included some observational account of 
attempted treatment.  The only reports that included direct comparison with untreated patients 
were the flupertine trial, and case series related to use of quinacrine and amantadine.  Agents used 
in the non-comparative observational reports included antiepileptic agents (levetiracetam, 
phenytoin, topiramate), an antifungal agent (amphotericin), antidepressant agents (imipramine, 
venlafaxine), interferon, vidarabine and a variety of antioxidants and vitamin supplements.  
Although in a few cases some impression of transient improvement was reported, there was no 
dramatic effect on the patients expected disease progression or outcome with any of these 
treatments, and it is not possible to draw any meaningful conclusions from these isolated case 
reports or small case series.  The review also identified several reports related to treatment of 
patients with the anticoagulant pentosan polysulphate; this has been examined in more detail 
elsewhere and is discussed below. 
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Experience with pentosan polysulphate in the UK and Japan 
Pentosan polysulphate is a polyanion molecule chemically related to heparin, which is used as an 
orally administered medication for interstitial cystitis223.  It has been found to reduce PrPSc 
aggregation in vitro, and also to prolong incubation times in some animal models224.  When 
administered orally or intravenously, it has very poor bioavailability in the central nervous system, so 
its use when administered directly into the cerebral ventricles via a surgically placed catheter and 
pump has been investigated.  Most of the published experience of this treatment comes from Japan, 
where a lot of the relevant preclinical research was carried out; and from the UK, where the 
treatment has been used particularly in a number of young patients with vCJD.  In the UK, a formal 
observational study of seven patients receiving the treatment was carried out and published by 
Professor Ian Bone and colleagues224.  In Japan, one “clinical trial” of 11 treated patients (with no 
comparison group) has been published225.  The conclusion from these studies has been that there is 
no convincing evidence that pentosan polysulphate slows the rate with which patients progress to a 
state of very severe disability, but that there have been a number of patients who have survived for 
very prolonged periods (longer than any previously published patients with the same disease type), 
in such a state of severe disability while receiving the treatment.  There are potential confounders in 
that those patients and families willing to pursue this invasive treatment option may well be more 
likely to pursue other potentially life-prolonging interventions such as aggressive treatment of 
infections in the late stages of disease, insertion of artificial feeding tubes, or even artificial 
ventilation, which others might feel to be inappropriate.  However, it is not clear whether the long-
survival of some pentosan polysulphate treated cases have in fact received interventions of this 
type, and it remains a possibility that the treatment does indeed have a real treatment effect. 
 
In terms of lessons for future trial design, the experience with pentosan polysulphate illustrates very 
clearly the limitations of survival as an outcome measure.  Our objective is to find a treatment that 
alters the progression of the disease in order to keep patients well and able to function for as long as 
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possible, not one that keeps patients alive after they have reached a state of akinetic mutism.  
Relying on survival as an outcome measure means that we may not be able to distinguish between 
the two. 
 
German trial of flupertine 
A trial of flupertine for human prion disease was carried out in Germany, with patients recruited 
from those referred to the German National CJD Surveillance Unit between 1997 and 2001226.  The 
investigators acknowledged that the usefulness of survival as an outcome measure was limited, and 
therefore used cognitive assessment (primarily using the change in score on the ADAS-Cog scale 
between the initial assessment and the best score achieved during follow-up) as their primary 
outcome measure.  To allow this, the inclusion criteria for the trial specified that patients should be 
able to achieve an arbitrarily set minimum score on the cognitive tests being used to be eligible for 
enrolment in the trial.  The trial found a statistically significant difference between the treatment 
and placebo groups, with less deterioration in performance on the ADAS-Cog in the patients 
receiving flupertine.  The magnitude of this difference (12 points on the ADAS-Cog) was felt to be of 
clinical significance.  There was no significant difference in survival between the two groups.  From 
682 patients assessed for eligibility for the trial, only 28 met the inclusion criteria and were 
randomised.  These all presented as sporadic CJD, but 2 were unexpectedly found to have 
pathogenic PRNP mutations, altering the diagnosis to IPD.  The reasons for exclusion of the other 
654 patients were reported as “either other disease or not fulfilling dementia tests”, but the relative 
contributions from these two criteria are not reported.  Surveillance data from the German 
surveillance unit covering the same period have been published separately41, and report annual 
rates of around 100 probable or definite sporadic CJD cases covering the same period, so it is likely 
that the large majority of patients were excluded based on inability to engage with or achieve the 
minimum score in the cognitive tests.  This would be in keeping with experience from the PRION-1 
trial where only 9% of enrolled sCJD patients were able to complete the ADAS-Cog at their initial 
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assessment121.  As a result, the patients included in the flupertine trial were highly selected and 
represent a very skewed sample of CJD patients, with those having slowly progressive disease and 
relatively preserved language and cognitive function being over-represented.  In keeping with this, 
the distribution of codon 129 genotypes in the study population was skewed strongly away from 
MM homozygotes, and PrPSc types away from those with type 1 PrPSc. 
 
This trial represents a landmark in that it was the first randomised controlled trial to be performed in 
patients with prion disease, and demonstrated that this is possible.  Although it achieved a positive 
and statistically significant result (p = 0.02), the small number of patients, who for the reasons 
described were taken from a small and skewed subgroup of the overall population of referred 
patients, combined with the remarkable heterogeneity of clinical progression in prion disease (as 
clearly demonstrated in the work presented in this chapter), do raise concerns that this may have 
been a chance finding.  The natural history and variability of the ADAS-Cog as an outcome measure 
in this population had not been defined prior to the trial.  The applicability of the results outside of 
the small minority of patients that were eligible is also a limitation of the study. 
 
French/Italian trial of doxycycline 
In January 2014, Haik et al reported a randomised, placebo-controlled trial of doxycycline as a 
treatment for prion disease227.  This involved patients from both France and Italy, constituting the 
first international collaborative trial in prion disease.  In total 121 patients were recruited from 
amongst 663 referrals.  The proportion of referred patients being enrolled in the trial was much 
higher in Italy than in France, with the main reason given as failure to meet the inclusion criteria, 
suggesting that referral patterns are different between the two countries with fewer non-prion 
disease patients being referred in Italy.  The primary outcome was survival, with a number of clinical, 
laboratory and imaging measures used as secondary measures, but not presented in the published 
report as only a small minority of patients were able to have these measures/investigations done.  
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The trial found no significant difference in survival between the treatment and placebo groups (and 
in fact was stopped prematurely on the basis of futility after an interim analysis showed no sign of 
efficacy).  This was in contrast to two earlier observational reports suggesting that patients treated 
with doxycycline had longer disease durations when compared with historical untreated cases.  The 
authors of the trial report acknowledge that these earlier observational reports may have been 
subject to selection bias, with patients that have a slower disease progression being more likely to 
receive treatment with doxycycline as they have not yet reached a very advanced stage of disease 
(when attempted treatment would often be seen as inappropriate) when they are diagnosed and 
offered the experimental treatment, but the historical “normal” data with which they were 
compared will include the majority of cases who progress very rapidly.  This illustrates clearly the 
risks inherent in over-interpreting any non-randomised treatment study, as well as specific 
challenges with use of historical controls. 
 
The trial did not involve any enrolment criteria aimed at excluding patients at advanced stages of 
disease, other than some trial centres (those in Italy) excluding patients that had had symptoms for 
more than 6 months.  While increasing the numbers of patients eligible and the applicability of 
results, it is likely that patients at very advanced stages of disease will not be able to benefit from 
any treatment and that their inclusion will therefore lead to trials underestimating the efficacy of a 
treatment.  There are also ethical considerations in treating patients with a very high burden of 
neurological damage with treatments that may prolong survival but are far less likely to lead to any 
meaningful recovery of function.  The ideal solution to this problem is to achieve very early diagnosis 
in all cases so that they can be enrolled at a stage when they have only mild disability.  Although 
improving early diagnosis must be a priority, the speed of progression of sCJD, combined with its 
rarity, make it likely that many patients will continue to be diagnosed at an advanced stage of 
disease.  It is therefore necessary to consider this issue in trial design, and consider ruling out 
individuals with very advanced disease.  As the doxycycline trial illustrates, time-based criteria (e.g. 
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months from onset) are not useful for dividing prion disease patients into stages of disease 
progression because of the marked variability in rate of decline, so criteria based on a functional 
assessment would be more useful. 
 
American trial of quinacrine 
Based on the encouraging preclinical evidence regarding quinacrine’s in vitro inhibition of prion 
replication discussed above in relation to the PRION-1 trial, a clinical research group led by Michael 
Geschwind at the University of California San Francisco also planned and carried out a clinical trial of 
quinacrine228.  This enrolled patients with sCJD from 2005 to 2009, and did include criteria to exclude 
very severely impaired patients:  patients had to be able to swallow and follow simple one-step 
commands to be eligible for the trial.  From 425 patients referred for consideration, 69 were 
evaluated by the trial team, and 54 were randomized (although 3 subsequently found to have a 
PRNP mutation were not included in the analysis).  The study design involved randomization to 
treatment with either quinacrine or placebo for a period of two months, after which patients and/or 
carers could elect to receive open-label quinacrine if desired.  The primary outcome was survival 
over the course of the two month randomized treatment period.  A range of secondary outcome 
measures including functional and cognitive rating scales were also used (including several which 
were used in PRION-1 and are discussed in more detail below).  This design, and the sample 
size/power calculation used were based on experience from the same research group’s observation 
of sCJD patients that chose to receive open label “compassionate treatment” with quinacrine 
compared with those that did not choose to receive this treatment, which suggested that average 
survival was increased from 0.9 months to 3.2 months in those receiving quinacrine, and that 
randomizing 30 patients to each group in a randomized trial would provide 80% power to 
demonstrate a doubling in survival rate over 2 months.  The primary outcome analysis showed no 
survival benefit in the quinacrine group (and in fact a non-significant trend towards increased 
survival in the placebo group).  Analysis of secondary outcomes suggested that the quinacrine group 
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declined less in scores on two functional scales (the modified Rankin scale and the Clinician’s 
Dementia Rating (CDR)).  However, given that ten secondary outcome measures were used, the 
levels of significance for these differences (p values of 0.03 and 0.01 respectively) are not strong, 
and the effect sizes are difficult to interpret:  change in mean values are quoted but these have little 
meaning for categorical rating scales such as these, particularly when the range of scores in the 
study group are extremely wide.  For the statistical comparison, the authors appropriately used non-
parametric methods based on rank transformation of the scores (Quade’s rank analysis of 
covariance), but only reported the p values generated by these tests.  There were also some baseline 
differences in the groups, including somewhat lower modified Rankin scores in the Quinacrine group 
(suggesting that they were more functionally impaired), and some difference in distribution of codon 
129 genotypes, which did not reach statistical significance in itself but nevertheless has the potential 
to substantially affect results as this is such a strong modifier of disease progression. 
 
This trial provides a number of very valuable insights into the challenges of planning prion disease 
trials.  Most strikingly, there was a great disparity between the conclusions taken from the 
preliminary observational study on which the trial design was based and the results of the trial itself.  
As seen in the PRION-1 trial120, the choice made by prion disease patients and/or their carers 
regarding whether to receive a potentially life-prolonging treatment is very strongly confounded 
with respect to other factors affecting rate of disease progression and survival.  Patients with more 
slowly progressive disease, who are less severely impaired at the time of making the decision, are 
more likely to choose to receive treatment.  Although this can be taken into account by stratifying 
groups (e.g. by level of functional impairment at enrolment as was done in the PRION-1 analysis), 
there is still a chance that other, unmeasured factors will confound the results.   Geschwind’s 
quinacrine trial clearly illustrates the value of randomization in eliminating what was an apparently 
strong, but in fact probably spurious, treatment effect in the observational study.  As decisions about 
trial design, including sample size, were made based on the over-estimate of treatment effect from 
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the observational study, it is likely that the trial was not powered to demonstrate a more modest 
effect that might exist.   It also illustrates again the lack of an ideal outcome measure for use in this 
sort of trial:  the authors acknowledge that functional and/or cognitive scales may have a role, and 
there was very wide variability in estimated difference in survival between groups of this size. 
 
Building on PRION-1 to plan towards future clinical trials 
The PRION-1 trial demonstrated that a large prion disease clinical trial in the UK is feasible, but was 
limited by the lack of a validated measure of clinical progression120.  Anticipating this issue, the trial 
protocol included a variety of existing rating scales designed to probe neurological, cognitive, 
psychiatric and general functional status. Analysis of the performance of eight of these scales in 
PRION-1 in terms of validity, practicality and statistical power in simulated clinical trials supported 
the use of functionally-orientated measures relative to global, neurological, cognitive or psychiatric 
scales121. However, a number of unresolved issues remained:  no single scale captured progression 
across the full range of functional domains affected by any of the individual categories of prion 
disease; patients could not be visited frequently enough to capture the very rapid decline which is 
typical of Creutzfeldt-Jakob disease (CJD); floor effects (large numbers of subjects with the worst 
possible score) were observed in all scales except the Glasgow Coma Score (GCS); and the patient 
sample was too small to allow reliable analysis of important aetiological or severity-stratified 
subgroups229. 
 
Some other specific challenges to the design of prion disease trials are also relevant.  The 
heterogeneity of the diseases increases the natural variation in any outcome measure used, which 
will tend to reduce statistical power, so that greater numbers of subjects are needed for a beneficial 
effect to be successfully proven.  In combination with the rarity of the diseases, this represents a 
substantial challenge as it may be very difficult to recruit sufficient numbers in a feasible timescale 
for a trial. 
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The majority of patients are diagnosed (and enrolled into research studies) at an advanced stage of 
disease, and initiating a putative disease-modifying treatment at this stage may be futile, or may be 
felt to be clinically inappropriate.  Improving early diagnosis and referral is therefore another key 
parallel goal to drug development. 
 
The project presented in this chapter aimed to build on the experience from the PRION-1 trial with 
the large amount of additional clinical data now available from the Cohort study, to develop a single, 
functionally-orientated and validated outcome measure, tailored to the particular demands of a 
prion disease clinical trial.  As a starting point elements of three rating scales that showed relative 
strengths in the PRION-1 analysis and are well established in other neurological settings were 
modified and combined:  the Barthel Activities of Daily Living Index (Barthel)190, the Clinical 
Dementia Rating Sum of Boxes (CDR)191, and the GCS192.  The process by which this initial scale was 
established and then refined is described in detail below. 
 
In developing an optimal outcome measure, statistical and methodological concerns must be 
balanced with clinical and human considerations.  It should measure something that is important to 
patients and carers, so that a statistically defined benefit in a treatment trial will translate into a 
meaningful, worthwhile benefit for patients.  To achieve this, qualitative data was collected from 
patients’ relatives and carers on which manifestations of prion disease were of greatest concern to 
them, so that these could be reflected in the domains assessed by the scale. 
 
In the PRION-1 trial many patients with very rapidly progressive disease were only assessed on one 
occasion, limiting the amount that they can contribute to the statistical power of a clinical trial, 
particularly if its outcome is the rate of change in a measure of severity121.  To address this, the 
reliability of the novel scale used over the telephone was assessed, which would allow much higher 
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assessment frequency.  The scale’s reliability when administered by different healthcare 
professionals (doctors and nurses) was also assessed, which again would allow more frequent 
assessment and more flexibility in planning trial follow-up protocols. 
 
Introduction to Rasch Analysis 230 
To validate a novel rating scale that consists of a number of ordered categorical items, several 
requirements must be met if the scale is to be used to generate meaningful summed total scores, 
change scores, and have parametric statistics applied to it (all of which would be advantageous if not 
essential in a clinical trial outcome measure).  Rasch analysis is a method for demonstrating that 
these requirements are met, as well as exploring and refining other characteristics of a rating scale.  
It involves testing the fit of a dataset generated using a rating scale to a mathematical measurement 
model: the Rasch model.  If problems are identified that compromise the fit, adjustments can be 
made to the scale to address these, and the analysis repeated using the modified dataset.  In this 
way the scale can be improved through an iterative process, aiming to find a version that fits the 
Rasch model well. 
 
To understand the Rasch model and Rasch analysis, it is helpful to consider an ideal rating scale, 
which would satisfy all of the requirements of Rasch analysis. The scale should consist of a range of 
items, ranging from “easy” (where most individuals in the test population achieve the threshold for 
the item) to “hard” (where very few do).  The “difficulty” of an item is termed its Item Location.  If an 
individual reaches the threshold for a “hard” item, then it should be likely that they will also reach 
the threshold for all “easier” items in the scale.  The likelihood of an individual reaching the 
threshold for any given item within the scale should be predictable by their overall score on the scale 
(or their Person Location), representing the single construct that the scale is measuring, or the 
‘latent trait’ in the model:  this is the assumption of unidimensionality, which must be satisfied for a 
fit to the Rasch model to be satisfactorily achieved.  This aspect of the Rasch model can be seen as a 
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probabilistic form of Guttman scaling230:  a perfect ‘Guttman pattern’ is achieved when there is a 
strict hierarchy of item difficulty, so that achievement of a certain item threshold implies that all 
easier items are definitely also achieved.  Rasch analysis modifies this to allow that there should be a 
high probability that easier items are achieved.  The degree to which a Guttman pattern is achieved 
gives an indication of the strictness of the hierarchy of item difficulty.  
 
The spread of items across the range of “difficulty” should be appropriately targeted for the 
population in whom the scale will be used, ideally so that average overall score on the scale lies 
close to the numerical midpoint of the scale, and so that there is good coverage of the full range of 
“ability” seen in the population. 
 
The way that each item within a scale behaves should be the same for all individuals, and groups of 
individuals, in the tested population: there should be no differential item functioning (DIF).  For 
example, an item threshold should not be more difficult to achieve for men than for women, or for 
older patients than for younger patients.  Rasch analysis includes systematic assessment for DIF. 
 
Particular issues may arise for a scale including items that have multiple response categories 
(polytomous items): for example an item that scores 0 if a person cannot mobilise at all, 1 if they 
need help to mobilise and 2 if they can mobilise independently.  The thresholds of the response 
categories should be appropriately ordered:  in the example, this means that patients that can 
mobilise independently should generally achieve a higher overall score in the scale than those who 
need help to mobilise, who should achieve a higher score than those that are immobile.  This is 
systematically assessed during Rasch analysis, and if anomalies are identified these can be dealt with 
(for example by combining 2 adjacent response categories into a single category, or even dropping a 
disordered item from the scale entirely). 
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Ideally, there should not be a strong dependency between items within the scale: the likelihood of a 
particular item threshold being reached should be determined by the overall scale score (Person 
Location) to a greater extent than it is determined by any other individual item within it.  This may 
not be achieved if there is redundancy between items:  for example if a patient’s ability to walk with 
assistance, and a patient’s ability to walk unaided were included in a scale as separate items, one 
would expect the response to one to be closely dependent on the other.  If this is the case, it may be 
appropriate to combine items to form “super-items” and eliminate this problem of dependency:  in 
this example this would produce the polytomous item from the previous example. 
 
If a novel scale can be validated with Rasch analysis using the large dataset collected from the 
patients enrolled in PRION-1 and the Cohort study, we can be confident that the scale will have the 
appropriate statistical properties to be used in a clinical trial:  it will be meaningful to consider a 
single sum total score as an overall measure of disease severity, to compare numerical change in 
score or rate of change in score between groups, and to use parametric statistics to analyse these 
data. 
 
Integrating different approaches to scale development 
Although the statistical approach to scale development exemplified by Rasch analysis is vitally 
important, it must be balanced with a clinical and pragmatic perspective on the design of a rating 
scale.  It must be ensured that the scale continues to measure factors that are meaningful to 
patients and carers, that it includes assessment of the full range of different domains affected by the 
disease, that it remains practical and easy to use both for the researcher and for the subject, and 
that other aspects of its reliability and validity are maintained (e.g. inter-rater reliability).  To do this 
it is essential to bear in mind the clinical context of the patients enrolled in these studies, and also of 
the practical, logistical aspects of the research studies themselves, so that these can inform 
decisions made at all stages of the process.  The scale’s performance relative to existing scales can 
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also be examined, to assess whether it overcomes some of their limitations, particularly those 
identified from previous analysis of the scales data from PRION-1121. 
 
Establishing a natural history data set 
Together, PRION-1 and the National Prion Monitoring Cohort constitute the largest single 
prospective clinical study of prion disease that has been carried out.  Once we have established a 
novel rating scale specifically tailored to capture the progression of prion disease in the large dataset 
from these studies, we have an opportunity to illustrate the natural history of these diseases in more 
detail than has previously been possible.  This is of considerable interest in itself, but may also play a 
valuable role in the planning of future clinical trials.  As discussed above, the recruitment of 
sufficient numbers of patients to achieve statistical power in a prion disease clinical trial over a 
feasible timescale is challenging, and the natural history dataset established from these studies may 
provide a historical control group for future trials, with major benefits for statistical power.  
Particular issues and challenges raised by this approach are discussed in detail below. 
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Methods 
Patient referral, clinical diagnosis and enrolment 
Although these were discussed in the General Introduction above, it is useful to revisit the 
particulars of the system of referral and enrolment here to set the scene for this project. 
 
A national referral system for prion diseases was set up in the UK in 2004.  UK neurologists were 
asked by the Chief Medical Officer to refer all patients with suspected prion disease jointly to the 
National CJD Research and Surveillance Unit (Edinburgh, UK) and to the NHS National Prion Clinic 
(London, UK).  This enables epidemiological surveillance, provision of specialist clinical care and also 
participation in clinical research, including the PRION-1 trial (2001-2007)120 and the National Prion 
Monitoring Cohort study (2008-2012) (referred to henceforth as simply “Cohort study”).  See 120 for 
details of enrolment into the PRION-1 trial, which were similar to those described for the Cohort 
Study below. 
 
The Cohort study began in October 2008, and aimed to enrol all symptomatic patients with prion 
disease in the UK thereafter.  This includes all cases of probable or definite sporadic Creutzfeldt-
Jakob disease (sCJD), variant CJD (vCJD), iatrogenic CJD (iCJD), and inherited prion disease (IPD).  Also 
eligible for enrolment are asymptomatic individuals known to be at risk of inherited prion disease 
(tested asymptomatic gene mutation carriers or untested first degree relatives of those with a 
confirmed pathogenic PRNP mutations), or vCJD (recipients of implicated whole or leucodepleted 
blood transfusion notified by the Health Protection Agency). A small group of healthy controls were 
also recruited (friends or relatives without pathogenic PRNP mutations or other known risk factors). 
At risk individuals and healthy controls did not contribute to the development of rating scales. 
 
Enrolment by National Prion Clinic staff took place at hospitals, nursing homes, hospices and 
patients’ homes around the UK. Diagnoses and eligibility were reviewed by senior National Prion 
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Clinic clinicians (Professor John Collinge, Dr Simon Mead and/or Dr Peter Rudge) within a week of 
enrolment, or prior to enrolment if there was clinical uncertainty. Probable sCJD diagnosis was made 
according to WHO criteria, with the addition of brain MRI as a supportive investigation following 
recent recommendations (pathological signal change on FLAIR or diffusion weighted sequences in 
the basal ganglia, thalamus and/or ≥2 cortical regions)34.  Patients not meeting criteria for probable 
sCJD could be enrolled if this was thought to be the most likely clinical diagnosis at review by an 
expert panel.  Probable vCJD diagnosis was made according to WHO criteria231.  Inherited prion 
disease was diagnosed by gene test.  iCJD was diagnosed using sCJD criteria with a relevant history of 
exposure.  If patients died during the study and underwent post mortem examination, or had 
relevant tissue biopsy (brain or tonsil) during life, the pathological results were used to confirm 
diagnosis. 
 
A further 26 patients were recruited but not included in study participant totals or any analysis 
because an alternative diagnosis became more likely than prion disease during follow-up, due to 
their clinical course (e.g. persistent improvement) and/or clinical investigation results (e.g. presence 
of serum voltage-gated potassium channel complex antibodies, post-mortem results).  
 
Consent and ethics 
Informed consent was obtained directly from study participants if possible, or otherwise from 
relatives, carers or Independent Mental Capacity Advocates as appropriate.  Ethical approval was 
obtained from the Scotland A Research Ethics Committee (Cohort) or the Eastern Research Ethics 
Committee (PRION-1). 
 
Stratification and assessment schedule 
Participants were stratified at enrolment to the Cohort according to their likely rate of disease 
progression based on diagnosis: 
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(i) Symptomatic patients with sCJD, vCJD, iCJD and forms of inherited prion disease likely to 
have rapid clinical progression (due to 4 octapeptide repeat insertion (4-OPRI), E200K, 
D178N, E211Q or V210I mutations) 
(ii) Symptomatic inherited prion disease patients likely to have slow progression (those with 5-
OPRI, 6-OPRI, P102L, P105L, Q212P, A117V or Y163X mutations) 
(iii) At-risk and healthy control individuals 
 
Patients in stratum (i) had face-to-face follow-up assessments initially every 6 to 8 weeks.  If clinical 
progression proved to be slower than the expected significant deterioration over this interval (i.e. 
minimal or no change in MRC Scale over 6-8 weeks), study physicians could decide to reduce follow-
up frequency for subsequent assessments.  Patients in strata (ii) and (iii) had follow-up assessments 
every 6 to 12 months. The following rating scales were administered at study assessments:  Barthel 
ADL index190, CDR191, GCS192, Rankin232, Mini Mental State Examination (MMSE)233.  In September 
2009 an initial combination scale was also introduced, as described below.  In addition, a systematic 
clinical history, neurological examination and a short neuropsychological test battery were done at 
all assessments, unless precluded by the level of disease severity or patient fatigue. From May 2010 
patients in stratum (i) also had telephone assessments every 1 to 2 weeks between follow-up 
assessments.  These were discontinued if there was minimal change between consecutive 
assessments (usually at worst possible score). 
 
Survey of carer priorities 
The Barthel ADL Caregiver Interview Summary form was used to gather semi-quantitative data from 
relatives/carers on the aspects of prion disease of greatest importance to them and the patients in 
their daily lives. Up to four symptoms or impairments of greatest concern to them at the time of 
assessment were ranked in order of subjective importance.  This was completed at 69 assessments, 
by carers of patients affected by different prion disease types. These data were supplemented by 
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discourse analysis of 10 in-depth structured interviews with carers, which was carried out my 
another member of the team (Liz Ford, Research Nurse) and is not reported here. 
 
Development pathway for novel rating scale 
Building on and extending the analysis of the pre-existing scales in PRION-1121, an iterative approach 
was taken to develop and refine a novel scale.  An initial version took into account the relative 
performance and limitations of different pre-existing scales and their subcomponents in the PRION-1 
analysis, the reported priorities of patients and carers, and the pooled clinical experience of the 
National Prion Clinic medical, nursing and neuropsychology staff.  This scale version was then 
administered at all Cohort assessments alongside the range of scales above (from September 2009), 
as well as over the telephone (from May 2010). 
 
The performance of this scale version was assessed with respect to ease of use, ability to capture 
clinically evident decline, inter-rater reliability (assessed using Interclass Correlation Coefficient and 
Bland-Altman plot), reliability of use over the telephone, floor and ceiling effects. As it consisted of a 
combination of slightly modified subcomponents from existing scales used in PRION-1 and 
throughout the Cohort, a close approximation of the scale could be calculated for all assessments 
carried out prior to its introduction, allowing a larger number of patients and assessments to be 
included in sensitivity/additional analysis. 
 
Rasch analysis 
Rasch analysis was performed with support from statistician Zoe Fox, and Research Assistant Jessica 
Lowe.  The analysis was performed using each individual’s first two initial scale version assessments 
after September 2009, to ensure that the analysis was not unduly affected by a small minority of 
patients with many assessments, while still permitting testing the function of the scale over time. 
Rasch analysis was performed using Rasch Univariate Measurement Model (RUMM) 2030 software, 
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using the partial credit variant of the polytomous model234.  The following recommended230 iterative 
steps were taken to assess and optimise the fit of the scale to the Rasch model (1) Exploring item-
person interactions (to examine the degree to which the Guttman pattern was achieved) and item-
trait interactions using χ2-based fit statistics; (2) Rescoring items that demonstrated disordered 
thresholds (i.e. an item’s scoring categories do not progress in a logical order); (3) Removing the 
most poorly fitting items, or combining items into super-items where appropriate;  (4) Examining 
local dependencies between items that could confound the assumption of unidimensionality of the 
scale, and dropping items when misfit was still apparent; (5) Investigating differential item 
functioning (DIF) for gender, age, time of assessment (first vs. second assessment), assessor (doctor 
or nurse administering scale) and mode of assessment (telephone versus face-to-face).  A random 
sample of later follow-up assessments were also analysed to evaluate whether there was DIF for the 
selection of the follow-up visit to include in the main analysis; (6) Examining local dependencies 
using residual correlation matrices, and exploring unidimensionality of the scale using principal 
components analysis to select the highest positive and highest negative items followed by post-hoc 
t-tests on person locations determined by these items; (7) Reviewing summary fit statistics after all 
modifications to the scale were made. Cronbach’s Alpha statistic was used to confirm reliability of 
the fit statistics. The final scale, termed the MRC Prion Disease Rating Scale (or simply the MRC 
Scale) was selected when satisfactory fit was achieved overall, no items showed poor fit and the 
scale was shown to be compatible with unidimensionality. To increase numbers, a sensitivity analysis 
was also performed using scores derived from the individual component scales (Barthel, CDR, GCS) 
prior to September 2009 (the novel “Tools”  item was scored as missing) for individuals who did not 
have two scores post-September 2009. 
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Results 
Patients 
437 patients consecutively enrolled into the Cohort and/or PRION-1 studies (up to April 2012) were 
included in the analysis; 240 patients with sCJD, 25 with vCJD, 12 with iCJD, and 81 with 
symptomatic IPD together with 34 individuals at risk of IPD, 10 at risk of vCJD, and 35 healthy 
controls.  311 patients died during the period of study, 192 (62%) of these underwent post mortem 
examination, which confirmed the diagnosis of prion disease in all cases.  81 (19%) had diagnosis 
confirmed in life by gene test (all IPD) or tissue biopsy (some also with post mortem examination).  
165 (38%) were diagnosed using clinical and investigation findings alone. 
 
Figure 33.  Study profile.  iCJD = iatrogenic CJD; IPD = inherited prion disease; NPMC = National 
Prion Monitoring Cohort; PM = post mortem; sCJD = sporadic CJD; vCJD = variant CJD. 
 
Figure 33 illustrates enrolment, stratification, follow-up and drop-out from the studies.  97% of 
symptomatic patients judged eligible for the Cohort study at the initial National Prion Clinic 
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assessment were enrolled, suggesting that the study is highly effective at capturing recognised prion 
disease in the UK. Less than 1.5% withdrew from the studies.  The baseline characteristics of the 
patients are shown in Table 21. 
 
Table 21.  Baseline characteristics of patients included in this study. 
 
Scale development 
Table 22 summarises the scale development process.  
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Initial scale Carer priorities and clinical validity Inter-rater reliability Rasch Analysis MRC Prion Disease Rating Scale
Item Derived from… Problems identified Modifications Kappa Modifications Problems identified Modifications Included? Recalculated Kappa Maximum Score
(n = 54) (n = 54) (Total 20)
Bowel function Barthel Continence - - 0.74 - Fit improved by re-scoring
Adjacent levels 
collapsed
Yes 0.78 1
Bladder function Barthel Continence - - 0.71 - Fit improved by re-scoring
Adjacent levels 
collapsed
Yes 0.89 1
Grooming Barthel Personal care
Personal care over-
represented relative to other 
domains
- 0.67 - Item dependency with Bathing Item dropped No - -
Toilet use Barthel Personal care - - 0.81 - - Yes 0.81 2
Feeding Barthel Personal care Floor effect Extra level added 0.70 - Fit improved by re-scoring
Adjacent levels 
collapsed
Yes 0.83 2
Transfers Barthel Mobility - - 0.73 - Item dependency with Mobility
Mobility Barthel Mobility
"Wheelchair independent" 
very rarely applicable
Rewording 0.81 - Levels disordered
Dressing Barthel Personal care - - 0.39 Item dropped - - No - -
Stairs Barthel Mobility - - 0.82 - - - Yes 0.82 2
Bathing Barthel Personal care Floor effect Extra level added 0.66 - Fit improved by re-scoring
Adjacent levels 
collapsed
Yes 0.73 1
Best verbal response GCS Speech - - 0.85 - - - Yes 0.85 4
Use of tools Novel item Cognition - - 0.72 - - - Yes 0.72 1
Memory CDR Cognition
Expressive dysphasia typically 
obscures verbal memory
Rewording, to 
account for dysphasia
0.64 - Fit improved by re-scoring
Orientation CDR Cognition Floor effect Extra level added 0.80 Item merged
Item dependency with 
Memory/Language
Judgement/Problem 
solving
CDR Cognition - - 0.74 - Fit improved by re-scoring
Adjacent levels 
collapsed
Yes 0.82 1
Adjacent levels 
collapsed  Items 
merged
Yes 0.70 3
Items merged Yes 0.67 2
 
Table 22.  Summary of scale development process. 
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Ranked symptoms and impairments reported by caregivers using the Barthel ADL Caregiver 
Interview Summary form were grouped into functional domains.  The most frequently recorded 
were within domains of mobility (55/236 ranked items, 23%), personal care/continence (30/236, 
13%), communication/speech (29/236, 12%), behaviour/hallucinations (29/236, 12%), 
eating/swallowing (27/236, 11%) and cognition/memory/navigation (21/236, 9%). Symptoms or 
impairments from other domains were reported in <6% of responses. These were the key domains 
for representation in our outcome measure.   
 
The initial scale consisted of slightly modified versions of all subcomponents of the Barthel ADL 
Index, the Memory, Orientation and Judgement/Problem-solving subcomponents of the CDR, the 
Best Verbal Response subcomponent of the GCS and a novel subcomponent assessing ability to use 
tools (15 items, 35 thresholds) 121.  It was designed for completion based on a brief interview with a 
closely-involved relative or carer as inability of patients to participate was a major cause of poor 
completion rates for some scales in PRION-1.  Compared with their parent scales, minor 
modifications were made to a number of subcomponents at this stage to make them more easily 
applicable to prion disease patients e.g. to account for severe expressive dysphasia/mutism, and to 
add additional intermediate response categories at severe levels of impairment, aiming to improve 
discrimination and reduce floor effects. 
 
The initial scale was completed on a total of 977 occasions, in 266 patients.  This consisted of 498 
face-to-face assessments and 479 telephone assessments.  The scale proved to be simple and easy 
to use, being completed in less than 5 minutes.  In addition to this, an approximation of the initial 
scale could be calculated from Barthel, CDR and GCS scale data for a further 839 assessments pre-
September 2009.   
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The initial scale was acquired over the telephone by a doctor and a specialist nurse within 24 hours 
of each other on 50 occasions, over the telephone by a nurse within 24 hours of a face-to-face 
assessment by a doctor on 2 occasions, and by both doctor and nurse attending the same visit on 2 
occasions.  In all cases each assessor was blinded to the other’s score.  Agreement across all paired 
assessments was good or excellent (Cohen’s kappa > 0.6) for all but three items; Dressing, which was 
subsequently dropped from the scale; Best verbal response, which subsequently underwent item 
threshold re-scoring; Orientation, which was subsequently merged with Memory to form a ‘super-
item’. 
 
Rasch analysis 
The fit to the Rasch model of the 15 item initial scale was first assessed in all individuals across all 
symptomatic disease types, and demonstrated poor fit in this heterogeneous population (χ2=166.16, 
df =30, p<0.0001).  As Rasch analysis relies on the assumption that there is a single construct being 
measured by all items in a scale, the inclusion of patients with different disease types which are 
known to vary widely in their typical clinical progression could plausibly make it impossible to 
establish a fit to the Rasch model using the whole dataset.  As our primary objective was to develop 
an outcome measure tailored to sCJD, all other disease groups were excluded and the analysis 
repeated using 205 records from 132 sCJD patients. Fit improved somewhat, but was still 
unsatisfactory (χ2=77.01, df =30, p<0.0001) so further exploratory analyses were performed to 
identify the reasons for this. 
 
The 15 individual items were examined for threshold ordering, individual item fit, differential item 
functioning (DIF) and local item dependencies, and changes made to address these issues as 
recommended with consequent improvements in fit (e.g. rescoring of disordered items, dropping of 
most poorly fitting item)230.  These changes are summarised in Table 22.  Item dependencies were 
identified between Grooming and Bathing; Transfers and Mobility; Toilet and Stairs; Bathing, 
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Orientation and Memory.  Two “super-items” were created by combining pairs of heavily dependent 
items in a clinically meaningful way: Transfers and Mobility; and, Memory and Orientation.  The 
structure and scoring of these super-items can be seen in Table 23.  Once item re-scoring and local 
dependencies were addressed, items were dropped if fit was still not achieved. 
A revised scale including all of these modifications (subsequently termed the MRC Prion Disease 
Rating Scale) demonstrated a good fit (χ2=25.19, df =22 , p=0.29). The mean fit residual for all 11 
items in this scale was -0.498 with an SD of 0.993, illustrating a good fit of the items to the model.  
Cronbach’s alpha was 0.91, implying a high level of confidence in the reliability of the assessment of 
fit, and the Person Separation Index was 0.90. No individual item had a fit residual of magnitude >2. 
Examination for DIF for all items across all person factors confirmed the data to be free of DIF when 
Bonferroni probability adjustment for multiple testing was applied, with gender, age quartile, 
assessor (doctor or nurse), and assessment mode (face-to-face or telephone) included as person 
factors. 
 
Principal components analysis showed that items assessing speech and cognitive functions (Speech, 
Memory/Orientation, Judgement and Use of tools) were positively loaded while negatively loaded 
items assessed some aspects of mobility, personal care and continence (Toilet, Bowels, Bladder, 
Stairs, Mobility/Transfers); feeding and bathing had no strong loading.  Comparing the person 
locations from positively loaded items with a factor loading >0.4 (speech and memory/orientation) 
to negatively loaded items with a factor loading <-0.4 (toilet, stairs, bladder, bowels and 
transfers/mobility) produced significant results at the 1% level in 9/205 (4.4%) individuals and at the 
5% level in 16/205 (7.8%) individuals. Overall, our analyses of multidimensionality suggest that 
differential progression in speech/cognitive and mobility/personal care/continence domains is the 
second most important dimension (after the Rasch model) but did not grossly compromise the 
unidimensionality of the scale and the construct of sCJD disease progression.  
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Including earlier data derived from the original component scales (Barthel, CDR, GCS) along with the 
data collected using the initial scale allowed a total of 380 scales in 239 sCJD patients to be analysed.  
The overall fit to the Rasch model was less good but remained acceptable (χ2=33.75, df =22 , 
p=0.052), suggesting that the modified items introduced for the initial scale were performing better 
than pre-existing scale components.  These item modifications were therefore retained in the final 
scale.  The MRC Scale derived for rapidly progressive patients, including a rapidly progressive subset 
of IPD (all patients in stratum (i)) also demonstrated acceptable fit to the model (χ2=30.14, df = 22, p 
= 0.11). Unsurprisingly, the MRC scale derived for IPD patients alone and for all symptomatic 
patients (all disease groups including stratum (ii)) continued to result in a poor fit due to the 
heterogeneity of clinical syndromes that comprise IPD (patients with Gerstmann-Sträussler-
Scheinker syndrome typically having an early disease course dominated by ataxia and other physical 
impairments with relative preservation of cognitive function, while in those with 6-octapeptide 
repeat insertion (6-OPRI) prion disease cognitive impairments typically predominate with physical 
functioning relatively preserved until the later stages of the illness). 
 
The final format of the rating scale is shown in Table 23.   
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Item Category criteria Score
At least one episode of incontinence in last 7 days 0
Continent for last seven days 1
Always incontinent or catheterised 0
Continent or occasional accidents 1
Fully dependent 0
Needs some help 1
Independent 2
Fully dependent 0
Needs some help 1
Independent 2
Unable or NG/PEG/RIG fed (takes nothing by mouth) 0
Needs help but can swallow (even if unsafe) 1
Independent 2
Bedbound, unable to sit 0
Can sit, but cannot mobilise OR transfer without help (from person or walking aid) 1
Can transfer OR mobilise independently OR both 2
Unable 0
Needs help 1
Indpendent 2
Mute 0
Incomprehensible sounds OR single words 1
Sentences BUT difficulty finding words OR often confused/disorientated 2
Normal conversation 3
Shows no awareness of surroundings OR any evidence of memory 0
Evidence of retaining some highly learned material (e.g. recognising familiar 
people) OR awareness of surroundings BUT no evidence of acquiring new material
1
Able to retain some new information BUT memory consistently impaired 2
Memory normal OR some impairment off and on 3
Unable to show any judgement or problem-solving 0
Able to show some judgement or problem-solving, even if this is severely impaired 1
Unable to use any tools or objects 0
Able to use some tools or objects, with help if necessary 1
Bowel function
Bladder function
Toilet use
Bathing
Feeding
Use of tools
Transfers and 
mobility
Stairs
Best verbal 
response
Memory and 
orientation to 
surroundings
Judgement and 
problem solving
 
Table 23.  The final MRC Prion Disease Rating Scale. 
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The inter-rater reliability in administration between doctors and nurses of the final scale as a whole 
was excellent (Interclass Correlation Coefficient =0.96).  This is illustrated in Figure 34, which shows a 
Bland-Altman plot for all paired assessments. 
 
Figure 34.  Bland-Altman plot illustrating agreement on paired MRC Prion Disease Rating Scale 
assessments.  Total of 63 paired assessments included.  The area of the coloured circles is 
proportional to the number of paired assessments from each category with that score 
combination: i.e. larger circles represent multiple superimposed data points. 
 
Figure 35 shows the correlation of the MRC Scale with MMSE, Rankin and GCS across all assessments 
at which these scales were acquired.  This illustrates the novel scale’s relative resistance to floor 
effects, as patients at minimum (or unrecordable) score for MMSE or Rankin can still be separated 
by the novel scale. Whilst GCS has ability to separate patients scoring zero on the novel scale (GCS 
ranging 3-11), these distinctions are difficult to interpret clinically and have little or no relevance to 
the meaningful day-to-day functions that the scale is aiming to capture.  
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Figure 35.  Correlation of the MRC Scale with other commonly used rating scales. The area 
coloured for each circle is proportional to the total number of patients from each aetiological 
group of prion disease with these scores. 
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The natural history of prion diseases 
Figure 36 shows individual patient trajectories for the MRC Scale over time, colour-coded by disease 
type.  Stratum (ii) patients have been included for comparison purposes with the caveat that the 
MRC Scale is not measuring a single progression construct in these patients, as demonstrated by the 
Rasch analysis reported above. Grey lines connect the last recorded score to the date of death, 
which is imputed as the worst-possible score (0). These plots illustrate the remarkable heterogeneity 
of disease progression between, and to a lesser extent within, prion disease types.  Several distinct 
patterns of progression are apparent:  rapid decline over weeks or a few months (mostly sCJD 
patients) and slow decline over years (almost exclusively patients with IPD).  A slightly less rapid 
decline is observed in sCJD patients who are heterozygous at PRNP codon 129, vCJD and iCJD 
patients and some IPD patients (see Figures 36 and 37). In all groups, decline measured with the 
MRC Scale generally appears to be linear. 
 207 
 
 
 
Figure 36.  Trajectories of change in patients up to 600 days post enrolment for all patients 
(combined), sCJD, IPD, iCJD or vCJD only. Three broad patterns are seen: a slow decline in IPD 
patients, a rapid and somewhat variable decline in all aetiological groups, and a pattern of decline 
followed by a pre-terminal plateau at low levels of function in all aetiological groups. All sCJD 
trajectories are also shown for the first 100 days only for clarity of short duration cases. Data are 
also available up to 10 years in some IPD patients. 
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Figure 37. Trajectories of sCJD patients either homozygous (129MM or 129VV) at codon 129 of the 
prion protein gene or heterozygous (129MV). This genetic factor appears to be a strong 
determinant of rates of decline. 
 
In most rapidly progressing patients, death occurs shortly after a very low score is reached, but in 
some there is an extended “pre-terminal plateau” phase at a very low score.  A prion disease clinical 
trial design needs to consider these different patterns of decline.  
 
Figure 38 illustrates the typical progression of a sCJD patient through the functional/cognitive 
milestones of the MRC Scale, and the spread of difficulty of items in the five measured domains. 
These observations are in keeping with clinical experience of these patient groups and are consistent 
with validity of the MRC Scale.   
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Figure 38.  Representation of the pattern of decline in a sCJD patient that would be most consistent with the Rasch model.  Progression is represented 
on the underlying logit scale used in the Rasch analysis.  This diagram illustrates the validity of the progression construct, as the ordering of the items is 
consistent with clinical experience and there is a reasonable spread of item difficulty in different functional domains.
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Discussion 
This project sought to overcome fundamental obstacles on the route to developing effective 
treatments for prion disease:  the lack of both a validated outcome measure for clinical trials and a 
large resource of clinical progression data.  Using a range of complementary approaches, and taking 
into account previous analysis of rating scales data from the PRION-1 trial121, a bespoke rating scale 
has been developed, refined and validated in the context of the Cohort study, the largest 
prospective clinical study of the natural history of prion disease.  The novel outcome measure aims 
to maximise the likelihood of future trials giving a clear answer on therapeutic efficacy. This study 
also illustrates again that the advanced neurodisability at referral of sCJD patients to our clinical 
research team is a major outstanding problem for UK clinical trials: improved early diagnosis and 
referral will be key to success of clinical trials. 
 
A new outcome measure for clinical trials 
Prion disease trials have and will continue to use survival as a key outcome measure, but this has 
major limitations.  It does not directly measure progression of disease, as patients may survive for 
long periods in a very advanced stage of disease or may die for reasons not directly related to 
disease progression (e.g. aspiration pneumonia).  Existing rating scales, which are well validated in 
other neurological settings, are far less well suited to prion disease.  For example, the MMSE and 
ADAS-cog, routinely used as outcome measures in Alzheimer’s disease clinical trials, suffer from a 
marked floor effect121 and fail to capture the profound physical impairments which are fundamental 
features of these diseases and may be present despite preserved cognitive function.  
 
The need for better outcome scales is increasingly recognised in the wider field of clinical 
neurodegeneration research, including the role of more advanced statistical validation methods such 
as Rasch analysis.  A 2009 paper by Black et al235 summarises a roundtable discussion on outcome 
measures for Alzheimer’s disease clinical trials, organised by the Alzheimer’s Association, and 
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acknowledges the value of this approach.  A pair of recently published papers presented work done 
using data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study applying both 
traditional psychometric approaches and Rasch analysis to the ADAS-cog, and identified important 
limitations to the usefulness of this widely used outcome measure236,237.  
 
The remarkable clinical heterogeneity of prion disease, combined with its rarity, represents a major 
challenge to trial design.  Very inclusive enrolment criteria will maximise patient numbers, but may 
have a paradoxically negative effect on statistical power if they greatly increase variability, or reduce 
the possible benefits that can be observed either due to permanent neurological damage which 
cannot be rescued, or due to relatively preserved functioning at enrolment.  Designing a single 
outcome measure that can capture rapid global decline in a patient with sCJD and changes in 
patients with slowly progressive IPD equally well has not been possible. IPD patients are highly 
variable in clinical presentation with predominantly motor or predominantly cognitive progression. It 
is likely that the detection of subtle changes required to define the onset of disease in IPD will 
require analysis of neuropsychological testing which is ongoing in the Cohort study.  The findings of 
this study suggest that, for maximum efficiency, the main group that should be targeted for future 
trial recruitment should be those stratum (i) patients not already at very low levels of functioning. 
This group of patients were also most likely to choose to take the investigational drug quinacrine in 
PRION-1120. 
 
While efforts have been made to design a scale that reflects the priorities of patients and their 
careers, a compromise must be struck with methodological concerns.  The novel scale does not 
include any direct assessment of neuropsychiatric symptomatology, sleep disturbance or movement 
disorder (e.g. myoclonus), all of which are common features of prion disease, and are of concern to 
patients and carers.  These features have limited value as markers of disease progression however, 
as they often fluctuate through the course of the disease, may improve in the later stages, and may 
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be significantly affected by non-disease-modifying treatments (e.g. benzodiazepines, 
anticonvulsants).  As such they are not included in the outcome measure, but they remain clinically 
important features of these diseases, and other work is ongoing to improve the way in which they 
are assessed and treated, including that included in chapter 5 of this thesis on the behavioural and 
psychiatric features of prion disease. 
 
Analyses of the baseline predictors of rates, patterns of decline, simulations of clinical trials to 
estimate power and fitting of linear mixed models are ongoing. 
 
Establishing a natural history dataset and historical control group for trials 
The data included in this study, combined with data that continues to be collected using the MRC 
Prion Disease Rating Scale through the Cohort study, represents a large and detailed natural history 
dataset, and it is hoped that this can act as a supplementary historical control group against which to 
compare treatment groups in future trials, with potentially large benefits for statistical power.  To 
this end, the dataset has been made available to other physicians conducting clinical trials, and 
research groups worldwide have been encouraged to take advantage of this in planning clinical 
trials.  To enable the direct comparison of results from different studies, we have proposed that the 
MRC Prion Disease Rating Scale should be adopted as a standard outcome measure for prion disease 
clinical research.  
 
The use of a historical control group can be an appropriate alternative methodology to a 
straightforward randomised controlled trial in specific circumstances: where it is not felt that 
randomisation to a placebo/control arm would be acceptable, either ethically or to participants (as 
in recent drug industry trials of alternative monotherapy agents for treating refractory 
epilepsy238,239); or where it would be practically very difficult to enrol sufficient numbers of 
participants in a feasible timeframe to achieve an adequately powered study.  Both of these are 
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relevant to a prion disease clinical trial.  Experience in the PRION-1 trial showed that prion disease 
patients and their relatives are reluctant to be randomised, and that their decisions about whether 
to receive an experimental therapeutic are strongly associated with variables that have a 
confounding effect on outcomes, such as level of disability at enrolment120.  The rarity of the 
conditions, particularly when combined with their marked clinical heterogeneity, clearly represent a 
challenge to enrolling sufficient numbers of patients prospectively for a well powered study. 
 
It is therefore appropriate to include a historical control group in plans for future therapeutic clinical 
trials in prion disease, but there are a number of important considerations in doing so.  The value of 
randomizing patients to concurrent treatment and control arms in a randomized controlled trials 
that it will tend to eliminate any confounding factors that might lead to spurious differences in 
outcome: including both factors that are known to be relevant and are recorded for all participants 
(and often presented as evidence that randomization has produced well-matched groups), but also 
importantly any unknown and/or unmeasured factors, as these are likely to be balanced between 
the two randomly assigned groups.  When a historical control group is used, any factors that have 
changed between the collection of the control data and the treatment data have the potential to 
produce a confounding effect.  Factors that are known to be associated with differences in the 
outcome may be recorded and efforts made to match the historical control group to the treatment 
group, but there is no way to eliminate or adjust for the effect of unknown factors. 
 
In the case of future prion disease trials, some of the potential confounding effects may be of our 
own making.  As discussed above, efforts are being made to improve the early diagnosis and referral 
of patients with prion disease, partly so that they may be offered enrolment in clinical trials at a 
stage before very significant neurological damage has occurred.  However, any changes in the 
referral pattern over time will have the potential to confound the results of a historically controlled 
trial, and will need to be very carefully accounted for.  Similarly, the increasing recognition of more 
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atypical clinical presentations of prion disease (particularly more slowly progressive forms of sCJD), 
represents another potential confounding factor. 
 
There are particular statistical issues that must be considered in performing sample size calculations 
for historically controlled trials.  More recent analysis of these240 has highlighted the importance of 
taking into account that the outcome in the historical control group does not represent the true 
control population value (as had been assumed in earlier proposed methods241), but is itself an 
estimate based on a sample and is subject to random effects, and this must be incorporated into the 
calculation.  The fact that the MRC-PDRS outcome measure has been developed and validated using 
a dataset which is itself to be used as a historical control group in future trials using this outcome 
measure, adds an additional dimension.  The statistical properties of the scale when it is used to 
collect new prospective data in a future trial may be somewhat different from those in the dataset in 
which it has already been iteratively refined, due to simple natural variation. 
 
Thoughts on wider relevance 
Clinical research into rare diseases is extremely challenging for logistic, statistical and financial 
reasons, but it is essential that we work towards overcoming these challenges.  Considered together, 
“rare diseases” make up a significant proportion of the burden of neurological disease, and it is 
essential to collect systematic data on which to base the treatment of these patients. Studying rare 
diseases can often provide valuable insights into more common conditions.  In the wider field of 
neurodegeneration there is great interest in the hypothesis that templated protein misfolding 
mechanisms (referred to as “prion-like”) may be fundamental to a wide range of other conditions 
including Alzheimer’s and Parkinson’s diseases3.  Demonstrating a disease-modifying effect of a 
therapeutic agent in prion disease may therefore lead to insights with wider implications. 
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CHAPTER 7. GENERAL DISCUSSION AND DIRECTIONS FOR FUTURE RESEARCH 
 
This thesis presents several independent but inter-related projects from the laboratory and the 
clinic.  The search for an effective disease-modifying therapeutic agent for prion disease is of 
paramount importance in this field of research, but this cannot occur in isolation.  We must aim to 
reach a situation in which patients are diagnosed as early as possible using reliable and specific tests, 
and where their progression through the disease and any response to treatment can be monitored 
in an accurate and meaningful way both with clinical rating scales and using biomarkers.   We must 
also continue to improve our understanding of the symptoms of these diseases and how to treat 
these effectively and safely; even if a disease-modifying agent is found this will remain extremely 
important, particularly for complex and distressing symptoms such as the behavioural and 
psychiatric manifestations studied in Chapter 5 above, which may themselves have an impact on 
patients’ ability to engage with and benefit from disease-modifying treatments. 
 
Molecular Diagnostics 
Since the projects presented in Chapters 2, 3 and 4 above were performed, work on the Direct 
Detection Assay has continued, particularly efforts to further define its specificity with a view to a 
possible role as a screening test that could be applied on a large scale to improve the safety of UK 
blood or organ donations135.  This study involved testing samples 5000 US blood donors (presumed 
to be non-BSE-exposed), 200 UK blood donors, and 352 patients with non-prion neurodegenerative 
diseases, and found no false positives, suggesting extremely high levels of specificity exceeding the 
threshold of 99.5% that have been suggested for a vCJD blood screening test 
(http://ec.europa.eu/health/medical-devices/files/meddev/2_14_4_ol_en.pdf).  It is important to 
note that the sensitivity of the DDA for detecting pre-clinical vCJD infection is unknown as no 
samples taken from patients prior to the onset of symptoms are available to test, and the clinical 
significance of a positive test in an asymptomatic individual is unknown (particularly given the 
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possibility of chronic asymptomatic carrier states).  Currently UK blood donations are screened for a 
number of infections (including syphilis, HIV, Hepatitis B and C), and if found to be positive the 
donors are informed and appropriately advised by a doctor regarding any need for further tests or 
treatment, and on their suitability to be a blood donor in future 
(www.blood.co.uk/resources/leaflets/tests-on-your-blood/).  Clearly if the DDA is to be 
implemented as a screening test for blood donations, very careful consideration will need to be 
given to the process by which samples are tested and in what way the results are fed back to the 
donors. 
 
The possible application of the DDA as a blood-based biomarker to track disease progression or 
response to treatment will require further investigation.  Unless further cases of vCJD occur, it is not 
likely to have any role as a therapeutic biomarker in its current form, as it has only been found to be 
positive in a very small number of cases of sCJD135 and IPD (as reported in Chapter 2), and no clear 
correlation with stage of disease progression has been demonstrated.  If further cases of vCJD do 
appear, then re-assessing the DDA’s sensitivity as a diagnostic test for vCJD prospectively will also be 
important because of the various methodological limitations imposed by the scarcity of samples that 
are discussed in Chapter 2 above. 
 
Following on from the work using the DDA in CSF presented in Chapter 3, the surprising results of 
initial testing of patient CSF samples, with lower signal in prion disease patient samples than in 
controls, will require further investigation.  In particular, looking for correlations between the DDA 
signal produced by any CSF sample, and its overall PrP content as measured using alternative 
methods such as ELISA would be useful, as one explanation of the observed results would be that 
the specificity for disease-related PrP is reduced when the DDA is used in CSF and it is simply acting 
as a quantitative test for PrP.  Another question that should be explored further is whether the DDA 
has a differential ability to detect disease-related PrP from different prion strains (e.g. to detect 
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vCJD-related PrP much more readily than sCJD-related, as suggested by the brain homogenate/CSF 
spike experiments in Chapter 3) or disease-related PrP from different tissues:  e.g. the PrP in 
peripheral blood may be in a very different form and environment than that in CSF or in brain 
homogenate. 
 
This work on the DDA in CSF is at a relatively early stage overall, and a great deal of progress would 
be needed before it could be considered as a potential diagnostic marker or biomarker of disease 
progression.  In contrast, the RT-QuIC technique (reviewed in the introduction to Chapter 3) does 
appear to have value as a diagnostic test, particularly for sCJD, and could also be explored as a 
potential biomarker that might be incorporated into clinical trials.  This could be investigated most 
effectively by studying serial CSF samples taken from patients enrolled in prospective clinical studies 
such as the Cohort, so that results can be correlated with measures of disease progression, such as 
the MRC Scale, as well as with chronological progress through the disease and other known 
phenotype modifiers such as codon 129. 
 
Although, laboratory-based (or imaging-based) biomarkers are of secondary importance to clinical 
outcome measures that have a direct relevance to patients, they can be extremely useful as an 
adjunct to these.  They may help to provide proof of concept that a therapeutic agent is engaging 
with a disease process, and may provide an early indication that a treatment is having some effect 
before this becomes apparent from analysis of the primary clinical data.  This is particularly true for 
preventative treatments (e.g. measuring cholesterol in patients taking statins to prevent 
cardiovascular disease), but may also be the case in situations where clinical data is likely to have a 
lot of inherent variability and noise (as is the case in prion disease) where it may take longer for a 
clinical benefit to become statistically apparent. 
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Clinical rating scale development 
The MRC Scale has major strengths as an outcome measure for clinical studies of prion disease, and 
we hope that it will be adopted widely as a standard tool.  This will allow pooled and/or comparative 
studies between different research groups, which can be of great value in the study of rare diseases 
such as these.  The large dataset collected using the MRC Scale in the ongoing Cohort study can now 
be used to carry out more sophisticated statistical modelling of rates of decline in different groups of 
patients, and to analyse for any factors predicting this rate of decline.  The ultimate aim of this 
process would be to stratify patients at the point of clinical trial enrolment into groups with a well-
defined expected rate of decline on the MRC Scale, so that comparisons can be made within these 
groups with major benefits for statistical power resulting from reduction in variability. 
 
Study of behavioural and psychiatric features 
Following the work presented in Chapter 5, modifications were made to the Cohort study’s protocol 
to include a neuropsychiatric rating scale that has been validated for use in other dementia 
populations, the Neuropsychiatric Inventory203.  This should allow prospective collection of more 
complete and robust data than was available for this project, which identified a number of 
weaknesses in the way these symptoms were being assessed and recorded (e.g. under-estimation of 
agitated symptoms, as these were not included in the tick-box list for symptoms present at each 
study assessment; inability of most patients to engage with the Brief Psychiatric Rating Scale (BPRS)).  
As these symptoms are common and distressing, failing to adequately assess them would represent 
a substantial “blind spot” in any clinical research protocol, including that of future clinical trials. 
 
In terms of plans to improve the treatment of patients with these symptoms, it is necessary to think 
pragmatically.  The ideal would be to carry out randomised controlled trials (RCTs) of treatments 
that have shown promise in the observational study reported here, and these should be carried out 
if possible, but bearing in mind the substantial challenges to carrying out therapeutic trials in these 
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diseases (as discussed throughout this thesis) and the appropriate prioritisation of planning trials of 
putative disease-modifying agents, it is likely that we will need to base decisions about symptomatic 
treatment on lower quality observational data for the foreseeable future.  We must remember that 
RCTs of treatments for similar neuropsychiatric symptoms in other neurodegenerative diseases have 
often not confirmed anecdotal impressions of efficacy (e.g. use of antipsychotics and 
antidepressants in Alzheimer’s disease, as reviewed in the introduction to Chapter 5), highlighting 
the difficulties of interpreting less robust evidence such as that presented in this study, where there 
is often a tendency to over-estimate efficacy.  This is particularly important in the context of the 
safety concerns around use of anti-psychotic medication.   
 
Thoughts on the past, present and future of prion disease research 
The strange and tragic history of prion diseases, particularly in the UK, has led to a remarkable 
amount of progress in this wide-ranging field of research.  Despite the rarity of the diseases, they are 
now arguably better understood than many much more common neurodegenerative conditions.  
Several clinical trials have been performed showing that this is feasible in these rare and often 
rapidly progressive diseases, and there is very encouraging pre-clinical evidence for novel 
treatments, particularly mono-clonal antibodies against PrP132,242,243. 
 
Translating encouraging preclinical evidence into successful clinical trials and meaningful benefit for 
patients is a major hurdle, and one with which many different fields of neurodegeneration research 
are currently struggling.  While prion disease research has some particular advantages that may 
make translation more feasible, such as the fact that the same diseases can affect both humans and 
laboratory animals, the challenge should not be underestimated.  It is vital to appreciate that finding 
an effective therapeutic agent in itself will not be enough to translate this into a robustly proven 
therapy that will benefit patients.  Approaches such as those used for the studies presented in this 
 220 
thesis must occur alongside to lay the groundwork for clinical trials that will have the best possible 
chance of success if, or hopefully when, an effective therapeutic agent is found. 
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